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SUMMARY 
In addition to the classic catabolic effects, it is now widely accepted that parathyroid 
hormone (PTH) exerts anabolic effects on bone, when administered intermittently. As 
a result of the regenerative characteristic, Teriparatide (Forsteo® Europe, Forteo® 
U.S.A., Eli Lilly) which is a recombinant PTH (1-34), was recently approved for 
treatment of osteoporosis in the USA and the Europe.  The dual actions of PTH are 
mediated primarily through PTH receptor 1 (PTH1R), which is a class II G protein-
coupled receptor. PTH1R can activate diverse signaling pathways, including 
cAMP/PKA and PLC/PKC pathways (Vilardaga et al., 2011). 
Periodontitis is an inflammatory disease, which manifests clinically as loss of 
supporting periodontal tissues. Accumulating evidences in vivo and vitro indicate that 
the intermittent PTH administration exerts anabolic effects on periodontal ligament 
(PDL) tissue and alveolar bone (Nohutcu et al., 1995; Ouyang et al., 2000; Barros et 
al., 2003; Lossdörfer et al., 2005, 2006b). Understanding the physiology of PTH1R is 
crucial to promote the regenerative effect of PTH. PTH1R has been exclusively 
studied in kidney and bone cells. However, the knowledge on PTH1R characteristics 
and physiology in PDL cells is still in its infancy. 
In this study, we characterized the PTH1R in PDL cells, in terms of its cellular 
localization, binding affinity, density, signal transduction and gene regulation, and 
compared these characteristics with those of PTH1R in human osteosarcoma cell 
line (MG63) and Human Embryonic Kidney 293 cells (HEK293). In the second part, 
we transplanted human PDL cells into immunodeficient nude mice and evaluated in 
vivo the regenerative capacity of PDL cells upon intermittent hPTH (1-34) 
administration. 
PTH1R mRNA and protein were detected in PDL, MG63 and HEK293 cells. Like 
other GPCRs, PTH1R was found on the plasma membrane and in the cytoplasm of 
the three cell lines, while they were to some extent also present in the nuclei of PDL 
and MG63 cells. Binding characteristics of PTH1R were cell type specific in the 
examined three cell lines, with PDL cells demonstrating a low binding affinity 
(Kd=1030±10 nM) and a relative high number of receptors (3.03±0.57 million 
receptors/cell). Dexamethason and 1,25-dihydroxyvitamin D3 increased the 
expression level of PTH1 mRNA in PDL cells (12-fold and 14-fold of the 
corresponding control group, respectively), whereas the effect of hPTH (1-34) on 
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receptor mRNA expression was depended on the mode of its administration. The 
response of cAMP in MG63 and HEK293 cells was additive with growing 
concentration of hPTH (1-34), while it was concentration dependent in PDL cells. 
However, in all three cell lines, we observed a cross-talk between the cAMP/PKA and 
PLC/PKC signaling pathways, which were regulated oppositely at a given 
concentration of hPTH (1-34). The results of the in vivo experiments proved that the 
implanted human PDL cells not only survived, but also were able to develop a 
bone/cementum like tissue which closely resembles natural bone or cementum and 
this capacity was significantly enhanced by intermittent PTH administration. 
Zusammenfassung 
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ZUSAMMENFASSUNG 
Neben dem klassischen katabolen Effekt von Parathormon (PTH), wurde aktuell 
auch eine anabole Wirkung von intermittierend appliziertem PTH auf den Knochen 
erkannt. Aufgrund seiner regenerativen Wirkung wurde Teriparatide (Forsteo® 
Europa, Forteo® U.S.A., Eli Lilly)  ein rekombinantes PTH (1-34), in den USA und 
Europa zur Therapie von Osteoporose zugelassen. Die dualen Wirkungen von PTH 
werden primär über den PTH Rezeptor 1 (PTH1R) vermittelt, der der Klasse II der G-
Protein gekoppelten Rezeptoren angehört. Durch Ligand-induzierte Aktivierung des 
PTH1R werden verschiedene intrazelluläre Signalwege, wie z.B der cAMP/PKA - und 
der PLC/PKC-Signalweg, reguliert (Vilardaga et al., 2011). 
Parodontitis ist eine entzündliche Erkrankung, die zur irreversiblen Zerstörung des 
Zahnhalteappartes führt. Ergebnisse von Untersuchungen in vitro und in vivo deuten 
darauf hin, dass intermittierendes PTH eine anabole Wirkung auf das 
Parodontalligament (PDL) Gewebe und den Alveolarknochen hat (Nohutcu et al., 
1995; Ouyang et al., 2000; Barros et al., 2003; Lossdörfer et al., 2005, 2006b). Die 
Aufklärung der Physiologie dieses Rezeptors ist äußerst wichtig für die Optimierung 
der regenerativen Wirkung von PTH. PTH1R wurde exklusiv in den Zellen der Nieren 
und des Knochens untersucht. Allerdings stecken unsere Kenntnisse über die 
Physiologie des PTH1R in PDL Zellen  noch in den Kinderschuhen. 
In der vorliegenden Arbeit wurde der PTH1R in PDL-, MG63- und HEK293-Zellen 
bezüglich seiner zellulären Lokalisation, Bindungsaffinität, Rezeptordichte, 
Signalvermittelung und Genregulation charakterisiert, beziehungsweise wurden diese 
Charakteristika mit denen des PTH1Rs in MG63- und HEK293-Zellen verglichen. Der 
zweite Teil der Arbeit beschäftigte sich mit der Untersuchung der regenerativen 
Kapazität von transplantierten humanen PDL Zellen durch intermittierend 
angewandtes hPTH (1-34). 
PTH1R-mRNA und-Protein konnten in PDL-, MG63- und HEK293-Zellen 
nachgewiesen werden. Wie andere GPCR, zeigte PTH1R in allen untersuchten 
Zelllinien eine Zellmembran-ständige und cytoplasmatische Lokalisierung, während 
die Präsenz des Rezeptors zum Teil auch in den Zellkernen der PDL- und MG63-
Zellen gezeigt werden konnte. Die Bindungeigenschaften von PTH1R scheinen 
zelltypspezifisch zu sein, wobei in PDL-Zellen eine geringere Affinität bei hoher 
Anzahl des Rezeptors festgestellt wurde (Kd=1030±10 nM, 3.03±0.57 Millionen 
Zusammenfassung 
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Rezeptoren/Zelle). Eine Stimulation der Zellen mit Dexamethason oder 1,25-
Dihydroxyvitamin D3 steigerte die mRNA Expression von PTH1R (12 - und 14 - fach 
jeweils im Vergleich zu der Kontrollgruppe), während der Effekt des hPTH (1-34) von 
der Art der Administration abhängig war. Die cAMP-Akkumulation in MG63- und 
HEK293-Zellen stieg mit aufsteigender Konzentration des hPTH (1-34), während sie 
in PDL-Zellen von der Konzentration des Hormons abhängig war. Interessanterweise 
wurde eine “cross-talk’’-Interaktion zwischen den cAMP/PKA- und PLC/PKC-
Signalwege festgestellt, wobei die beiden Signalwege durch die jeweilige PTH- 
Konzentration gegenläufig reguliert wurden. Die Ergebnisse der Tierversuche 
belegten, dass die transplantierten humanen PDL-Zellen nicht nur überlebten, 
sondern auch ein Knochen/Zementum ähnliches Gewebe bilden konnten, und dass 
diese Differenzierung durch intermittierend zugeführtes hPTH (1-34) gesteigert 
werden konnte. 
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1 INTRODUCTION 
1.1 Periodontitis 
 
Periodontitis, also known as periodontal disease, is a bacterially induced chronic 
inflammation of the periodontium. The periodontal diseases range from the relatively 
benign form of gingivitis to aggressive periodontitis, depending on the severeness of 
the infection and the response of the host. Gingivitis, the most common form of 
periodontal disease, is characterized by inflammation, swelling, and bleeding of the 
gums and results most often from bacterial plaque. It is non-destructive and 
reversible with professional treatments. However, if not treated adequately, gingivitis 
can advance to periodontitis, which is a destructive form of the periodontal disease. 
In severe form, it triggers the degradation of periodontal connective tissue and 
alveolar bone, resulting in the most common cause of tooth loss in the world. 
 
               
 
Figure 1.1 Schematic illustrations of Periodontitis (Taken from: Periodontitis Types: Periapical and Apical, 
Chronic and Aggressive Periodontitis, http://periodontitis.dentalbuzz.org). A: Healthy periodontium B: Moderate 
periodontitis. C: Severe periodontitis. 
 
Periodontitis is a very common disease worldwide and associated with diverse 
physiological disorders such as cardiovascular disease (Kebschull et al., 2010), 
dyslipidemia (King, 2008), Type 2 diabetes (Seymour et al., 2007), low birth weight 
(Offenbacher et al., 1996) in otherwise healthy individuals  and metabolic syndrome 
in hemodialysis patients (Chen et al., 2011). 
Besides bacterial plaque, genetic as well as environmental factors have been proven 
to cause periodontal disease, especially tobacco use (Pihlstrom et al., 2005). 
Additionally, several physiological disorders, such as dermatological, haematological, 
granulomatous, immunosuppressive, and neoplastic diseases can exert an effect on 
periodontitis (Pihlstrom et al., 2005). 
A B C 
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1.2 Periodontal ligament  
 
The periodontium is a topographically complex organ that surrounds and supports 
the teeth. The structures comprising the periodontium include two soft tissues: 
gingiva, periodontal ligament and two hard tissues: cementum and alveolar bone. 
While each of the periodontal components has a specialized tissue architecture and 
characteristic biochemical composition, they interact dynamically and influence the 
cellular activities of each other (Bartold, 2006). 
 
Periodontal ligament
Gingiva
Cementum
Alveolar bone
Crown
Roots
 
 
Figure 1.2 Components of the periodontium (Modified after: Periodontal Ligament - Studio Dentaire, 
http://www.studiodentaire.com). The four structural components of the periodotium, two soft connective tissues: 
gingival and periodontal ligament and two hard tissues cementum and alveolar bone are indicated in red. They 
interact with each other and together support and maintain the physiological activity of teeth. 
 
The periodontal ligament, abbreviated as the PDL, is a highly specialized soft 
connective tissue embedded between the cementum covering the tooth root and 
alveolar bone. Thus, forming a link between the tooth and the bone, the ligament 
supports not only teeth, but also contributes to tooth nutrition, homeostasis, and 
repair of damaged tissue (Bartold et al., 2000). It ranges in width from 0.15 to 0.38 
mm, reaching the thinnest portion around the middle third of the root (Nanci and 
Bosshardt, 2006). Upon aging, the thickness of this ligament decreases 
progressively. 
This tissue is characterized by rapid turnover and high remodeling rates, which are 
essential for maintaining the width and integrity of the PDL as the teeth assume new 
positions in the jaws in response to changing forces such as mastication, speech and 
Introduction 
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orthodontic tooth movement (Beertsen, 1975; Berkovitz and Shore, 1995). Both 
turnover and remodeling are precisely regulated by the complex interplay between 
breakdown and synthesis of extracellular matrix components, specifically the 
collagenous meshwork (Beertsen et al., 1997). The collagen degradation is thought 
to be a result of collagen phagocytosis by fibroblasts without the involvement of 
collagenases (Beertsen et al., 1997). Moreover, the PDL is considered to be involved 
in repair, remodeling, and regeneration of the adjacent tissues, cementum and 
alveolar bone (Boyko et al., 1981; Nyman et al., 1982).  
Similar to all soft fibrous connective tissues, the PDL consists of a fibrous matrix 
embedded in a gel of ground substance containing cells, blood vessels and nerves 
(Berkovitz, 1990). Its fibrous elements consist of mostly bundles of collagen fibers, 
which are distributed throughout the space of the periodontal ligament to join the 
tooth to the alveolar bone. The predominant collagens of the PDL are type I and III 
(Berkovitz, 1990; Takayama et al., 1997), which traverse the ligament space and 
insert into the cementum and bone surface as Sharpey’s fibers. Additionally, the 
presence of collagen type V (Becker et al., 1991), type VI (Becker et al., 1991), XII 
(Dublet et al., 1988) and Oxytalan (Fullmer, 1958) in the PDL have been also 
reported. Aside from these fibrous elements, several matrix proteins are found in the 
periodontal ligament, including proteoglycans (Häkkinen et al., 1993) and 
glycoproteins such as undulin, tenascin, and fibronectin (Zhang et al., 1993). The 
ground substance of the PDL is structure-less and has been estimated to be 70% 
water. It is thought to have a pivotal role on the tooth’s ability to withstand mechanical 
stress loads (Nanci and Bosshardt, 2006).  
The PDL consists of a heterogeneous cell population that includes fibroblasts, 
cementoblasts, osteoblasts, endothelial progenitor cells, epithelial cell rests of 
Malassez, macrophages, osteoclasts and progenitor/stem cells (Ten Cate, 1998). 
While fibroblasts, macrophages, undifferentiated progenitor/stem cells, neural 
elements, and endothelial cells are found throughout the PDL, osteoblasts and 
osteoclasts reside on the alveolar bone side. Epithelial rests of Malassez cells and 
cementoblasts are localized close to the root surface of the tooth (Marchesan et al., 
2011) whereas progenitor/stem cells are observed adjacent to blood vessels in the 
PDL (Gould et al., 1977). 
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Figure 1.3 Overview of the structure and components of the periodontal ligament tissue (PDL) (Taken 
from: Marchesan et al., 2011). The structure and heterogeneous cell population of periodontal ligament, along 
with its vascular and extracellular matrix elements are illustrated. The different cells are depicted in different 
colors: osteoblasts (orange), osteoclasts (pink), fibroblasts (green), stem cells (purple), cementoblasts (blue), 
epithelial cells rest of Malassez (ERM) (aqua), macrophages (grey). Blood vessels emerge from the alveolar 
bone, along with nerve fibres. 
 
 
1.3 PDL fibroblasts 
 
PDL fibroblasts, referred to as PDL cells, are the predominant cell type (Beertsen et 
al., 1997) and are thought to be mainly responsible for PDL homeostasis and 
regeneration (Lekic and McCulloch, 1996). The fibroblasts of the ligament are 
thought to originate in part from the ectomesenchyme of the investing layer of the 
dental papilla (Ten Cate et al., 1971), which may impart these cells specialized 
characteristics. The rapid turnover rate and remodelling of collagen in the PDL is 
considered to be the result of the phagocytosis by the periodontal fibroblasts. 
Moreover, they may provide a reservoir for mineral-forming cementoblasts or bone-
forming osteoblasts (McCulloch et al., 2000).  
Apart from theses unique properties, PDL fibroblasts exhibit osteoblastic properties 
such as alkaline phosphatase activity (Yamashita et al., 1987), production of bone 
sialoprotein in response to 1,25-dihydroxyvitamin D3 (Nojima et al., 1990) and 
responsiveness to parathyroid hormone (Nojima et al., 1990). Furthermore, they 
have been shown to express not only proteins with osteoblastic properties such as 
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the runt-related transcription factor-2 (RUNX-2), osterix (Kato et al., 2004), 
osteocalcin (OSC) (Li et al., 2001), osteopontin (OPN) (Lekic et al., 2001; Li et al., 
2001), periostin (Horiuchi et al., 1999), osteonectin (OSN) and type I collagen (Col I) 
(Lukinmaa and Waltimo, 1992), but also receptor activator of NF-kappa B ligand 
(RANKL) and osteoprotegerin (OPG), which play a pivotal role in the regulation of 
bone metabolism (Wada et al., 2001). PDL cells from rat were able to form 
mineralized nodules in vitro, although the mineralized nodules appeared to be 
different from those produced by osteoblasts (Cho et al., 1992). Other reports have 
shown the presence of type XII collagen (Col XII) (Karimbux et al., 1992), alpha-
smooth muscle actin (a-SMA) (Arora and McCulloch, 1994) and scleraxis (Seo et al., 
2004) in  PDL fibroblasts.  
In addition to their fibroblastic and osteoblastic properties, PDL cells demonstrate 
also functional characteristics of leucocytes and leucocyte-derived cells (e.g. 
macrophages) involved in classical innate immunity (Jönsson et al., 2011). It has 
been shown that ligament fibroblast cells up-regulated transcript and protein levels of 
several cytokines and chemokines upon stimulation with inflammatory promoters 
such as bacterial lipopolysaccharides (Jönsson et al., 2011). 
These findings suggest that PDL fibroblasts contain a variety of subpopulations with 
different functional characteristics, although morphologically they look alike. 
However, whether these subsets are derived from a single type of progenitor cell is 
still unknown. Phenotypically stable but functionally different fibroblast 
subpopulations have been reported also in skin and other tissues (Hassell, 1993). 
PDL fibroblasts are large cells with a spindle-shaped, elongated appearance in vitro, 
which is characteristic of fibroblast-like cells (Somerman et al., 1988). However, in 
vivo, they show an irregular disc-shape with a mean diameter of about 30 µm (Shore 
and Berkovitz, 1979). These cells have a prominent nucleus with approximately 25 % 
of the cell by volume (Berkovitz, 1990), and an extensive cytoplasm containing an 
abundance of organelles such as rough endoplasmic reticulum (5-10 % of the 
volume of the cytoplasm), mitochondria, golgi complex and vesicles. They possess a 
well-developed cytoskeleton and show frequent adherens and gap junctions (Nanci 
and Bosshardt, 2006). In the ligament, the fibroblasts are oriented parallel to the 
collagen fiber bundles and extend cytoplasmic processes that wrap around them 
(Beertsen et al., 1997). 
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1.4 Periodontal regeneration 
 
Traditional treatment modalities of periodontitis include nonsurgical debridement of 
root surfaces or root canals, as well as resective surgery that provide better access 
to reshape the surrounding bone or root apex (Bashutski and Wang, 2009). Although 
these therapies have been established as effective treatment regimens in periodontal 
disease, the destruction of the attachment apparatus or bone is often the outcome 
and healing is always by repair (Bashutski and Wang, 2009). Since repair does not 
fully restore the function or structure of the destroyed tissue, new approaches such 
as regenerative therapies that aim to restore lost tissue through the regeneration of 
cementum, PDL, and alveolar bone have been introduced. These methods include 
bone replacement grafts, guided tissue regeneration and growth factors / cytokines / 
host modulating agents. 
In bone replacement grafts, a ‘‘filler’’ bone graft material is introduced into the 
periodontal defect in the hope of inducing bone regeneration (Bartold et al., 2000). In 
guided tissue regeneration, occlusive barrier membranes are employed to inhibit the 
rapid downgrowth of epithelial cells and gingiva fibroblasts from a periodontal wound, 
which allows other regenerative cells (osteoblasts, PDL cells, cementoblasts) to 
repopulate the area and promote periodontal regeneration (Bashutski and Wang, 
2009). Platelet-rich plasma (PRP) and growth factors such as bone morphogenic 
proteins (BMPs), platelet-derived growth factor  (PDGF), and enamel matrix proteins 
(EMD) are the most commonly used agents to promote the healing and regeneration 
potential of periodontal destructed tissue (Heijl et al., 1997; Giannobile and 
Somerman, 2003; Jung et al., 2003; Nevins et al., 2005). Other therapeutics 
including collagen fragments bound to bone grafts, parathyroid hormone (Liu et al., 
2009), and transforming growth factor beta 3 (Teare et al., 2008) have also been 
shown to promote the regenerative potential on the damaged tissue. Additionally, the 
application of cell-based, protein-based and genetic engineering approaches in 
periodontal tissue regeneration are currently under investigation (Rios et al., 2011). 
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1.5 Parathyroid hormone in PDL regeneration 
 
Progressive periodontitis often results in alveolar bone resorption, and ultimately 
leads to the loss of teeth. Accordingly, the arrest of bone resorption and regeneration 
of alveolar bone are of significant importance.  
Parathyroid hormone (PTH), an endogenous hormone, is involved in bone 
remodelling by exerting its catabolic effects (bone resorption) and anabolic effects 
(bone formation), depending on its administration mode (Neer et al., 2001). The 
prevailing view of catabolic effects of PTH suggests that PTH enhances production of 
receptor activator of nuclear factor- кB ligand, macrophage colony-stimulating factor 
and possibly other cytokines (i.e., IL-1, IL-6, and TNF-α) and downregulates the 
production of osteoprotegerin (Murray et al., 2005). 
The anabolic activity of PTH on osteoblasts has been studied intensively both in vivo 
and vitro. Preclinical studies and small clinical trials have proven distinct anabolic 
effects of intermittent PTH administration on bone (Rubin et al., 2002; Turner, 2002). 
In another study, both full length PTH (1–84) and teriparatide (PTH 1–34) 
administration resulted in a rapid up-regulation of markers of bone formation, but a 
down-regulation of markers of resorption (Hodsman et al., 2003, 1993). Daily 
injections of PTH (1–84) or PTH (1–34) increase bone mass and reduce the 
incidence of fracture in postmenopausal women, in elderly men, and in women with 
glucocorticoid-induced osteoporosis (Jilka, 2007). The anabolic effect of intermittent 
PTH has also been extensively demonstrated in mice and rats (Hodsman et al., 
2002). These findings finally resulted in an approval of the PTH therapy for 
osteoporosis by the US Food & Drug Administration (FDA) for FORTEO® (PTH). 
Although the exact underlying mechanism accounting for the anabolic effect of 
intermittent PTH remains to be elucidated, emerging evidence indicates that the 
increase in bone formation is largely due to an increase in the number of  
osteoblasts, which is mediated by repeated delays of osteoblast apoptosis (Jilka et 
al., 1999), enhancing the recruitment of preosteoblasts from marrow stromal cells 
and stimulating the maturation of lining cells (Jilka, 2007). 
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Figure 1.4 Proposed cellular mechanisms accounting for the anabolic effect of intermittent PTH (Taken 
from: Jilka, 2007). Intermittent PTH has been proposed to increase osteoblast number by: (A) increasing the 
development of osteoblasts, (B) inhibiting osteoblast apoptosis, and (C) reactivating lining cells to resume their 
matrix synthesizing function. 
 
The anti-apoptotic signaling pathways triggered by intermittent PTH involve cAMP-
mediated activation of protein kinase A (PKA), subsequent phosphorylation and 
inactivation of the pro-apoptotic protein Bad, and increased transcription of survival 
genes like Bcl-2 (Bellido et al., 2003). On the other hand, intermittent PTH has been 
shown to decrease the expression of histone H4, a marker of the cell cycle (Onyia et 
al., 1995), and expression of the cell cycle inhibitors p27KIP1 and p21Cip1 (Qin et al., 
2005), in metaphyseal bone of young rats, a site rich in replicating osteoblast 
progenitors. This fact together with the results of other in vivo and in vitro studies 
strongly suggests that intermittent exposure to PTH causes an exit of osteoblast 
progenitors from the cell cycle, which leads to the differentiation and suppression of 
proliferation of these cells (Jilka, 2007). 
Based on the anabolic properties of PTH established in osteoblasts and the fact that 
the PDL cells show osteoblastic characteristics, there have been numerous studies 
conducted both in vivo and vitro to elucidated the effect of PTH on PDL cells. The 
results of these studies have indicated that periodontal ligament cells respond to PTH 
in a osteoblastic manner, both in vitro (Nohutcu et al., 1995; Ouyang et al., 2000; 
Lossdörfer et al., 2005, 2006b) as well as in in vivo models (Barros et al., 2003). The 
involvement of PTH in the regulation of periodontal activities is further supported by 
the fact that PTH and parathyroid gland extract enhance tooth eruption and 
orthodontic tooth movement (Schneider et al., 1972; Davidovitch et al., 1972). 
Moreover, PTH receptors were immunohistochemically detected in rat cementoblasts 
(Tenorio and Hughes, 1996). Recently, Bashutski et al. reported markedly improved 
clinical and radiographic outcomes in patients with severe, chronic periodontal 
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disease who underwent periodontal surgery and received daily injections of 
teriparatide (Bashutski et al., 2010). Taken together, these lines of evidence suggest 
that PTH, currently approved for use in osteoporosis therapy, might also contribute to 
treatment of periodontal disease. In addition, bisphosphonates, another category of 
drugs, approved for the treatment of osteoporosis, have been evaluated for their 
therapeutic benefit in periodontal diseases, with promising results (El-Shinnawi and 
El-Tantawy, 2003). 
 
 
1.6 Parathyroid hormone 
 
Parathyroid hormone (PTH) is a single-chain polypeptide of 84 amino acids, which is 
synthesized in and secreted by the parathyroid glands (Habener et al., 1978). PTH is 
formed as a 115-amino acid polypeptide precursor (pre-pro-PTH) which then 
undergoes two successive proteolytic cleavages (Habener et al., 1976). First, in the 
rough endoplasmic reticulum, the NH2-terminal peptide of 25 amino acids is cleaved 
from pre-pro-PTH and yields pro-parathyroid hormone (pro-PTH), an intermediate 
precursor of 90 amino acids, which is subsequently transported to the golgi 
apparatus, where the NH2-terminal hexapeptide of pro-PTH is removed, resulting in 
the formation of active PTH (84 amino acids) (Habener et al., 1978). 
The primary amino acid sequence of PTH is highly conserved among mammalian 
species (Figure 1.4). While the strongest homology resides in the N terminus of the 
molecule (32 of the first 38 residues), the greatest evolutionary variation is evident in 
the middle region of the hormone (between residues 39 and 52). In the C-terminal 
region, from 53 to 84, several stretches of high homology can be found. A number of 
residues are conserved also in the chicken and zebrafish sequences. Furthermore, 
sequence from 65 to 78 varies at only three positions among mammals (Murray et 
al., 2005). 
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Figure 1.5 Amino acid sequences of intact PTH from several mammalian species (Taken from: Murray et al., 
2005). Amino acids are denoted by the single-letter abbreviation for each of the indicated species. Shading 
indicates residues in hPTH that are conserved in other species, and those residues conserved in all species 
shown are indicated in bold. 
 
In addition to intact PTH (1–84), parathyroids also secrete relatively high 
concentrations of heterogenous C-terminal fragments, which are thought to be 
inactive in classical terms (Murray et al., 2005). While another source of the C-
terminal fragments is the proteolysis of intact PTH by Kupffer cells in liver, there is no 
direct evidence that N-terminal fragments are produced in vivo by metabolic cleavage 
or gland secretion under normal physiological conditions (Murray et al., 2005). Both 
the liver and kidney take part in the clearance of the circulating intact PTH and C-
terminal fragments (Murray et al., 2005). 
PTH regulates serum calcium concentration via acting directly on bone to increase 
calcium resorption and on kidney to increase calcium reabsorption in renal tubules 
(Potts et al., 1995). Additionally, PTH inhibits reabsorption of phosphate in kidney, 
stimulating its excretion (Pullman et al., 1960; Beutner and Munson, 1960). PTH has 
been also shown to act indirectly on intestine to promote absorption of calcium, which 
is mediated by 1,25-dihydroxyvitamin D3 (Lawson et al., 1971). Apart from actions on 
calcium and bone metabolism, PTH has been also reported to have proliferative 
effects on blood and liver cells (Rixon et al., 1958; Whitfield et al., 1969; Rixon and 
Whitfield, 1972). 
The secretion and synthesis of PTH is regulated by a number of factors such as 
calcium, phosphate and 1,25-dihydroxyvitamin D3 level. A particular characteristic of 
the parathyroid gland is its sensitivity to small changes in serum calcium, which leads 
to large changes in PTH secretion, with a sigmoidal type response (Silver et al., 
1999). Serum calcium is the chief regulatory signal for PTH secretion, and a 
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decrease in extracellular calcium enhances not only the PTH secretion but also 
increases PTH gene expression level and parathyroid cell proliferation (Silver et al., 
1998). The parathyroid recognizes the changes in serum calcium via a G-protein 
receptor coupled on the cell membrane of parathyroid cells, the calcium sensing 
receptor (CaSR) (Brown et al., 1993). Conversely, CaSR activation by increased 
extracellular calcium induces the release of intracellular calcium, which in turn inhibits 
secretion of PTH (1–84) (Friedman and Goodman, 2006). Inhibition of PTH (1–84) 
secretion is accompanied by enhanced proteolysis of the NH2 terminus of PTH, with 
the attendant secretion of PTH (7–84) and other NH2-terminal truncated PTH peptide 
fragments (Friedman and Goodman, 2006). 
A high serum phosphorus concentration has been shown to be associated with an 
increase in PTH secretion (Silver and Levi, 2005). The effect of phosphate is 
considered to be posttranscriptional and independent of 1,25-dihydroxyvitamin D3 
and calcium (Kilav et al., 1995). 1,25-dihydroxyvitamin D3 dramatically decreased the 
levels of PTH mRNA in the parathyroids of normal rats at physiologically relevant 
doses without changing the levels of serum calcium (Shvil et al., 1990). Unlike 
phosphate, the effect of 1,25-dihydroxyvitamin D3 on the PTH gene was shown to be 
transcriptional (Silver et al., 1986). 
Studies on the structure and function of PTH have revealed that most of the 
biological activity of intact PTH (1–84) resides in the 1-34 N-terminal fragment of the 
hormone. It was found that a synthetic bovine (b)PTH(1–34) was able to generate the 
major biological actions of the full-length native bPTH (1-84), including activation of 
adenylyl cyclase in bone and kidney cells, increased urinary excretion of cAMP and 
phosphate in rats, and elevation of blood calcium in rats, dogs, and chickens (Murray 
et al., 2005). Moreover, Teriparatide has a similar binding affinity for PTH receptor 1 
as PTH (1–84) (Brixen et al., 2004). Teriparatide (ForsteoA or ForteoA, Eli Lilly), a 
recombinant human PTH (1–34) (hPTH [1–34]), was first approved in the United 
States in November 2002 for the treatment of osteoporosis in men and women and 
became available in other countries, such as the United Kingdom and several other 
countries in the European Union, in April 2003 (Quattrocchi and Kourlas, 2004). 
These facts, together with the practical difficulties in synthesizing large quantities of 
chemically pure PTH (1–84), led to the widespread use of recombinant PTH (1–34) 
as a surrogate for intact PTH in studies of hormone effect in vitro and in vivo. 
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While synthetic PTH (1–31), (1–34) and (1–38), seem to have the same anabolic 
effect on bone as PTH (1–84) (Brixen et al., 2004), PTH peptides lacking one or 
more amino acid residues such as PTH (2–34), N-terminal truncated peptides such 
as PTH(3–34) and PTH(7–34) bind with affinities considerably lower than that of 
PTH(1–34) (Friedman and Goodman, 2006; Murray et al., 2005). On the other hand, 
PTH (3–38), did not demonstrate an anabolic effect (Armamento-Villareal et al., 
1997). Based on these observations, it appears that the first two amino acids are 
essential for biological activity, and the bone promoting properties are fully 
maintained in the 1–31 N-terminal domain of PTH.  PTH (1–14) was shown to be the 
shortest native N-terminal PTH peptide for which some cAMP agonist activity could 
be detected (EC50 ~200 µM) (Luck et al., 1999). Studies on the structure and activity 
of the PTH (1–14) scaffold have shown that the first 9 amino acids are essential for 
receptor activation, and also that amino acid substitutions at several positions 
[Ala3,12,Gln10,Arg11,Trp14] in PTH(1–14) led to improved potency in stimulating 
cAMP accumulation, which was 250 times that of native PTH(1–14). By the same 
substitutions, the otherwise inactive PTH (1–11) could also be activated (Shimizu et 
al., 2000b). The modified PTH (1–14) has led to define the minimum N-terminal PTH 
agonist pharmacophore, which resides within the first 9 amino acids of the hormone, 
whereby the amino acids were covalently bound to the juxtamembranedomain using 
a tetraglycine linker (Shimizu et al., 2000a). 
Although carboxyl fragments such as PTH (44–68), PTH (53–84), and PTH (39–84) 
did not compete for binding with PTH (1–34) radioligands, nor did they activate 
adenylyl cyclase in renal membranes or bone cells (Murray et al., 2005), both in vitro 
and in vivo studies indicate that the C-terminal part of PTH may have significant 
biological effects in bone (Hodsman et al., 2005). It has been reported that C- 
terminal PTH fragments may enhance osteocyte apoptosis (Divieti et al., 2001), and 
C-terminal fragments containing at least the last 30 or more amino acids of PTH 
increase production of alkaline phosphatase and other markers of osteoblast activity 
(Sutherland et al., 1994). 
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1.7 Parathyroid hormone related peptide 
 
PTHrP was discovered in association with humoral hypercalcemia of malignancy 
syndrome and certain types of cancer in affected patients. The hypercalcemia, 
caused by the uncontrolled secretion of PTHrP, is a result of promoted Ca2+ 
resorption from bone and suppression of urinary Ca2+ loss (Guerreiro et al., 2007). 
PTHrP is widely expressed in a large variety of normal adult and fetal tissues, 
including cartilage, heart, kidney, hair follicles, placenta, breast, lungs, and many 
epithelial tissues (Schipani and Provot, 2003). This peptide has a pivotal role in 
regulating embryonic development of the skeleton and other tissues via intracellular, 
paracrine, and endocrine pathways (Gardella and Jüppner, 2001). Human PTHrP 
protein is encoded by a single gene, and generated by alternative splicing of the 
primary transcript as one of three variants of 139, 141 or 173 amino acids (Mannstadt 
et al., 1999). Both PTH and PTHrP bind to parathyroid hormone/parathyroid hormone 
related peptide receptor (PTH1R) (see section 1.6), and exert anabolic effects on 
bone (Stewart, 1996). 
PTH and PTHrP share significant sequence homology within the first 13 amino acid 
residues, which underlines the functional importance of the N-terminal residues in 
receptor signaling. However, the sequence homology decreases siginficantly in the 
14–34 region, showing no recognizable similarity beyond residue 34 (Mannstadt et 
al., 1999). For both PTH and PTHrP, the 15–34 region functions as the principal 
PTH1R binding domain 
 
 
1.8 G-protein coupled receptors  
 
GPCRs comprise the largest family of membrane proteins in the human genome, 
mediate most cellular responses to hormones and neurotransmitters, and are 
responsible for vision, olfaction and taste. Based on the similarity of their sequence 
and structure, GPCRs in vertebrates are commonly divided into five families: 
rhodopsin (family A), secretin (family B), glutamate (family C), adhesion and 
Frizzled/Taste2 (Fredriksson et al., 2003). These receptors are characterized by a 
common structural signature of seven hydrophobic transmembrane (TM) segments, 
with an intracellular carboxyl terminus and an extracellular amino terminus. 
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Figure 1.6 Seven transmembrane helix structure of GPCRs (Taken from: Kobilka, 2007).  GPCRs contain an 
intracellular carboxyl terminus, an extracellular amino terminus and seven transmembrane helix segments. Cell 
membrane (green); Ligand peptide (yellow); 
 
The G proteins comprise α, β and γ subunits. The α subunit is responsible for GTP 
and GDP binding for GTP hydrolysis, whereas the β and γ subunits are associated in 
a tightly linked βγ complex. GPCRs activate intracellular heterotrimeric G-proteins by 
stimulating the exchange of bound GDP in the α-subunit for GTP. Binding of GTP 
induces the dissociation of the α subunit from the βγ dimer, both being able to 
regulate the activity of target enzymes or channels responsible for the cellular 
response. There are at least 18 different human Gα proteins to which GPCRs can be 
coupled (Hermans, 2003; Wong, 2003). These Gα proteins form heterotrimeric 
complexes with Gβ subunits, of which there are at least 5 types, and Gγ subunits, of 
which there are at least 11 types (Hermans, 2003). Depending on the type of G 
protein to which the receptor is coupled, a variety of downstream signaling pathways 
can be activated. Consequently, the Gα- and Gβγ-subunits stimulate effector 
molecules, which include adenylyl and guanylyl cyclases (AC and GC), 
phosphodiesterases, phospholipase A2 (PLA2), phospholipase C (PLC) and 
phosphoinositide 3-kinases (PI3Ks), thereby activating or inhibiting the production of 
a variety of second messengers such as 3'-5'-cyclic adenosine monophosphate 
(cAMP), cyclic guanosine monophosphate (cGMP), diacylglycerol (DAG), inositol 
(1,4,5)-trisphosphate (IP3), phosphatidyl inositol (3,4,5)-trisphosphate, arachidonic 
acid and phosphatidic acid, in addition to promoting increases in the intracellular 
concentration of Ca2+ and the opening or closing of a variety of ion channels 
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(Marinissen and Gutkind, 2001). Furthermore, GPCRs may also activate intracellular 
pathways independently of G-proteins, possibly by the regulation of effector 
molecules through novel molecular mechanisms (Marinissen and Gutkind, 2001). 
 
 
 
Figure 1.7 Diversity of GPCRs (Taken from: Marinissen and Gutkind, 2001). Various ligands, including biogenic 
amines, amino acids, ions, lipids, peptides and proteins, activate cytoplasmic and nuclear targets with or without 
heterotrimeric G-proteins, by binding GPCRs on cellular membrane. Such signaling pathways regulate key 
biological functions such as cell proliferation, cell survival and angiogenesis. Abbreviations: DAG, diacylglycerol; 
FSH, follicle-stimulating hormone; GEF, guanine nucleotide exchange factor; LH, leuteinizing hormone; LPA, 
lysophosphatidic acid; PAF, plateletactivating factor; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; 
PLC, phospholipase C; S1P, sphingosine-1-phosphate; TSH, thyroid-stimulating hormone. 
 
The ligand efficacy is defined as the effect of a ligand on the structure and 
biophysical properties of a receptor. Based on their efficacy, natural and synthetic 
ligands are divided into four groups: full agonists – capable of maximal receptor 
stimulation; partial agonists – unable to elicit full activity even at saturating 
concentrations; neutral antagonists – with no effect on signaling activity; and inverse 
agonists – reduce the level of basal activity of the receptor. 
The signal triggered by the exposure of GPCRs to agonists is attenuated by 
desensitization of the receptors, which is a combined consequence of several 
different mechanisms. These mechanisms include the uncoupling of the receptor 
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from heterotrimeric G proteins in response to receptor phosphorylation, the 
internalization of cell surface receptors to intracellular membranous compartments, 
the lysosomal and plasma membrane degradation of receptors, and the down-
regulation of receptor mRNA and protein synthesis (Ferguson, 2001). The time 
course of these processes ranges from seconds (phosphorylation) to minutes 
(endocytosis) and even hours (down-regulation). The outcome of receptor 
desensitization varies from absolute termination of signaling to the attenuation of 
agonist potency and maximal responsiveness and is regulated by multiple factors, 
which include receptor structure and cellular environment (Ferguson, 2001). 
 
 
1.9 PTH receptor 1 
 
The pleiotropic actions of PTH are mediated primarily through the binding and 
activation of the PTH/PTH-related peptide (PTHrP) receptor (PTH1R), which is highly 
expressed in a variety of tissues, with highest expression in the kidney, bone, and 
cartilage (Langub et al., 2001). PTH binds also to a second receptor (PTH2R) with a 
distinct pharmacology (Gensure et al., 2005). Both PTH receptors are the class B G 
protein-coupled receptors (GPCRs), to which the receptors for secretin, calcitonin, 
glucagons and several other peptide hormones also belong. One prominent feature 
of these peptide hormone receptors, which can be distinguished from other classes 
of GPCRs, is their relatively large glycosylated N-terminal extracellular domain (~170 
aa in PTH1R) containing six conserved cysteine residues, as well as by several other 
conserved amino acids that reside throughout the N-terminal domain, the membrane-
embedded helixes, and the connecting loops (Gardella and Jüppner, 2001). 
The complementary DNA (cDNA) encoding the PTH1R was first cloned in 1991 by 
COS-7 expression using an opossum kidney cell cDNA library (Juppner et al., 1991) 
Since then, PTHR1 has been cloned in a number of other species such as, rat 
(Abou-Samra et al., 1992), human (Schipani et al., 1993), mouse (McCuaig et al., 
1994), pig (Smith et al., 1996), zebrafish (Rubin and Jüppner, 1999), as well as rabbit 
(Lu et al., 2001). Human PTH1R has 95% sequence homology with pig and dog, 
90% with rat and mouse and 79% with opossum. The PTH1R gene consists of 2007 
bp mRNA, which contains 14 exons and two transcript variants encoding the same 
protein with 593 amino acids (NCBI Reference Sequence: NM_001184744.1). In 
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addition to bone, kidney and cartilage, PTH1R expression was also found in heart 
and smooth muscle, skin, uterus, placenta, mammary gland, liver, ovary and testis 
(Ureña et al., 1993). 
Like other members of class B GPCRs, PTH1R contains an extended N-terminal 
extracellular domain, a seven hydrophobic helical transmembrane domain (TMDs), 
and an intracellular cytoplasmic domain. The N-terminal domain is glycosylated at 
four asparagine residues clustered near the junction with the first TMD such as N151, 
N161, N166 and N176, at least one of which is required for the expression, ligand 
binding, and signal transduction of the PTH1R (Zhou et al., 2000). Additionally, the 
N-terminal domain contains three disulfide bonds involving six highly conserved 
cysteines, Cys48/Cys117, Cys108/Cys148, and Cys131/Cys170 (Grauschopf et al., 
2000). The C-terminal domain contains several serine residues that undergo 
phosphorylation upon ligand binding (Hodsman et al., 2005). 
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Figure 1.8 Schematic representation of the PTH1R (Taken from: Gensure et al., 2005). The amino acid 
sequence of the PTH1R is represented in single-letter amino acid code in open circles, with the predicted 
locations of the transmembrane domains. Black circles represent amino acid positions for N-linked glycosylation, 
N151, N161, N166 and N176. The inverted triangle indicates the cleavage site for the 23-amino acid signal 
sequence. 
 
The essential role of the PTH1R in endochondral bone development is underscored 
by the diseases such as Blomstrand’s lethal chondrodysplasia, Jansen’s 
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metaphyseal chondrodysplasia and enchondromatosis that are caused by mutations 
of this protein. Blomstrand’s lethal chondrodysplasia is caused by inactivating 
mutations in the PTH1R and characterized by prenatal lethality, premature and 
abnormal bone mineralization and ossification, and shortened limbs. Defects in tooth 
and mammary gland development were also noted as a result of the disease.  
Jansen’s metaphyseal chondrodysplasia is a rare autosomal dominant disorder 
characterized by short-limbed dwarfism secondary to severe abnormalities of the 
growth plate, and hypercalcemia. Three different heterozygous PTH1R mutations 
have been found to be responsible for the disease, which at cellular level lead to 
increases in basal cAMP. Enchondromas are common benign cartilage tumors of 
bone that can occur as solitary lesions or, in enchondromatosis, as multiple lesions. 
The heterozygous missense mutation identified in the PTH1R is responsible for the 
disorder (Schipani and Provot, 2003). 
 
 
 
Figure 1.9 PTH1R related diseases (Taken from: Schipani and Provot, 2003). The PTH1R-mutations identified 
are represented in patients with Jansen’s metaphyseal chondrodysplasia (in green), Blomstrand’s lethal 
chondrodysplasia (in red), and enchondromatosis (in yellow). 
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1.10 PTH and PTH1R interactions  
 
The general mechanism of PTH-PTH1R interaction has been deduced from an 
extensive series of studies including mutational analysis of both receptor and the 
ligand, use of ligand and/or receptors chimeras, as well photo-affinity cross-linking of 
ligands using photoreactive groups. These analyses suggested a simple “two-site 
model” of PTH-PTH1R interaction that involves two principal components: (1) an 
interaction between the C-terminal region of PTH (1–34) and the N-terminal domain 
of the receptor, which contributes predominantly to binding affinity; and (2) an 
interaction between the N-terminal domain of the ligand and the juxtamembrane 
region of the receptor comprised of the seven TMDs and their connecting intra- and 
extracellular loops, which contributes to receptor activation (Figure 1.8) (Gardella and 
Jüppner, 2001). 
 
     
 
 
Figure 1.10 Representation of the “two-site model” and photoaffinity cross-linking of PTH to the PTH1R 
(Taken from: Gensure et al., 2005). A: The interaction between PTH (1–34) and PTH1R involves two principal 
mechanistic components: (1) an interaction between the C-terminal domain of PTH(1–34), represented by 
residues 17–31, and the N-terminal extracellular domain of the receptor; and (2) an interaction between the N-
terminal domain of PTH, represented by residues 1–9, and the juxtamembrane region of the receptor. These two 
components of the interaction are postulated to contribute predominantly to binding affinity and receptor 
activation, respectively. B: A representation of the ligand-receptor through photoaffinity cross-linking is shown. 
The ligand is represented by the heavy filled bar. Segments and defined residues of contact in the receptor are 
indicated by open boxes and open circles, respectively. 
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1.11 PTH1R signaling 
 
Like all members of the Family B receptors, the PTH1R is coupled to signal effector 
molecules by heterotrimeric G proteins. Studies of the signaling  properties of clonal 
PTH1Rs expressed in heterologous cell lines, such as LLC-PK1, COS-7, or HEK 293 
kidney cells or CHO cells, have revealed that this single receptor type is capable of 
activating multiple signaling pathways, including adenylyl cyclase (AC), 
phospholipase C (PLC), phospholipase D (PLD), protein kinase C (PKC), and 
mitogen-activated protein kinase (MAPK) as well as of increasing the concentration 
of cytoplasmic Ca2+ (Hodsman et al., 2005). 
Following ligand binding, the PTH1R receptor can activate AC through the action of 
Gs (Gαs), and PLC through Gq (Gαq). Activated AC then stimulates the formation of 
3,5-adenosine monophosphate (cAMP), which in turn binds to the regulatory subunit 
of the enzyme PKA that releases the active catalytic subunit of the enzyme. On the 
other hand, activated PLC cleaves phosphatidylinositol (4,5)-bisphosphate (PIP2) 
into diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate (IP3). Subsequently, DAG 
activates PKC, and IP3 results in increased intracellular free Ca2+, which then 
promotes PKC translocation to the plasma membrane, and then activation by DAG 
(Schipani and Provot, 2003). 
 
PTH
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Figure 1.11 Gs (Gαs) and Gq (Gαq) transduction signaling pathways mediated by PTH1R (Taken from: 
Vilardaga et al., 2011). Up on ligand binding, PTH1R undergoes conformational changes, which induce its 
coupling with heterotrimeric G proteins (Gαβγ), and catalyzes the exchange of GDP for GTP on the a-subunit. 
This event triggers the dissociation the α unit from βγ dimer. GS activates AC leading to cAMP synthesis, which in 
turn activates PKA. Gq activates PLC, which cleaves PIP2 into DAG and IP3. DAG then activates PKC and IP3 
diffuses through the cytosol and activates IP3-gated Ca2+ channels in the membranes of the endoplasmic 
reticulum, causing the release of stored Ca2+ into the cytosol. The increase of cytosolic Ca2+ promotes PKC 
translocation to the plasma membrane, and then activation by DAG 
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The N-terminal truncated PTH peptides have been shown to activate PKC(s) in cells 
expressing endogenous or transfected recombinant PTH1Rs (Hodsman et al., 2005). 
On the other hand, studies of cells stably expressing the transfected PTH1R indicate 
that activation of PLC, which can lead to activation of PKC via generation of IP3 and 
DAG, requires the intact N terminus of the ligand (Takasu et al., 1999). These 
findings indicate that PTH1R can activate PKC(s) via a PLC-independent pathway, 
which is triggered by C-terminal ligand determinants, such as the residues 29–32 of 
PTH (Jouishomme et al., 1994). Indeed, PTH1R has been shown to activate PLD in 
the distal tubule cells of the kidney, whereas in proximal tubule cells it activated PLC 
(Friedman et al., 1999). Moreover, PTH (1–31) found unable to activate PKC in some 
systems, could nevertheless activate PKC in others (Hodsman et al., 2005). Thus, 
PTH1R might recognize different portions of the ligand as activation determinants for 
various phospholipases, depending on the cellular milieu (Whitfield et al., 2001). 
Moreover, PTH1R can also couple to other subtypes of G proteins, including Gi/o, 
which can inhibit adenylyl cyclase (Mahon et al., 2006), and Ga12/13 which activates 
phospholipase D and RhoA in osteosarcoma cells challenged with PTH (Singh et al., 
2005). 
As with most GPCRs, the activation of PTH1R leads to the phosphorylation of its 
cytoplasmic tail by G protein-coupled receptor kinases (GRKs), which then facilitate 
the association with ß-arrestin proteins, resulting in internalization and 
desensitization of the receptor (Malecz et al., 1998; Tawfeek et al., 2002). Mapping of 
the phosphorylation acceptor sites of the opossum PTH1R receptor using 
mutagenesis approaches revealed that six serine residues at positions 483, 485, 
486, 489, 495, and 498 are the sites for PTH-stimulated receptor phosphorylation, 
with the serine residue at position 489 being required for phosphorylation (Tawfeek et 
al., 2002). These residues correspond to S489, S491, S492, S495, S501, and S504 
of the rat PTH1R (Tawfeek et al., 2002). Albeit the importance of the phosphorylation 
in PTH1R receptor internalization, it appears to be cell line and/or receptor species 
dependent, whether receptor internalization requires phosphorylation or not (Malecz 
et al., 1998; Tawfeek et al., 2002). 
Arrestins are cytoplasmic proteins that bind to phosphorylated GPCRs and uncouple 
them from their cognate G proteins; thereby inactivate agonist-mediated G protein-
signaling (Wang et al., 2009). ß-Arrestin1 and ß-arrestin2 are widely expressed and 
play a pivotal role in regulation of the functions of many GPCRs, including the 
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PTH1R (Malecz et al., 1998; Ferrari et al., 1999). The interaction of ß-arrestin1 or ß-
arrestin2 with phosphorylated PTH1R is considered to be the likely mechanism of 
desensitization of the PTH1R-activated responses (Tawfeek et al., 2002). The ß-
arrestins serve as an adaptor molecule that targets activated and phosphorylated 
receptors to clathrin-coated pits (Ferguson et al., 1996; Goodman et al., 1996). 
 
 
 
Figure 1.12 Schematic overview of ß-Arrestins associated with many GPCRs (Taken from: Hall and 
Lefkowitz, 2002). ß-Arrestins interact with GPCRs, uncoupling them from G-protein and also acting as scaffold 
proteins to facilitate multiple interactions between GPCRs and cytoplasmic proteins. 
 
ß-Arrestin-PTH1R interactions lead to internalization (endocytosis) of the receptors 
which are either destined for degradation, resulting in receptor down-regulation (Tian 
et al., 1994; Ureña et al., 1994b; Massry and Smogorzewski, 1998), or recycled back 
to cell surface, leading to receptor resensitization (Chauvin et al., 2002). 
In addition, ß-arrestin-associated GPCRs may also initiate activation of MAPK 
pathways, independent of classical G protein-mediated second messenger systems 
(Hall and Lefkowitz, 2002). 
Na+/H+ exchange regulatory factor 1 (NHERF1), also known as ezrin-radixin-moesin-
binding phosphoprotein-50 (EBP50), is a cytoplasmic scaffolding protein that recruits 
various cellular receptors, ion transporters, and other proteins to the plasma 
membrane of epithelia and other cells (Wang et al., 2009). NHERF1 contains 2 
tandem N-terminal postsynaptic density 95/discs large/ zona occludens (PDZ) 
domains and a C-terminal merlin-ezrin-radixinmoesin (MERM) domain, through which 
it connects to actin bundles (Vilardaga et al., 2011). The PTHR harbors a C-terminal 
PDZ-like ligand domain that recognizes the PDZ1 domain of NHERF1 and the PDZ2 
domain of NHERF2, leading to PTH1R binding to these domains (Songyang et al., 
1997; Mahon et al., 2002; Mahon and Segre, 2004). NHERF1-null mice exhibited 
decreased phosphate reabsorption and elevated urinary phosphate excretion 
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because of reduced apical membrane tethering of the Npt2, the major hormone-
regulated sodium-phosphate cotransporter in the renal proximal tubule. Although 
serum calcium level was unchanged, increased excretion secondary to complexation 
with phosphate was observed. Moreover, reduced bone mineralization was found 
(Shenolikar et al., 2002). On the other hand, humans with NHERF1 mutations 
present with renal stones or bone demineralization (Karim et al., 2008). These 
findings underscore the primary role of NHERF1 in associating with and modulating 
PTH1R activity. 
NHERF1 promotes membrane retention of the PTH1R by inhibiting receptor 
endocytosis in several cell models both endogenously and exogenously expressing 
NHERF1, and for this effect both intact NHERF1 PDZ and MERM domains are 
essential (Wang et al., 2007). Moreover, the presence of NHERF1 suppresses 
PTH1R desensitization, and inhibiting NHERF1 restores receptor desensitization. 
This action appears to be due to preventing ß-arrestin2 from binding to the PTH1R, 
rather than altered receptor phosphorylation (Wang et al., 2009). Altogether, these 
actions may avert PTH resistance and downregulation of the PTH1R. In addition, 
NHERF2 can switch PTH1R signaling from AC to PLC by assembling a signaling 
complex that incorporates the PTHR, phospholipase C, and actin filaments (Mahon 
et al., 2002). 
 
 
1.12 PTH2R 
 
The PTH2R was first identified in 1995 through homology screening of a human brain 
cDNA library for other members of the class II GPCR family (Usdin et al., 1995). In 
humans, the PTH2 receptor is abundantly expressed in the brain, and found also in 
pancreas, testis, placenta, and lung. However, it was not detected on northern blots 
of human kidney mRNA or in bone-derived cell lines using RT-PCR (Hoare et al., 
1999). In rats, PTH2 receptor expression was found in a number of discrete nuclei in 
the brain, vasculature, heart, scattered endocrine cells, as well as in pancreas. In the 
rat kidney, it is expressed by an extremely small number of cells, which are near the 
vascular pole of glomeruli (Usdin et al., 1996). Besides rat and human, zebrafish has 
also been reported to possess PTH2R, in addition to its PTH1R and a novel PTH3R 
with high homology to the PTH1R (Gensure et al., 2004). 
Introduction 
 
 
28 
The PTH2R shows 70% amino acid sequence homology and 52% identity to PTH1R. 
The highest amino acid sequence homology resides within the transmembrane 
domain, while it is as low as 14% within the C-terminal domain (Bisello et al., 2004). 
Like the PTH1R, the PTH2R exhibits dual signaling in response to PTH (1–34), 
coupling strongly to stimulation of cAMP accumulation, and more weakly, in a cell-
specific manner to increases in intracellular calcium concentration (Usdin et al., 
2002). In rats, PTH was reported to weakly stimulate cAMP accumulation via the 
PTH2R receptor, while no considerable increase in intracellular calcium was 
detectable (Goold et al., 2001). 
The PTH2 receptor is also activated by tuberoinfundibular peptide of 39 residues 
(TIP39), a secreted peptide that is highly expressed in testis and, at lower levels, in 
various central nervous system cells, liver, and kidney (John et al., 2002). 
Conversely, in spite of a binding with moderate affinity, TIP 39 does not activate 
PTH1R (Hoare et al., 2000). 
TIP39 appears to be distantly related to PTH and PTHrP. In most assays, the first 34 
residues exhibit full activity, eight of which are identical in PTH and PTHrP from all 
species, and 11 are identical in mammalian peptides (Usdin, 2000). Residues at a 
number of additional positions are similar in size, charge, or hydrophobicity. TIP39 
contains three of the residues shared by all mammalian PTH and PTHrP species and 
another five residues that are present in most of these peptides. If similar residues 
are considered, the homology between TIP39 and PTH or PTHrP increases to almost 
50% (Usdin et al., 2000). 
 
 
 
Figure 1.13 Sequence alignment of bTIP39 with PTH and PTHrP (Taken from: Usdin, 2000). The currently 
known sequence of bTIP39 is aligned to the N-terminal residues of PTH and PTHrP from several species. 
Colored backgrounds are used to indicate residues that are identical in TIP39 and PTH or PTHrP, and colored 
letters are used to indicate residues with similar properties. Numbering refers to residues of mature PTH. 
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The activation of human PTH2R via TIP39 triggers both cAMP and intracellular Ca2+ 
signaling, but in a different manner other than via PTH (Bisello et al., 2004). While 
PTH stimulation of cAMP formation is brief and rapidly resensitizes, the response to 
TIP39 is sustained and remains partly desensitized for a prolonged period (Bisello et 
al., 2004). 
 
 
1.13 Aim of the study 
 
PTH1R has been exclusively studied in bone and kidney cells, however not yet in 
PDL cells.  In order to elevate the actions of PTH on PDL tissue regeneration, it is 
crucial to understand the physiology of PTH1R in PDL cells. In light of this, we aimed 
to clarify the characteristics of PTH1R in PDL cells and compare its characteristics to 
those of MG63 and HEK293 cells. 
The objectives of the present study were to: 
1. Detect and quantify PTH1R mRNA in PDL, MG63 and HEK293 cells 
2. Detect and localize PTH1R in PDL tissue in vivo as well as in cultured PDL cells 
3. Screen for a PTH1R-positive subpopulation in PDL, MG63 and HEK293cells 
4. Study the effect of dexamethason, 1,25-dihydroxyvitamin D3  and hPTH(1-34) on 
the expression level of PTH1R mRNA 
5. Reveal the signaling pathways involved in mediating the actions of hPTH (1-34) on 
PDL, MG63 and HEK293 cells 
6. Study the effect of intermittent hPTH (1-34) on human periodontal ligament cells 
transplanted into immunodeficient nude mice 
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2 MATERIALS AND METHODS 
2.1 Materials 
 
2.1.1 Equipment 
 
Equipment Supplier 
Autoclave Model Varioklav 25T H+P Labortechnik GmbH 
Axioskope 2 Microscope Carl Zeiss AG 
Centrifuge 5804 R Eppendorf 
Centrifuge 5415 R Eppendorf 
ChemiDoc™ XRS Bio-Rad Laboratories GmbH  
TCS SP2 Laser Scanning Spectral Confocal 
Microscope  
Leica Microsystems 
Dounce Homogenizer 1 ml Tissue Grinder Wheaton 
Flow Cytometer LSR II BD Bioscience 
Freezer (-20°C)  Liebherr Premium 
Freezer (-80°C)  Revco 
Fridge (4°C)  Liebherr Premium 
Fluorescence Microscope Axio Imager A1 Carl Zeiss AG 
FugeOne™ Microcentrifuge Starlab Groupe 
Haemocytometer Neubauer improved Brand GmbH + CO KG 
iCycler iQ™ Real-Time PCR Detection 
System 
Bio-Rad Laboratories GmbH 
Incubator (cell culture) Thermo Electronic 
Laboport Vacuum Pump KNF Neuberger GmbH 
Light Microscope Axiovert 25 Carl Zeiss AG 
Magnetic Stirrers MR 3001 Heidolph Instruments GmbH & Co. KG 
Microwave Siemens 
MS2 Minishaker IKA®-Werke GmbH & Co 
Multi-channel Pipettes Eppendorf 
Multipette® plus Eppendorf 
Nanodrop ND-1000 Peqlab Biotechnologie GmbH 
Paraffin Oven  Memmert GmbH & Co. KG 
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pH-meter 
Wissenschaftlich-Technische Werkstätten 
GmbH 
Pipetboy Eppendorf 
Pipetman Gilson 
PowerPac BasicTM Power Supply Bio-Rad Laboratories GmbH 
PowerPac HCTM Power Supply Bio-Rad Laboratories GmbH 
PowerWave X UV-Vis Plate Reader BioTek Instruments, Inc. 
Precision Weigher A 120 S Sartorius AG 
Mini-PROTEAN Tetra Cell, Bio-Rad Laboratories GmbH 
PTC-200 DNA Engine GMI 
Rocker PMR-30 Grant-bio Cambridgeshire 
Sonopuls HD 2070 Bandelin Electronic  GmbH & Co. KG  
Sterile Workbench HeraSafe Heraeus-Christ 
Sub-Cell® GT Agarose Gel Electrophoresis 
Systems 
Bio-Rad Laboratories GmbH 
Thermo Block Biometra Biomedizinische Analytik GmbH 
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad Laboratories GmbH 
Wallac WIZARD γ-counter  PerkinElmer  
Water Bath Memmert GmbH & Co. KG 
 
 
2.1.2 Plastic and glassware 
 
Item Supplier 
96-well Flat Bottom Transparent Microplate Greiner Bio-One GmbH 
Adhesive Plate Seals ABgene 
Blot Absorbent Filter Paper Bio-Rad Laboratories GmbH 
Cell Culture Dishes Greiner Bio-One GmbH 
Cell Culture Flasks (T-75/175 cm2) Greiner Bio-One GmbH 
Cell Culture Multiwell Plates (24,12 and 6-well plates) Greiner Bio-One GmbH 
Cover Slips Carl Roth GmbH + Co. KG 
Combitips Plus (2.5 mL/10 ml) Eppendorf 
Cryogenic Vials Nalge Nunc 
Filtertips Starlab 
Gelfoam® Sullivan-Schein 
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Luer Slip Syringes (2 mL/5 ml) Sartorious Stedim Biotech 
Microcentrifuge Tubes (1.5 mL, 2 ml) Eppendorf 
Microscope Cover Glasses (15 mm Ø) Marienfeld GmbH & Co. KG 
Microscope Slides (75x25x1.0 mm) Thermo Scientific 
Filter Papers (Folded Filters) Roth 
Parafilm Pechiney 
PCR Tubes (0.2 ml) Bio-Rad Laboratories GmbH 
Pipette Tips Sarsted AG & Co. 
Polypropylene Tubes (15 ml and 50 ml) Greiner Bio-One GmbH 
Polystyrene Round-Bottom Tubes (5 ml,12x75 mm) BD Bioscience 
Serological Pipettes (5 ml, 10 ml, 25 ml) Corning Incorporated 
Single-Use Filter Unit (0.2 µm) Sartorius Stedim Biotech 
Sterile Filters Millipore 
Test Tube Soda Glass VWR 
 
 
2.1.3 Chemicals 
 
Chemical Specification Supplier 
0.01% Poly L-Lysine  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
0,05 % (w/v) Trypsin 
-EDTA 
 
Invitrogen GmbH 
Karlsruhe, Germany 
 
Forene® 
 
2 vol% isoflurane 
Abbott GmbH & Co. KG 
Wiesbaden, Germany 
30% H2O2 Hydrogen peroxide 
Merck KGaA  
Darmstadt, Germany 
30% Acrylamid/Bis 
Solution 37.5:1 
(2.6% C) 
 
Bio-Rad Laboratories GmbH 
Munich, Germany 
Accutase  
PAA Laboratories GmbH 
Pasching, Austria 
Acetone  
Merck KGaA 
Darmstadt, Germany 
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Agarose Promega 
Madison, WI, USA 
Albumin Standard  
Pierce 
Rockford, USA 
Alizarin Red S 
3,4-Dihydroxy-9,10-dioxo-2-
anthracenesulfonic acid sodium salt 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Aprotinin  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
 
APS 
 
Ammonium persulfate 
 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
β-glycerolphosphate β-glycerolphosphate disodium salt 
Fulka Chemie GmbH 
Buchs, Switzerland 
β-Mercaptoethanol  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Boric acid  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Bromphenol Blue  
Roth GMBH 
Karlsruhe, Germany 
BSA Bovine Serum Albumin 
Roche Diagnostics GmbH 
Mannheim, Germany 
Citric Acid 
Monohydrate 
 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Cruz MarkerTM 
Molecular Weight 
Standards 
 
Santa Cruz Biotechnology 
CA, USA 
DAB Diaminobenzidine 
Pierce 
Rockford, USA 
DABCO 
Triethylendiamin, 1,4-
Diazabicyclo[2.2.2]octan 
Roth GMBH 
Karlsruhe, Germany 
DAPI 4',6-diamidino-2-phenylindole 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
DePeX  
Serva Electrophoresis GmbH 
Heidelberg, Germany 
Dexamethason  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
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DMEM 
Dulbecco's Modified Eagle Media 
DMEM (1X), liquid - with 
GlutaMAX™ I, Sodium Pyruvate 
Invitrogen GmbH 
Karlsruhe, Germany 
DMSO Dimethyl sulfoxide 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
DTT Dithiothreitol 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
EDTA 
Ethylenediamine tetraacetic acid 
Na2-salt 
CalBiochem 
San Diego, CA, USA 
EGTA 
Ethyleneglycol-O, O'-bis(2-
aminoethyl)-N, N, N', N'-tetraacetic 
Acid 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Ethanol  
Merck KGaA 
Darmstadt, Germany 
Ethidium bromide Ethidium Bromide (1% solution) Sigma-Aldrich Chemie GmbH 
Munich, Germany 
FBS Fetal Bovine Serum 
Invitrogen GmbH 
Karlsruhe, Germany 
GeneRuler™ 
DNA Ladder, Low 
Range 
 
MBI Fermentas GmbH 
 St. Leon-Rot, Germany 
Glycerol  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
H-8, Dihydrochloride 
(H8) 
PKA inhibitor 
Chamical formula: 
C12H15N3O2S · 2HCl 
Calbiochem, Germany 
HCl  
Merck KGaA 
Darmstadt, Germany 
HEPES Buffer 
(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) 
PromoCell GmbH 
Heidelberg, Germany 
Hoechst 33342 Dye  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
IBMX 3-isobutyl-1-methylxanthine 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
 
 
 
(Octylphenoxy)polyethoxyethanol, 
 
Sigma-Aldrich Chemie GmbH 
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IGEPAL® CA-630 Octylphenyl-polyethylene glycol Munich, Germany 
 
Isopropanol 
 
Merck KGaA 
Darmstadt, Germany 
iQTM SYBR® 
GreenSupermix 
 
Bio-Rad Laboratories GmbH 
Munich, Germany 
Leupeptin  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Light Green SF 
yellowish 
 
Chroma-Gesellschaft Schmidt 
GMBH & CO.  
Münster, Germany 
Mayer's 
haematoxylin 
 
Merck Eurolab AG 
Dietikon, Switzerland 
Methanol  
Merck KGaA 
Darmstadt, Germany 
Mowiol 4-88  
Roth GMBH 
Karlsruhe, Germany 
MOPS 
3-(N-Morpholino)propanesulfonic 
Acid Sodium Salt 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
NaOH  
Merck KGaA 
Darmstadt, Germany 
Nitrocellulose-
Membran 
 
Bio-Rad Laboratories GmbH 
Munich, Germany 
Non-Fat Dry Milk  
Bio-Rad Laboratories GmbH 
Munich, Germany 
Normal Goat Serum  
Dako 
Glostrup, Denmark 
PBS 
Dulbecco’s PBS (1x) without Ca & 
Mg 
(Phosphate buffered saline) 
PAA Laboratories GmbH 
Pasching, Austria 
PBS Tablets 
 
Phosphate Buffered Saline Tablets 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Penicillin / 
Streptomycin 
Penicillin (10000 U/ml) / 
Streptomycin (10 mg/ml) 
PAA Laboratories GmbH 
Pasching, Austria 
Peroxidase 
Substrate Buffer 
 
Thermo Scientific 
Rockford, USA 
Plasmocin™ Plasmocin Prophylactic CAYLA 
Materials and Methods 
 
 
36 
Toulouse, France 
PFA Paraformaldehyde 
Merck KGaA 
Darmstadt, Germany 
PMSF Phenylmethanesulphonyl Fluoride 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Ponceau S solution 
for electrophoresis 
(0.2 %) 
 
Sevra Electrophoresis GmbH 
Heidelberg, Germany 
Precision Plus 
Protein 
Kaleidoscope 
Standards 
 
Bio-Rad Laboratories GmbH 
Munich, Germany 
Protease Inhibitor 
Cocktail Tablets 
 
Roche Diagnostics GmbH 
Mannheim, Germany 
PVDF-membrane Polyvinylidene fluoride membrane 
Bio-Rad Laboratories GmbH 
Munich, Germany 
RestoreTM Western 
Blot Stripping Buffer 
 
Bio-Rad Laboratories GmbH 
Munich, Germany 
RIPA 
Radioimmunoprecipitation assay 
Composition: 25 mM Tris-HCl pH 
7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
 
RO-32-0432 
PKC inhibitor  
Chemical formula: C28H28N4O2 · HCl 
Calbiochem, Germany 
Sodium Azide  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Tri-Sodium Citrate 
Dihydrate  
 
Merck KGaA 
Darmstadt, Germany 
SDS Sodium Dodecyl Sulfate 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Sodium Vanadate  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
TBS 
Tris Buffered Saline (x10) 
20 mM Tris, 500mM NaCl, PH 7.4 
Bio-Rad Laboratories GmbH 
Munich, Germany 
 
TEMED 
 
N,N,N',N'-Tetramethylethylendiamin 
 
Bio-Rad Laboratories GmbH 
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Munich, Germany 
Tris Tris-[hydroxymethyl]amino-methane MP Biomedicals 
Illkirch Cedex, France 
0.5M Tris-HCl 
(PH6.8)  
Bio-Rad Laboratories GmbH 
Munich, Germany 
1.5M Tris-HCl 
(PH8.8)  
Bio-Rad Laboratories GmbH 
Munich, Germany 
Triton X-100  
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Tween 20 
Polyoxyethylene (20) Sorbitan 
Monolaurate 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Vitamin C Ascorbic acid 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
Vitamin D3 
1,25-Hydroxyvitamin D3 
Monohydrate 
Sigma-Aldrich Chemie GmbH 
Munich, Germany 
XEM-200 Xylol Substitute 
Vogel GmbH 
Giessen, Germany 
 
 
2.1.4 Kits 
 
Kit Supplier 
cyclic AMP (Direct) Enzyme Immunometric 
Assay (EIA) Kit 
Enzo Life Sciences GmbH 
Lörrach, Germany 
Fix&Perm Kit 
An Der Grub Bio Research GmbH 
Kaumberg, Austria 
Immuno Pure Metal Enhanced DAB 
Substrate Kit 
Pierce 
Rockford, USA 
iScript TM Select cDNA Synthese Kit 
Bio-Rad Laboratories GmbH 
Munich, Germany 
LIVE/DEAD® Fixable Dead Cell Stain Kit 
Invitrogen GmbH 
Karlsruhe, Germany 
Micro BCA Protein Assay Reagent Kit 
Pierce 
Rockford, USA 
Osteoprotegerin (OPG) ELISA Kit Immundiagnostik AG 
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Bensheim, Germany 
Osteocalcin (Mouse) ELISA Kit DRG Instruments GmbH 
Marburg, Germany 
PKC Kinase Activity Assay Kit 
Enzo Life Sciences GmbH 
Lörrach, Germany 
RNeasy Mini Kit 
Qiagen 
Hilden, Germany 
SuperSignal® West Pico Chemiluminescent 
Substrate Kits 
Pierce 
Rockford, USA 
SuperSignal West Femto Chemiluminescent 
Substrate Kits 
Pierce 
Rockford, USA 
 
 
2.1.5 Peptides 
  
Peptide Supplier 
Parathyroid Hormone (Human, 1-34) PeptaNova GmbH 
Sandhausen, Germany 
Parathyroid Hormone 1-34 (Human) [125I-
Nle8,18, Tyr34], 10 µCi 
Specific Activity: 81.4 TBq/mmol 
2200 Ci/mmol 
PerkinElmer Life Sciences, Inc. 
 Boston, USA  
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2.1.6 Antibodies 
 
Primary Antibodies 
Antibody Supplier Origin Concentration/Dilution 
ß-Actin  (AC-15)  Mouse 
Anti-human Monoclonal 
Antibody 
Santa Cruz 
Biotechnology 
CA, USA 
Mouse 
100 µg/mL 
 WB: 1:2000 
Parathyroid Hormone 
Receptor 1 
Mouse Anti-human 
Monoclonal Antibody 
[3D1.1] 
Santa Cruz 
Biotechnology 
CA, USA 
Mouse 
Epitope: 
Amino acids 
155-169 
200 µg/mL 
IF: 1:50 
ICC:1:50 
IHC:1:20 
FC: 5µl for 1x106 cells 
Parathyroid Hormone 
Receptor1 
Mouse Anti-human 
Monoclonal antibody 
[3D1.1] 
Abcam 
Cambridge, UK 
Mouse 
Epitope: 
Amino acids 
146-169 
200 µg/mL 
IF: 1:50 
ICC:1:50 
IHC:1:20 
FC: 5µl for 1x106 cells 
Normal Mouse IgG 
Santa Cruz 
Biotechnology 
CA, USA 
Mouse 
 
200 µg/0.5mL 
FC: 5µl for 1x106 cells 
Alkaline Phosphatase 
Rabbit Anti-human 
polyclonal antibody 
Quartett GmbH  
Berlin, Germany 
Rabbit Ready to use 
Osteocalcin Rabbit Anti-
human polyclonal 
antibody  
Abcam 
Cambridge, UK 
Rabbit IHC:1:50 
Osteopontin Rabbit Anti-
human polyclonal 
antibody 
IBL International 
GmbH 
Hamburg, 
Germany 
Rabbit IHC:1:100 
Anti-Nuclei, clone 235-1 
Monoclonal Antibody 
Millipore GmbH 
Schwalbach/Ts., 
Germany 
Mouse IHC:1:20 
Goat polyclonal 
Secondary Antibody to 
Mouse IgG - Fc 
Abcam 
Cambridge, UK 
Goat IHC:1:200 
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Secondary Antibodies 
Antibody Supplier Origin Concentration/Dilution  
Goat Anti-Mouse 
IgG HRP 
Santa Cruz 
Biotechnology 
CA, USA 
Goat 
200 µg/0.5mL 
WB: 1:1000 
Goat Anti-mous 
Dako EnVision®+ 
System-HRP (DAB) 
Dako GmbH 
Hamburg, Germany 
Goat Ready to use  
Goat Anti-rabit 
Dako EnVision®+ 
System-HRP (DAB) 
Dako GmbH 
Hamburg, Germany 
Goat Ready to use 
Texas Red®-X 
Goat Anti-mouse 
IgG (H+L) 
Invitrogen GmbH 
Karlsruhe, Germany 
Goat 
2 mg/mL 
IF: 1:500 
Alexa Fluor® 647 
goat anti-mouse 
IgG (H+L) highly 
cross-adsorbed 
Invitrogen GmbH 
Karlsruhe, Germany 
Goat 
 
2 mg/mL 
FC: 1:250 
 
 
IF: Immunofluorescence ; ICC: Immunocytochemistry ; IHC: Immunohistochemistry ; 
WB: Western blotting; FC: Flow cytometry 
 
 
2.1.7 Oligonucleotides 
 
Gene Sequence (5’→3’) 
β-actin CATGGATGATGATATCGCCGCG           (for) 
ACATGATCTGGGTCATCTTCTCG          (rev) 
 ALP GTGGAAGGAGGCAGAATTGACCA        (for) 
AGGCCCATTGCCATACAGGATGG        (rev) 
 PTH1R GGAATCAGACAAGGGATGGACATC      (for) 
TCGGTAGGCATGGCCTTTGTGATT       (rev) 
 TGF-ß1 GAGCCCTGGACACCAACTAT                 (for) 
GACCTTGCTGTACTGCGTGT                 (rev) 
Ocal ATGAGAGCCCTCACACTCCTCG            (for) 
GTCAGCCAACTCGTCACAGTCC            (rev) 
BMP-4 CCTGGTAACCGAATGCTGATGGTCG    (for) 
AGACTGAAGCCGGTAAAGATCCCGC    (rev) 
BMPR-1a GCTTCATGGCACTGGGATGAAATCA     (for) 
CGACAACATTCTATTGTCCGGCGTA     (rev) 
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BMPR-2 TGCGGCTGCTTCGCAGAATCAAGAA    (for) 
CCATTCTGAATTGAGGGAGGAGTGG    (rev) 
Cyclin D1 AGCTCCTGTGCTGCGAAGTGGAA         (for) 
AGTGTTCAATGAAATCGTGCGGGG       (rev) 
BMPR-1b AGCAAGCCTGCCATAAGTGAGAAGC    (for) 
ACAGGCAACCCAGAGTCATCCTCTT     (rev) 
Integrin A6 GAGATGGAGAAGTTGGAGGTGCA         (for) 
CGATCAAGGTCCATGTTTCCAGCA        (rev) 
Integrin B4 CTATGAGGCTGATGGCGCCAAC            (for) 
GCAGCTCCACGATGTTGGACGA            (rev) 
 BMP-2 CTCGGCCTTGCCCGACACTGA              (for) 
TAAGAAGCACGCGGGGACACGT           (rev) 
 
 
 
2.1.8 Software 
 
GraphPad PRISM™ 4.0    GraphPad Software, Inc. 
San Diego, CA, USA 
FlowJo 7.2.5     Treestar 
Ashland, OR, USA 
 
Quantity One software   Bio-Rad Laboratories GmbH,  
Munich, Germany 
KC4 software   BioTek Instruments, Inc. 
Bad Friedrichshall, Germany 
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2.2 Methods 
 
2.2.1 Primary cells  
 
PDL Cells 
Throught out the whole project, fifth passage periodontal ligament (PDL) cells of six 
different human donors (12-14 years of age) that showed no clinical signs of 
periodontitis were studied. The PDL cells were isolated from the middle third of the 
roots of premolars from teeth that had been extracted for orthodontic reasons, with 
informed parental consent and following an approved protocol of the ethics 
committee of the University of Bonn (Reference number 029\08). 
After extraction, the teeth were washed with PBS and the middle third of the 
periodontal ligament was scraped off using a sterile scalpel (Figure 2.1). The apical 
and gingival parts of the periodontal ligament were discarded to avoid contamination 
with cell types other than PDL fibroblasts. The scraped pieces were cultured as 
described in section 2.2.3 Cell Culture. The cells migrating out of the explants were 
splitted after reaching confluence. 
 
     
 
Figure 2.1 Isolation of PDL cells.  PDL cells were mechanically isolated from an extracted tooth and cultured in 
Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% FBS and 1% of an antibiotics mixture of 
Penicillin / Streptomycin. The cell culture was maintained at 37°C in an atmosphere of 100% humidity, 95% air, 
and 5% CO2. 
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2.2.2 Cell lines  
 
MG63 Cell line 
MG63 cells, a human osteosarcoma cell line, were purchased from European 
Collections of Cell Cultures (ECACC) (Now: Health Protection Agency). The cells 
were originally obtained from American Type Culture Collection (ATCC) with catalog 
number CRL-1427TM. 
 
HEK293 Cell line 
Human Embryonic Kidney 293 cells, referred to as HEK293 cells were generated by 
transformation of human embryonic kidney cell cultures. In this study, HEK293 T cell 
line was used which was a kindly gift from Prof. Dr. Sven Burgdorf (Life & Medical 
Sciences Institute, Bonn, Germany). HEK293T is an important variant of HEK293 cell 
line and contains the SV40 Large T-antigen, which allows for substantial replication 
of transfected plasmids containing the SV40 promoter by the T-antigen. 
 
 
2.2.3 Cell Culture 
 
Thawing of cells 
The cell lines frozen in cryovials were immersed immediately into a 37°C water bath 
until they were completely thawed and the contents were transferred to T-75 flasks 
containing culture medium. The cells were allowed to attach for 24 h prior to a 
change of the medium. 
 
Cell culture conditions 
PDL, MG63 and HEK293 cells were cultured in Dulbecco's Modified Eagle Media 
(DMEM) supplemented with 10% FBS and 1% of an antibiotics mixture of Penicillin / 
Streptomycin. The cell culture was maintained at 37°C in an atmosphere of 100% 
humidity, 95% air, and 5% CO2.  For different purposes, cells were seeded 
respectively in 10 cm petri dishes, T-75, 175 cm2 flasks, as well as 6-well, 12-well, 
24-well plates. 
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Splitting of cells 
Cells were trypsinized upon reaching a confluency of about 60-70%. For seeding and 
passaging, the medium was removed and the cells were washed once with PBS. 
Then, Trypsin / EDTA (2 ml for 10 cm dishes/T-75 flask, 500 µl for 6-well plates and 
200 µl for 24-well plates) was added and incubated at 37°C for 3-5 min. After slightly 
rocking, detached cells were resuspended in a three fold excess of growth media and 
separated to single cell level via pipetting in a sterile 50 ml Falcon tube. The cell 
suspension was then centrifuged at 500xg for 5 min and the supernatant was 
discarded carefully without disturbing the cell pellet. The cells were then counted with 
a hemocytometer (Hemocytometer Neubauer) according to manufacturer’s 
instructions after resupension in 1 ml PBS. Appropriate numbers of resuspended 
cells were used for seeding new dishes and plates. Cell growth was observed with an 
inverted microscope, Axiovert 25. 
 
Cell storage 
Cells were detached using Trypsin/EDTA solution, the contents was transferred into 
a 50 ml Falcon tube and centrifuged at 500xg for 5 min to remove the medium. The 
pellet was resuspended in the cell freezing media and dispensed into cryovials 
(1x106cells/ml). The cryovials were allowed to freeze at -20°C for 2 h and then at -
80°C overnight. The cells were transferred to liqui d nitrogen for long-term storage. 
 
Cell counting  
The cells were counted with a Neubauer Hemocytometer. 0.2 ml of the cell 
suspension was diluted in 0.2 ml of 0.1% Trypan blue in PBS (w/v). Subsequently, 10 
µl of well resuspended cell suspension was pipetted into Neubauer counting chamber 
and counted microscopically. Trypan blue is a dye that stains dead cells, while the 
live cells remain unstained. The total number of cells in the four marked squares 
(Figure 2.2) was counted. 
A hemocytometer consists of 2 chambers, each of which is divided into 9 squares 
with a surface area of 1.0 mm2. A cover glass is supported 0.1 mm over these 
squares so that the total volume over each square is 0.1 mm3 (1.0 mm2 x 0.1 mm) or 
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10-4 cm3. Since 1 ml is equivalent to 1 cm3, the cell concentration per ml is the 
average count per square x dilution factor x 104. 
  
      
                   
Figure 2.2 Counting cells with Neubauer hemocytometer. Cells stained with trypan blue were loaded onto the 
hemocytometer and the total number of cells in the four 4 squares (pointed in the figure) was counted. The cell 
number was calculated according to the following formula. Cells per ml = the average count per square x the 
dilution factor x 104. 
 
 
2.2.4 Stimulation of PDL cells  
 
For the functional studies, PDL cells of fifth passage from three donors were seeded 
in 24-well plates and cultured to confluency in DMEM supplemented with 10% FBS 
and 1% of an antibiotics mixture of Pen/Strep at 37°C with 5% CO 2.  For each donor, 
at any given concentration of the stimulant, duplicate test series were carried out. 
 
hPTH (1-34) 
Confluent PDL cells were treated with 10−8 M human PTH (1-34) [hPTH (1-34)] for 1, 
24 and 48 h within three incubation cycles of 48 h each. For the remaining time, 
experimental media was replaced by media without hPTH (1-34) to mimic an 
intermittent treatment effect. The hPTH (1-34) was diluted in culture medium from a 
10−4 M stock solution that was prepared in ddH2O according to the manufacturer’ 
instructions. 
 
 
 
Count the cells within  
the 4 corner squares 
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Dexamethason 
After reaching confluence, the PDL cells were treated with 10−6 M dexamethason for 
1, 2, 3, 4, 6, 14, 21 d. Dexamethason was prepared by dissolving the powder in 
100% ethanol. For control purposes, cells were treated with the same amount of 
solvent as in the stimulated group. 
 
Vitamin D3 
10−7 M 1,25-dihydroxyvitamin D3, dissolved in 100% ethanol, was applied to the 
confluent PDL cells for 2, 4 and 6 d, respectively. Ethanol-treated cultures served as 
controls. 
 
Inhibition of PKA and PKC 
Confluent PDL cells were cultured in the presence of 10−12 M hPTH (1–34) for 1 h 
and 24 h within a 48 h incubation cycle. For the remaining time, experimental media 
were replaced by tissue culture media without hPTH (1–34). These cycles were 
carried out three times resulting in a total experimental period of 6 days to mimic the 
anabolic effects of intermittent PTH. 1 h prior to treatment with intermittent 10-12 M 
hPTH (1–34) or vehicle, either the PKC inhibitor RO-32-0432 (10-6 M) or the PKA 
inhibitor H8 (10-5 M) was added to the cultures and remained in the medium for the 
entire experimental period. Vehicle-treated cultures for each treatment group and 
cells cultured in the presence of the respective inhibitors but without hPTH (1–34) 
served as controls. At harvest, osteoprotegerin production was determined as 
described in section 2.2.16. 
 
 
2.2.5 RNA isolation 
 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
following the protocol provided by the manufacturer. The RNA concentration was 
determined by a NanoDrop ND-1000 spectrophotometer. The total RNA was stored 
at -80 °C. 
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2.2.6 cDNA synthesis 
 
1 ug total RNA was reverse transcribed using the iScript TM Selected cDNA Synthese 
kit with oligo(dT)-primers. Buffer and cycling conditions were set according to the 
manufacturer’s instructions: 
 
 
Reaction set up 
Component                   Volume per reaction 
Nuclease-free water                                                Variable 
5x iScript select reaction mix                                   4 µl 
Oligo(dT)20 primer                                                    2 µl 
RNA sample (1 µg total RNA)                                  Variable 
iScript reverse transcriptase                                     1 µl 
------------------                                                  --------------------------- 
Total                                                                          20 µl 
 
The reaction mix was mixed gently and incubated for 90 min at 42°C, followed by a 5 
min incubation step at 85°C to inactivate reverse t ranscriptase. The synthesized 
cDNA was stored at -20°C. 
 
 
2.2.7 Real Time PCR 
 
Differential gene expression was analyzed by real-time PCR with the iCycler iQ™ 
using SYBR® Green as fluorophore. Real time PCR is a technique used to monitor 
the progress of a PCR reaction in real time. At the same time, a relatively small 
amount of PCR product can be quantified by recording the amount of fluorescence 
emission at each cycle produced by a reporter molecule, which increases as the 
reaction proceeds. By plotting the detected fluorescence against the cycle number on 
a linear scale, the amount of DNA present during the exponential phase of the 
reaction can be determined. The cycle at which the fluorescence from a sample 
crosses the threshold is called the cycle threshold, Ct (Figure 2.3). The lower a Ct 
value, the more copies are present in the specific sample. In general, the threshold is 
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set by the user and should be in the linear part of the reaction, but not more than half 
way up the linear part. 
 
Figure 2.3 Real time PCR Graph. In this Graph, the detected fluorescence is plotted against the cycle number 
on a linear scale. In real time PCR, the instrument measures the cycle number at which the increase in 
fluorescence (and therefore cDNA) is exponential. The exponential phase because it provides the most precise 
and accurate data for quantitation. The Threshold line (orange line) is the level of detection at which a reaction 
reaches a fluorescent intensity above background. The PCR cycle at which the fluorescence crosses the 
threshold is termed as Ct (red circles). 
SYBR® Green binds to the minor groove of the DNA double helix, but not to single 
stranded-DNA molecules, which leads to a substantial enhancement in fluorescence 
based on a change of the absorption characteristics upon DNA-binding. Since it does 
not distinguish between specific and nonspecific PCR products resulting from 
contamination, mispriming and primer-dimer artifacts, an important means of quality 
control is to check that all samples have a similar melting temperature. After real time 
PCR amplification, the cycler was programmed to do a melt curve analysis depicting 
the fluorescence change rate over time as a function of temperature. The melting 
temperature of a DNA double helix depends on its base composition. All PCR 
products for a particular primer pair should have the same melting temperature, 
unless there are nonspecific products. A negative control without template was 
performed to show the lack of intrinsic fluorescence. 
The relative gene expression was assessed by the method developed by M.W Pfaffl 
(Pfaffl, 2001) as shown below (Equation 2.1), with ß-actin serving as the endogenous 
reference gene. 
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Equation 2.1 The mathematical model of relative expression ratio in real-time PCR. The ratio of a target 
gene is expressed in a sample versus a control in comparison to a reference gene. Etarget is the real-time PCR 
efficiency of target gene transcript; Eref is the real-time PCR efficiency of a reference gene transcript; ∆CPtarget is 
the CP deviation of control – sample of the target gene transcript; ∆CPref = CP deviation of control – sample of 
reference gene transcript. The reference gene should be a stable and secure unregulated transcript, e.g. a house- 
keeping gene transcript. For the calculation of Ratio, the individual real-time PCR efficiencies and the CP 
deviation (∆CP) of the investigated transcripts must be known. Real-time PCR efficiencies were calculated, 
according to the formula: E = 10[–1/slope]. 
All primers used, unless specified otherwise, were self-designed and evaluated for 
specificity using a web-based primer design and analysis tool (NCBI/Primer-Blast 
program, http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The efficiencies of all the 
primers were determined by dilution series and the optimal annealing temperature 
was confirmed by performing a gradient PCR.  Finally the end-point PCR products 
were checked on the 2% agarose gel to assure the expected amplicon size and the 
specificity of the PCR. 
The real time PCR was performed using the iQTM SYBR® Green Supermix (Bio-Rad 
Laboratories GmbH, Munich, Germany) according to the manufacturer’s instructions 
as follows: 
Reaction set up 
Component    Volume per reaction 
iQTM SYBR® GreenSupermix   12.5 µl 
Primer mix                                                    0.125 µl 
cDNA template                                             1 µl 
Sterile water                                                 11.75 µl 
-----------------                                   --------------------------- 
Total                                                              25 µl 
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2.2.8 Agarose Gel Electrophoresis of DNA 
 
The separation of DNA fragments was performed using submerged horizontal 2% 
agarose gels. Agarose powder was dissolved in TBE-buffer and boiled in a 
commercial microwave until a clear, transparent solution was obtained. Ethidium 
bromide was added to a final concentration of 0.4 µg/ml. The Mini-Sub Cell GT 
system was assembled following the manufacturer’s instructions. Subsequently, the 
agarose gel was poured into the electrophoresis chamber and allowed to solidify. 
Before loading samples onto the gel, the gel was covered with the electrophoresis 
buffer (1xTBE). The DNA moves towards the anode due to the negatively charged 
phosphate groups. Runs were performed under constant voltage of 60 V to 120 V 
and migration of nucleic acids was monitored. Gels were documented using the 
ChemiDoc™ XRS. The size of the DNA fragments was assessed by comparing their 
size to that of the GeneRuler™ DNA Ladder, Low Range. 
 
TBE-buffer (10x) DNA loading buffer  (10x) 
Tris base 890mM Glycerol 24% (v/v) 
Boric acid 890mM Bromophenol blue spatula tip 
EDTA, pH 8.0 20mM   
 
Table 2.1 Composition of buffers used for agarose gel electrophoresis. 
 
 
2.2.9 Immunocytohistochemistry  
 
Tissue staining 
For immunohistochemical tissue staining, formalin-fixed and paraffin-embedded 
tissue sections were used. The tissue sections were deparaffinized in xylene, dipped 
in decreasing concentrations of alcohol, and then rehydrated in water. Endogenous 
peroxidase activity was blocked by incubating the slides in a solution of 700 µl H2O2 
(30%) in 70 ml methanol for 10 min. To unmask the antigen, the sections were 
immersed in 10 mM citrate buffer (pH 9.0) and heated to 80°C in an ovan for 30 min. 
Blocking was done with 4 % BSA/TBS for 30 min at RT. After an overnight incubation 
with primary anti-PTH1R mouse monoclonal antibody diluted 1:50 in 1% BSA/TBS in 
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a humidified chamber at 4°C, the slides were washed  with TBS buffer for 10 min. 
Then, the HRP-conjugated secondary antibody (Dako, Hamburg, Germany) was 
applied to each specimen and incubated for 1 h at RT. After washing 10 min with 
TBS, freshly prepared DAB substrate was added to the slides until a suitable staining 
developed. The sections were rinsed with water and counterstained with Mayer's 
haematoxylin. The sections were rinsed again in water and dehydrated by rinsing the 
sections in 100% ethanol and XEM-200, respectively twice for 2 min each. The 
specimens were mounted with DePex and examined under an Axioskope 2 
Microscope. Negative controls were included in each experiment to verify antibody 
specificity, by omitting the primary antibody. 
 
Immunofluorescence staining of cells 
PDL, MG63 and HEK293 cells were cultured on glass coverslips (Marienfeld GmbH & 
Co. KG, Lauda - Kölnigshofen, Germany) placed in 12-well plates and allowed to 
grow until 60-70% confluence at 37°C with 5% CO 2. After removal of the culture 
medium, cells were washed once with PBS and fixed with 500µl acetone for 10 min 
at -20°C. The acetone was removed and the coverslip s were washed with PBS prior 
to the antigen retrieval step. 500 µl of 10 mM citrate buffer (PH 9.0) was added to 
each well and the plate was heated for 30 min at 80°C in an incubator, followed by a 
washing step with PBS. Blocking was performed by incubating the cells with 1% BSA 
in PBS for 30 min at RT. Subsequently, the anti-PTH1R mouse monoclonal primary 
antibody (Abcam, Cambridge, UK) which was diluted 1:50 in 1% BSA, was applied to 
the specimens at 4°C over night. Afterwards, the ce lls were washed for three times 
with PBS for 5 min each, and subjected to the TexRed-conjugated secondary goat 
anti-mouse antibody (Invitrogen GmbH, Karlsruhe, Germany) that was diluted 1:500 
in 1% BSA for 1 h at RT.  After washing with PBS three times for 5 min each, cell 
nuclei were counter stained with DAPI diluted 1:5000 in ddH2O from the stock 
solution (1 mg/ml). Prior to mounting with 15 µl Mowiol, the specimens were washed 
with PBS and rinsined briefly in ddH2O. Stained cells were then examined with a 
Leica TCS SP2 Laser Scanning Spectral Confocal Microscope. Negative controls 
were included in each experiment to verify antibody specificity, by omitting the 
primary antibody. 
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Conventional DAB staining of cells  
PDL, MG63 and HEK293 cells were cultured on glass cover slips (Carl Roth GmbH + 
Co. KG, Karlsruhe, Germany) to 60-70% confluency at 37°C with 5% CO 2. The cells 
were then fixed with 4% paraformaldehyde (PFA) in PBS for 10 min at RT after 
washing with PBS. The endogenous peroxidase and non-specific antibody binding 
sites were blocked by incubating the specimen in 30% H2O2 in methanol for 10 min 
and 10% normal goat serum 30 min at RT, respectively. After each step, the 
specimens were washed with TBS for 10 min. Then the cells were exposed for 1 h to 
the primary anti-PTH1R mouse monoclonal antibody (Abcam, Cambridge, UK) 
diluted 1:50 in 1% BSA/TBS. After three washes in TBS, each for 5 min, a 
peroxidase coupled secondary anti-mouse antibody (DAKO EnVision+ System- HRP 
Labelled Polymer, DAKO, Denmark) was applied for 1 h at RT. Excessive antibody 
was removed by washing the cells three times with TBS (each time 5 min). The 
freshly prepared 3,3'-diaminobenzidine substrate (DAB) diluted 1:10 in Peroxidise 
Substrate Buffer was added and incubated for 10 min at RT. The cells were then 
counterstained 5 sec in Mayer's haematoxylin solution diluted 1:5 in ddH2O. After 
washing thoroughly with water, the specimens were rinsed two times each 2 min 
respectively in 100% ethanol and XEM-200 (Xylol substitute). The sections were 
mounted with DePeX and examined under an Axioskope 2 Microscope. Negative 
controls were included in each experiment to verify antibody specificity, by omitting 
the primary antibody. 
 
 
2.2.10 Flow cytometry analysis 
 
The proportion of the PTH1R-positive subpopulations in PDL, MG63 and HEK293 
cells were quantified by flow cytometry analysis. For this purpose, cells were seeded 
in T-75 flasks and allowed to reach confluency. In order to conserve the cell surface 
receptor proteins, accutase was applied for cell detachment. Accordingly, after 
removing the culture medium and washing with PBS, cells were exposed to 5 ml of 
accutase for 10 min at 37°C and centrifuged at 500x g for 5 min. The cell pellet was 
resuspended in 1 ml PBS and cell number was determined with a Neubauer 
Hemocytometer. 
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Cell surface staining 
Approximately 1x106 cells were incubated with 5 µl of primary mouse monoclonal 
antibody raised against PTH1R (Abcam, Cambridge, UK) in 100 µl ice cold PBS with 
1% BSA on ice for 30 min. After three washing steps with cell sorting buffer (1% 
BSA/PBS), cells were incubated on ice for 30 min with Alexa Fluor 647-tagged goat 
anti-mouse secondary antibody (Invitrogen GmbH, Karlsruhe, Germany) which was 
diluted 1:250 in 1% BSA/PBS.  
Because of the high autofluorescence in the short wave length region, the dead 
portion of PDL cells was excluded via the LIVE/DEAD® Fixable Dead Cell Stain Kit 
with near-IR (infra red) dye according to the instructions of the manufacturer. After 
removing the excessive antibody via centrifugation at 500xg at 4°C, the pellet was 
washed again with the cell sorting buffer and resuspended in 1 ml ice cold PBS. 1 µl 
of the freshly reconstituted fluorescent reactive dye was then added to the cell 
suspension and incubated on ice for 30 min in the dark. The cells were washed once 
and resuspended in 500 µl ice cold cell sorting buffer for further analysis. 
The dead cell discrimination of MG63 and HEK293 cells was achieved by Hoechst 
33342 dye. After washing off the excessive antibody, the pellet was resuspended in 
500 µl Hoechst 33342 dye which was diluted 1:20000 in cell sorting buffer from the 
stock solution. The cells were kept in the Hoechst 33342 dye solution on ice in the 
dark until the scheduled time for analysis. The whole procedure was carried out on 
ice in order to minimize cell surface receptor internalization. 
 
Intracellular staining 
After removal of PBS, about 1x106 cells were fixed with reagent A for 15 min and 
subsequently permeabilized with reagent B for 15 min using the Fix&Perm kit. In 
each step cells were exposed to the corresponding reagent for15 min followed by a 
washing step with cell sorting buffer. The same dilution of primary and secondary 
antibody as stated above was applied for 1 h at RT. Finally, the labeled cells were 
resuspended in 500 µl cell sorting buffer and kept in the dark until the scheduled time 
for analysis. 
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Flow cytometry analysis 
The quantitation of the PTH1R-positive proportion of the cells was performed using a 
LSRII flow cytometer. Before acquiring data, the compensation of Alexa Fluor 647 
against near-IR and vice versa was adjusted and the specificity of the staining was 
ensured with a mouse IgG antibody as negative control. The acquired data was 
analyzed by FlowJo 7.2.5. 
 
 
2.2.11 Competitive radioactive binding assay 
 
Performing the experiment 
In order to assess the binding affinity of PTH1R to hPTH (1-34) and the PTH1R 
density, homologous competitive radioactive binding experiments were performed 
using hPTH (1-34) as the cold ligand and its radioactive labeled homologue, human 
[125I]-[Nle8,18, Tyr34]-PTH (1-34) (PerkinElmer Life Sciences, Inc., Boston, USA), as 
the hot ligand. 
For this assay, PDL, MG63 and HEK293 cells were seeded in 24-well plates and 
grown to confluence at 37°C with 5% CO 2. Prior to the assay, the cells were 
subjected to whole cell binding buffer (DMEM supplemented with 5 % FBS and 0.5 % 
BSA) for 1 h. After removing the whole cell binding buffer, approximately 40,000cpm 
[125I]-[Nle8,18, Tyr34]-hPTH (1-34) and 12 concentrations of hPTH (1-34) spanning 
about six orders of magnitude (10-4.5,10-5,10-5.5,10-6,10-6.5,10-7,10-7.5,10-8,10-8.5,10-9,10-
9.5
, and 10-10 M), each prepared in a 7-fold concentrated solution in 30 µl binding 
buffer, were added to 150 µl binding buffer in each well and incubated at RT for 90 
min with gentle swirling. The final volume in each well was 210 µl. The unbound 
ligand was removed by washing the cells three times with 0.5 ml ice-cold PBS. The 
cells were then lysed by addition of 0.5 ml 1 N NaOH and the lysate was measured 
for 125I content in a Wallac WIZARD γ-counter. 
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Analyzing homologous competitive binding data 
Nonlinear regression analysis of the data was performed using GraphPad PRISM™ 
4.0). This program fits the data to the following equation and determines the inhibitory 
concentration 50% (IC50): 
 
]log[IClog[D] 50101
c)Nonspecifi(Total
cNonspecifiY
−+
−
+=  
Equation 2.2 Y is the total binding measured in the presence of various concentrations of the cold ligand (PTH), 
and log[D] is the logarithm of the concentration of competitor (PTH). Nonspecific is the binding in the presence of 
a saturating concentration of D, and Total is the binding in the absence of competitor. 
 
The concentration of unlabeled drug halfway between the upper and lower plateaus 
is called the IC50 (inhibitory concentration 50%) also called the EC50 (effective 
concentration 50%). 
 
 
 
Figure 2.4 Analyzing competitive binding data (Taken from GraphPad Prism).  The top of the curve is total 
binding which is a plateau at a value equal to radioligand binding in the absence of the competing unlabeled drug. 
The bottom of the curve is a plateau equal to nonspecific binding (NS). The difference between the top and 
bottom plateaus is the specific binding. The IC50 is the concentration of unlabeled drug that blocks half the specific 
binding. 
 
The Ki, the inhibition constant, can be calculated from the IC50 using the equation of 
Cheng and Prusoff (Cheng and Prusoff, 1973). 
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Equation 2.3 Euqation of Cheng and Prusoff (Cheng and Prusoff, 1973). The Ki is the concentration of the 
competing ligand that will bind to half the binding sites at equilibrium, in the absence of radioligand. Kd is the 
equilibrium dissociation constant. 
 
The equation is based on following assumptions: 
• Only a small fraction of both the labeled and unlabeled ligands has bound. 
• The receptors are homogeneous and all have the same affinity for the ligands. 
• There is no cooperativity - binding to one binding site does not alter affinity at 
another site. 
• The experiment has reached equilibrium. 
• Binding is reversible and follows the law of mass action. 
Because the labeled and unlabeled ligands used in this experiment were 
homologous and, thus, chemically identical, the assumption was made that both 
ligands have identical receptor affinities. This simplifies the equation of Cheng and 
Prusoff further to the following: 
 
[ ]dRadioliganICKK 50id −==  
Equation 2.4 The simplified form of Cheng and Prusoff equation for homologous competitive binding experiment. 
Kd is equal to Ki, as the hot and cold ligands are homologous. 
 
The concentration of the radioligand depends on the reaction volume and the amount 
of radioligand added to the reaction. Consequently, its calculation can be summed up 
as following: 
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Euqation 2.5 The concentration of hot ligand or radioligand depends on the amount of radioligand, C (cpm), in 
the reaction and the volume of reaction, V (mL), in each well. The reaction volume was 0.21mL. E is the efficiency 
of the gamma counter and in this case it was 87% (0.87). D is the radioactive decay factor (Table 2.2).  A 
Becquerel, Bq, equals one radioactive disintegration per second. As a result, it is further divided by 60. S is the 
initial specific activity of the radioligand, which is 81.4 TBq/mmol or 2200Ci/mmol. Bq = 1x10-12 TBq. The unit of 
[Radioligand] is M. 
 
Thus, using the equation (2.4) and (2.5), the binding affinity of the radioligand for the 
receptor (Kd) was determined. Kd is the concentration of ligand which occupies half of 
the receptors at equilibrium. A low Kd means that the receptor has a high affinity for 
the ligand. A high Kd indicates a low affinity to the ligand. 
To address the question of PTH1R density, the Bmax was calculated from the 
following equation: 
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Equation 2.6 To obtain the Bmax, specific binding (Top – Bottom) is divided by fractional occupancy.  
 
Bmax is the amount of ligand required to saturate receptors and a measure of the 
number of receptors at saturation. Based on the above equation, the receptor density 
can be elucidated as follow: 
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Equation 2.7 Using the Avogadro constant, the amount of specifically bound ligand at saturation (Bmax) can be 
transformed into the number of receptor molecules. The efficiency of the gamma counter is 87%. D is the 
radioactive decay factor (Table 2.2). 81.4x1012 (Bq / mmol) is the initial specific activity of the radioligand. The 
cell number was counted on the day of the experiment.  
 
For each cell line, experiments were performed in triplicate. 
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Table 2.2 Idione-125 decay chart. The half-life of idione-125 is 60 days (Taken from the product data sheet, 
PerkinElmer Life Sciences Inc., Boston, USA)  
 
 
2.2.12 Functional assays for PTH1R activity  
 
cAMP is one of the most important second messengers and modulates various 
cellular activities in different cell types of numerous species. Receptor-mediated 
activation of the G protein triggers the activation of adenylate cyclase (AC) which 
converts ATP to cAMP and subsequently activates protein kinase A (PKA). Protein 
kinase C (PKC) is a large superfamily of serine- and threonine-specific protein 
kinases that mediate essential cellular signals involved in activation, proliferation, 
differentiation and survival. The PKCs participate in cellular events via their activation 
by second messenger pathways such as diacylglycerol (DAG) and Ca2+.  
In order to assess the PHT1R activity, the quantitative determination of intracellular 
adenosine 3’,5’-cyclic monophosphate (cAMP) accumulation and protein kinase C 
(PKC) activity in the PDL, MG63 and HEK293 cells was performed using a 
commercially available cAMP enzyme immunometric assay (EIA) kit and a PKC 
activity assay kit, respectively.  
 
cAMP assay 
This assay is based on the competition between cAMP in the sample and a fixed 
amount of alkaline phosphatese-conjugated cAMP for a limited number of cAMP-
specific rabbit polyclonal antibody binding sites. As the concentration of the 
conjugated cAMP is kept constant while the concentration of cAMP in the sample 
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varies, the amount of conjugated cAMP that is able to bind to the rabbit polyclonal 
antibody will be inversely proportional to the concentration of cAMP in the sample. 
The rabbit polyclonal antibody-cAMP complex binds to the goat anti-rabbit IgG that 
has been previously attached to the well. The microplate is then washed to remove 
any excess conjugate and unbound sample. To determine the bound enzyme 
activity, a substrate solution is added to the well. The final product of this enzymatic 
reaction has a distinct yellow color and absorbs strongly at 405 nm. The intensity of 
this color, determined spectrophotometrically, is proportional to the amount of 
conjugated cAMP bound to the well, which is inversely proportional to the amount of 
cAMP present in the sample during the incubation. 
PDL, MG63 and HEK293 cells were seeded in 24-well plates and allowed to reach 
confluency. 3-isobutyl-1-methylxanthine (IBMX) is a non-specific inhibitor of 
phosphodiesterases and promotes the accumulation of cAMP in cells. After removal 
of the culture medium, cells were pretreated with DMEM supplemented with 1 % 
BSA, 20 mM Hepes and 1 mM IBMX for 1 h. The stimulation with various 
concentrations of hPTH (1-34) (10-6, 10-7, 10-8, 10-9, 10-10 and 10-12 M) continued for 
15 min at 37°C. Cells were lysed by treating the ce lls with 0.1 M HCl for 10 min at 
RT. Insoluble material was removed by centrifugation at 600xg. The supernatant was 
stored at -20°C until use.  
To normalize for the protein content, the measured cAMP concentration was divided 
by the total protein concentration in each sample. The samples were tittered back 
using 0.1 M NaOH for measurement of the total protein concentration via the Pierce 
BCA (bicinchoninic acid) Protein Assay kit.  
 
 
 
Figure 2.5 Schematic priniciple of cAMP assay (Adapted from cyclic AMP Direct assay kit from Assay Designs, 
Michigan USA). cAMP in the sample is in red color. Alkaline phosphates conjugated cAMP is in blue color. 
Primary rabit polycolonal antibody is in yellow color. The mircoplate is coated with goat anti-rabbit IgG. Upon 
substrate incubation, the reaction generates a yellow color which is read at 405nm. 
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PKC activity assay 
This assay is designed in form of a solid phase enzyme-linked immuno-absorbent 
assay (ELISA). In this assay, a specific synthetic peptide, which is readily 
phosphorylated by PKC, is immobilized on the wells of the provided microtiter plate.  
After adding the samples to the wells, the reaction is initiated by the addition of ATP.  
The kinase reaction is then terminated by emptying contents in each well. A 
phosphospecific substrate antibody that binds specifically to the phosphorylated 
peptide substrate is applied to each well. Subsequently, the primary phosphospecific 
antibody is detected by a peroxidase conjugated secondary antibody. Upon the 
addition of tetramethylbenzidine substrate (TMB), a color develops proportional to 
PKC phosphotransferase activity. The color development is stopped with acid stop 
solution and the intensity of the color is measured at 450 nm.  
The purified active PKC provided by the manufacturer is serially diluted and used as 
the positive control. Using the graph created by plotting the varying quantities of the 
purified active PKC against absorbance, the PKC kinase activity in the sample is 
assessed. The measured PKC kinase activity was normalized to the total protein in 
each sample. The total protein concentration was determined with the Pierce BCA 
Protein Assay kit. 
For this assay, PDL, MG63 and HEK293 cells were cultured to confluence in 24-well 
plates. After removal of the culture medium, the cells were subjected to various 
concentrations of hPTH (1-34) (10-6, 10-7, 10-8, 10-9, 10-10 and 10-12 M) for 15 min at 
37°C diluted in DMEM. The media was aspirated and t he cells were washed with ice 
cold PBS. Subsequently, the cells were incubated with 130 µl of the lysis buffer 10 
minutes on ice [20 mM MOPS, 50 mM β-glycerolphosphate, 50 mM sodium fluoride, 
1 mM sodium vanadate, 5 mM EGTA, 2 mM EDTA, 1% NP40, 1 mM dithiothreitol 
(DTT), 1 mM benzamidine, 1 mM phenylmethanesulphonylfluoride (PMSF) and 10 
µg/ml leupeptin and aprotinin]. The cells were scraped by a cell scraper on ice and 
the lysate was collected in a pre-chilled 1.5 ml microcentrifuge tube. After a 
centrifugation step at 13,000 rpm for 15 min, the clear supernatant was transferred to 
a pre-chilled 1.5 ml microcentrifuge. The samples were stored at -70°C untill the day 
of assay. 
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Figure 2.6 The principle chart of the PKC kinase activity assay (Taken from the PKC kinase activity assay kit 
from Assay Designs, Michigan USA).  
 
 
2.2.13 Total protein extraction 
 
For western blot analysis, PDL, MG63 and HEK293 cells were cultured in T-75 flasks 
at 37°C with 5% CO 2 and allowed to reach confluence. After removal of the culture 
medium, 5 ml PBS was added to the flasks. The cells were subsequently scraped by 
a cell scraper and collected into a 15 ml falcon tube. The remaining cells in the 
culture flask were washed with 5 ml PBS and taken into the same falcon tube, which 
was centrifuged for 5 min at 1500 rpm. The supernatant was decanted and the cell 
pellet was washed again with 5 ml PBS. After removal of the PBS, the cell pellet was 
resuspended in 200 µl RIPA buffer that was freshly mixed with protease-inhibitor-
cocktail and allowed to lyse on ice for 15 min. Cellular debris was excluded by 
centrifuging the cell lysate for 5 min at 12000 rpm at 4°C. The protein extract was 
stored at -20°C. 
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2.2.14 Protein quantification 
 
The protein extracted following the protocols described in above sections was 
quantified using the BCA Protein Assay Reagent kit.  
This assay is based on the combination of reduction of Cu+2 to Cu+1 by protein in an 
alkaline environment (the biuret reaction) with the highly sensitive and selective 
colorimetric detection of the resulting cuprous cation (Cu+1) by BCA (Smith, P.K., et 
al. 1985). This reaction generates a purple colored product formed by the chelation of 
two molecules of BCA with one cuprous ion. The BCA / copper complex is water-
soluble and has a strong absorbance at 562 nm that is nearly linear with increasing 
protein concentrations. 
The assay procedure was based on the instructions of the manufacturer. 25 µl of 
each standard or unknown sample was pipetted into a microplate in duplicate. 
Subsequently, 200 µl Working Reagent (WR) was added to each well. After mixing 
thoroughly on a plate shaker for 30 sec, the plate was incubated for 30 min at 37°C. 
The plate was cooled down to RT and the absorbance nm was measured at 562 with 
the PowerWave X UV-Vis plate reader. 
The WR was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B (50:1, Reagent A:B). A set of standards was made by diluting the bovine 
serum albumin (BSA) standard included in the assay kit. The protein concentration of 
the unknown samples was determined from the standard curve plotted for the BSA 
standards. 
 
 
2.2.15 Western Blot 
 
The PTH1R in PDL, MG63 and HEK293 cells was quantified at protein level by 
means of western blot analysis to acquire further information on the cellular 
localization of the receptors. After separation on sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), the extracted or fractionized 
proteins were blotted and detected on a membrane with an antibody raised against 
PTH1R. 
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Protein gel electrophoresis (SDS-PAGE) 
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate proteins based on their molecular weight. In SDS-PAGE, 
the samples are pre-treated with SDS combined with a reducing agent, such as ß-
mercaptoethanol (ß-ME) or dithiothreitol (DTT) by heating at 70°C or boiling briefly, 
which leads to the formation of a linear polypeptide chain. SDS is a strong anionic 
detergent that denatures by disrupting the secondary, tertiary and quaternary 
structures of the protein. ß-ME or DTT combined with a heating step disrupts all the 
disulphide bonds in the protein. Due to SDS, the proteins become overall negatively 
charged and migrate from cathode (-) to anode (+) in accordance to their size. 
In SDS-PAGE, to obtain optimal separation of proteins, a stacking gel is cast over the 
resolving gel. The stacking gel has a larger pore size, a lower pH and a different ionic 
content than the resolving gel. This allows the proteins to be concentrated into a tight 
band before entering the resolving gel. Protein separation is achieved in the resolving 
portion of the gel.  
For the separation of the PTH1R proteins, a 10% resolving gel was prepared as 
follows:  
 
10% resolving gel:  
ddH2O        4 ml 
30 % Acrylamide/ bis-acrylamide 37.5:1   3.3 ml 
1.5 M Tris-HCl (PH 8.8)      2.5 ml 
10% SDS 10%       0.1 ml 
10% APS        0.1 ml 
TEMED        0.004 ml 
 
The gel was then covered with isopropanol to get a horizontal gel surface and 
allowed to polymerize (>30 min). After removal of the isopropanol, a 5% stacking gel 
was cast on top of the resolving gel by combining the following: 
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5% stacking gel: 
ddH2O        1.4 ml 
30 % Acrylamide/ bis-acrylamide 37.5:1   0.33 ml 
0.5 M Tris-HCl (PH 6.8)      0.25 ml 
10% SDS       0.02 ml 
10% APS        0.02 ml 
TEMED        0.002 ml 
 
After the stacking gel had polymerized (>30min), the Mini-PROTEAN Tetra cell was 
assembled according to the instructions of the manufacturer and placed in the cell 
containing the running buffer. Typically, 20-40 µg of protein was mixed 6:1 with 6X 
Laemmli buffer (Laemmli, 1970) and heated for 5 min at 95°C. After loading the 
denatured protein sample and the molecular weight standards, the gel was run at 
200 V until the required resolution was obtained.  
 
Protein blotting 
The proteins resolved on the gel were transferred onto either a polyvinylidene fluoride 
(PVDF) membrane or nitrocellulose membrane by a semi-dry blotting method. After 
SDS-PAGE, the gel was immediately equilibrated in a small container of transfer 
buffer for approximately 15 min. The nitrocellulose membrane and filter papers were 
soaked also in transfer buffer for 15-30 min. (The PVDF membrane was first soaked 
in 100% methanol for 15 sec). The sandwich blot was assembled on the Trans-Blot 
SD Semi-Dry Transfer Cell in the order shown below. Transfer of proteins was done 
for 1 h at 15 V. 
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black (-)
filter paper
gel
membrane
filter paper
red (+)
 
 
 
 
Figure 2.7 Assembly order of the blot for Semi-dry Blotting (Taken from Bio-Rad). A: Semi-Dry Transfer Cell. 
1. Safety lid, 2. Cathode assembly with latches, 3. Three pieces blot filter paper, 4. Gel, 5. Nitrocellulose/PVDF 
membrane, 6. Three pieces blot filter paper 7. Spring-loaded anode platform, mounted on four guide posts, 8. 
Power cables, 9. Base, B: Assembly scheme of the Semi-dry Blotting. 
 
Protein detection  
Transfer efficiency was checked by staining the membrane with Ponceau S solution. 
After washing away the Ponceau S staining solution with water, the membrane was 
blocked in blocking solution on a rocker platform for 1 h at RT. Subsequently, primary 
PTH1R mouse monoclonal antibodies diluted 1:100 in blocking solution were applied 
overnight at 4°C.  Following three 10-min washes wi th wash buffer, the blot was 
incubated for 1 h at RT with the HRP-conjugated secondary goat anti-mouse 
antibody diluted 1:1000 in blocking solution.  After three washing steps of 10 min 
each with wash buffer and rinsing briefly in TBS, the blot was incubated 5 min in the 
SuperSignal West Femto Maximum Sensitivity Substrate working solution in the dark. 
The excess reagent was drained and the blot was covered with clear plastic wrap. 
Finally, the blot was visualized on a ChemiDoc™ XRS system and analyzed using 
Quantity One software. The size of the proteins was determined by comparing the 
protein bands with that of a molecular weight marker.  
 
Stripping for reprobing western blots 
In order to detect another protein or proteins of interest, the membrane was stripped 
using Restore™ Western Blot Stripping Buffer. This was done by incubating the 
A B 
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membrane in the stripping buffer for 15 min at RT with shaking, followed by a 
washing step with washing buffer. 
 
Used buffers and solutions: 
1. Laemmli buffer (6x) 
SDS (sodium dodecyl sulfate)   1.2 g 
bromophenol blue     6 mg 
glycerol      4.7 ml 
Tris 0.5 M (pH 6.8)     1.2 ml 
ddH2O       2.1 ml 
- Warmed with shaking till the solution was dissolved.  
- Added 0.93 g DTT. 
After completely dissolved, the buffer was aliquoted and stored at -20ºC. 
2. Running buffer:  1x Tris/Glycine/SDS 
10x Tris/Glycine/SDS (Bio-Rad) was 1:10 diluted in ddH2O 
3. Wash buffer:  0.1% Tween 20 /TBS 
0.1 ml Tween 20 + 99.9 ml TBS (Bio-Rad Laboratories GmbH, Munich, Germany) 
4. Transfer buffer: Tris/Glycin/20% Methanol  
20 ml Methanol +80 ml Tris/Glycin (Bio-Rad Laboratories GmbH, Munich, Germany) 
5. Blocking solution: 5% Milk/0.1% Tween 20 /TBS 
2.5g milk + 50 ml 0.1% Tween 20 /TBS 
6. SuperSignal West Femto Maximum Sensitivity Substrate working solution 
The two substrate components were mixed at a 1:1 ratio. 
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2.2.16 ELISA 
 
The Enzyme-Linked Immunosorbent Assay (ELISA) was first published by Engvall et 
al (1971) and the first microplate-based ELISA was established by Voller et al (1974). 
Osteoprotegerin levels in the conditioned media were assayed by a commercially 
available ELISA kit. The principle of this kit is based on a sandwich-type ELISA, in 
which two highly specific antibodies against OPG are used. The binding antibody is 
attached to the wells of the microtiterplate, while the detection antibody is labeled 
with biotin. In a first incubation step the samples and the biotinylated antibody against 
OPG react simultaneously with the pre-coated antibody on the microtiterplate. Thus, 
a “sandwich” complex is formed consisting of the binding antibody on the plate, OPG 
and the biotinylated detection antibody. In a second step, streptavidin-peroxidase is 
added, which reacts with the detection antibody. After incubation with the substrate, 
an acidic stopping solution is added, which changes the blue colour to yellow. The 
intensity of the yellow colour is directly proportional to the concentration of OPG in 
the sample. A dose-response curve of the absorbance units (at 450 nm) versus 
concentration is generated. OPG, present in the samples, is determined directly from 
this calibration curve. The data were assessed as a function of cell number to 
exclude the possibility that changes in osteoprotegerin production simply result from 
increased cell numbers due to the culture period and not from an altered production 
by the individual cell. 
 
 
2.2.17 Statistical analysis 
 
All statistical tests were performed by GraphPad PRISM™ 4.0. All values were 
expressed as mean ± standard error of mean (SEM), and compared using Student’s 
t-test, Dunnett-test, Bonferroni's and Tukey’s test. Statistical significance was 
accepted at p < 0.05. 
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2.2.18 Methods used in in vivo experiments 
 
Induction of osteoblastic differentiation 
Fifth passage PDL cells from two donors were cultured in 24-well plates at a seeding 
density of 10000 cells/well and stimulated with 10−6 M dexamethasone for 3 weeks to 
induce a more differentiated osteoblastic phenotype. 
 
CD-1® nude mice 
Twelve male, 4-6 weeks old, CD-1® nude mice with an average body weight of 20g 
(Charles River Laboratories, Germany), were stabilized at the animal research facility 
of the University of Bonn of Medicine. Mice were housed one per cage under specific 
pathogen-free conditions, in a continuously filtered room, maintained between 21-
22°C, with 40-60% humidity on 12 h light and dark c ycles and given free access to 
food and water. Animal body weights were recorded before the onset and at the end 
of the experiment. All experimental protocols were reviewed and approved by the 
ethics committee of the University of Bonn (reference number 887-50.103709.196). 
 
Surgical implantation of PDL Cells 
The PDL cells were resuspended each in fresh growth media, and 3×106 cells were 
incorporated into gelatin sponges 3–5mm in diameter by capillary action. The 
implantation procedure was adopted from Pettway et al (Pettway et al., 2008). 
According to this protocol, animals were anaesthetized with 2 vol% isoflurane and 
two midlongitudinal skin incisions, approximately 1cm in length, were made on the 
dorsal surface of each mouse. Blunt dissection was used to form subcutaneous 
pouches. Two implants per animal were inserted. Post surgically, mice were 
monitored daily for any signs of infection like shivering, lethargy, and diarrhea. 
Neither were signs of impaired healing nor adverse side effects of the procedures or 
drug dosage observed. 
 
Intermittent hPTH (1-34) administration 
In order to examine the mineralization capacity of PDL cells and the anabolic 
potential of intermittent hPTH (1-34) regarding the support of this capacity, mice were 
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randomly assigned to one of two experimental groups, with one group receiving daily 
subcutaneous injections of 40 µg/kg body weight recombinant human hPTH (1-34) 
for a period of 4 weeks starting at day 1 after PDL cell implantation, whereas the 
other group received sham-injections of an equivalent dose of saline. The dose of 
hPTH (1-34) used in these studies proved effective in previous experiments 
(Johnston et al., 2007). On day 28, the animals were anesthetized with isoflurane, 
blood (by means of cardiac puncture) and mineralized gelatin sponges were 
collected before euthanasia via cervical dislocation (Figure 2.8). 
 
 
 
Figure 2.8 Schematic illustration of in vivo injection of PTH (1-34) (adapted from: (Pettway et al., 2005). The 
experimental design was used to investigate the effect an intermittent anabolic hPTH (1-34) or vehicle (sterile 
water) treatment on human PDL cells transplanted into immunocompromised mice Subcutaneous injections were 
administered for 28 days beginning one day after implantation procedures.  
 
Preparation of paraffin tissue sections 
The explants were fixed in 4 % phosphate buffered (according to Sörensen) 
formaldehyde for 24 h at room temperature. Thereafter, they were first hydrated, then 
dehydrated in an ascending ethanol series and finally embedded in paraffin. As a 
next step, tissue sections of 5 µm thickness were cut in the sagittal plane, mounted 
on glass slides and dried at 37 °C overnight before  further processing. Tissue 
sections were deparaffinized by passing them through a descending series of ethanol 
ending with distilled water as described in section 2.2.9 (Tissue staining). 
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Immunohistochemistry 
The immunohistochemical staining of the paraffin embedded tissue sections was 
performed as described in section 2.2.9 (Tissue staining), with the exception of the 
used antibodies and the concentration of the antibodies. 
The presence of the transplanted PDL cells was confirmed by staining the nuclei of 
those cells using an antibody specific to human, but not mouse cells (diluted 1:20 in 
1% BSA/TBS). In order to avoid the unspecific binding of the secondary antibody, the 
slides were pre-incubated with a goat polyclonal secondary antibody to mouse IgG - 
Fc (diluted 1:200 in 1% BSA/TBS) for 1 h at room temperature prior to the incubation 
with the primary antibody. For a better contrast, the tissue sections were 
counterstained with light green, instead of Mayer's haematoxylin.  
For the staining of alkaline phosphotase, osteocalcin and osteopontin, sections were 
incubated with a polyclonal primary antibody of rabbit origin in a 1:50 (osteocalcin) or 
1:100 (osteopontin) working solution of 1% BSA/TBS either for 1h at room 
temperature (osteocalcin) or at 4°C overnight in a humidified chamber (ALP, 
osteopontin). The anti-ALP antibody was supplied in a ready-to-use working solution 
by the manufacturer. The slides were rinsed again and incubated for 30 min with a 
peroxidase labeled polymer conjugated to a goat anti-rabbit immunoglobulin provided 
as a ready-to-use solution as secondary antibody. The staining of PTH1R was 
performed as described in section 2.2.9 (Tissue staining). In order to prove the 
specificity of the immunoreactions, negative controls were carried out by omitting the 
primary antibody.  
 
Alzarin red staining 
The mineralization capacity of transplanted PDL cells was assessed by staining of 
the calcium deposits with alizarin red solution. To this end, a solution of 2% w/v 
alizarin red was prepared in ddH2O and the pH was adjusted to 4.1-4.3 using 0.5% 
ammonium hydroxide. Sections were deparaffinized and rinsed briefly in ddH2O. 
Thereafter, the sections were placed in alizarin red solution and observed 
microscopically until an orange-red color developed (~5 min). After removing the 
excess dye, the slides were dehydrated in acetone (20 dips) and then in acetone-
xylene (1:1) solution (20 dips). Finally, the slides were cleared in xylene and mounted 
with DePex. Red-orange color was considered positive for mineral deposition. 
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Alizarin Red S forms a chelate complex with calcium salts and therefore stains 
mineralized tissue.  
 
Semiquantitative assessment of the immunoreactivity 
Three representative sections per specimen were randomly selected for the 
assessment of the staining intensity for a particular antigen resulting in a total of 36 
specimens per experimental group. Immunoreactivity was determined 
semiquantitatively by assigning one of the following grades to the specimen: 0: no 
immunoreactivity; 1: weak immunoreactivity with only single cells presenting faint 
immunoreactions; 2: moderate immunoreactivity with about 50% of cells showing a 
visible immunoreaction; 3: strong immunoreactivity in most of the cells. 
Reproducibility of the readouts was ensured by analyzing 36 selected specimens in 
duplicate. An intraobserver error was demonstrated to happen in less than 4% of the 
cases and the deviation did not exceed one grade. 
 
Serum analysis of osteocalcin 
To demonstrate a systemic effect of the intermittent hPTH (1-34) administration on 
bone turnover, serum was isolated from blood via centrifugation at 1500 rpm for 30 
min at 4°C and stored in single use aliquots at -80 °C for future analysis. The 
quantification of serum levels of osteocalcin was performed using a commercially 
available ELISA assay (mouse) following the manufacturer’s instructions. The assay 
principle is the same as described in the previous section (2.2.16 ELISA), with the 
exception of used antibodies. 
 
Statistical analysis 
For any given experiment, each data point represents the mean ± SEM of 36 
independent specimens. Statistical significance of the data was analyzed using the 
Mann-Whitney-U Test. P-values <0.05 were considered to be significant. 
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3 RESULTS 
3.1 Primary characterization of PDL cells in vitro  
 
Morphological characterization 
At higher seeding densities, cultured PDL cells exhibited a fibroblast-like morphology 
with a spindle-like shape, which is typical of fibroblasts (Figure 3.1). When seeded at 
lower densities, the appearance of cell clusters was observed. The rate of cell growth 
varied among the donors. The doubling time of PDL primer cell lines generally 
ranged from 3 to 5 days.  These characteristics remained constant up to passage six. 
Figure 3.1, A and B represent the confluent and preconfluent stage of PDL cells, 
respectively. 
 
   
  
Figure 3.1 Confluent and preconfluent PDL cells.  PDL cells were mechanically isolated from an extracted 
tooth. In culture, PDL cells exhibited a spindle-shaped fibroblast-like morphology. A: PDL cells at confluent stage. 
B: PDL cells at preconfluent stage. Magnification: X100 
 
Molecular characterization 
The confluent and preconfluent PDL cells of the six donors were characterized for the 
mRNA expression level of marker genes involved in osteogenesis such as ALP, 
osteocalcin, PTH1R, bone morphogenetic protein (BMP)-2 and -4, bone 
morphogenetic protein receptor (BMPR)-1a, -1b and -2, integrin A6, integrin B4, 
transforming growth factor-β1 (TGF-β1) and cyclin D1. The confluent cells were 
cultured to ~100% confluence, while preconfluent cells to ~70% confluence. In data 
analysis, the mRNA expression level of these markers in confluent cells was 
compared to that in preconfluent cells. As shown in Figure 3.2, the confluent PDL 
A B 
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cells revealed a relatively higher gene expression level of these markers than 
preconfluent cells, with the highest being the expression level of osteocalcin (~26-
fold). Regarding PTH1R gene expression, the confluent cells showed an almost 15-
fold higher mRNA level than the preconfluent cells. The lowest difference was 
observed in cyclin D1 gene expression level, with almost 4-fold in confluent cells. 
As a result of these divergences which are caused by the state of confluency, we 
used the PDL cells at confluent stage in all forth coming experiments. 
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Figure 3.2 Characterization of confluent vs. preconfluent periodontal ligament (PDL) cell cultures. Fifth-
passage human PDL cells from six donors were cultured to either 70% confluence (preconfluent cells) or 100% 
confluence and were then characterized for the mRNA expression level of marker genes involved in osteogenesis 
such as [alkaline phosphatase (ALP), osteocalcin, parathyroid hormone receptor (PTH-R), bone morphogenetic 
protein (BMP)-2 and -4, bone morphogenetic protein receptor (BMPR)-1a, -1b and -2, integrin A6, integrin B4, 
transforming growth factor-β1 (TGF-β1) and cyclin D1 by the use of a microarray. For comparison, the expression 
level of the investigated genes in preconfluent cells was set to 1 and served as a reference for the expression at 
the confluent state. Each value represents the mean + SEM for 6 independent cultures 
 
 
3.2 Autofluorescence characteristics of PDL cells 
 
One prominent characteristic of PDL cells is the autofluorescence, which was first 
observed, as the fixed cells were stained using FITC-conjugated antibody and 
examined with a Zeiss Axioskop 2 fluorescence microscope. The unstained cells 
emitted a significantly high green fluorescence, which was at the same level as that 
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of the stained cells (Figure 3.3, A, B and C). However, no detectable red 
autofluorescence was observed using TRITC filter sets (Figure 3.3, D). 
 
    
 
 
Figure 3.3 Green autofluorescence of fixed PDL cells. After fixing with 4% paraformaldehyde for 10 min, PDL 
cells were stained for PTH1R using a FITC coupled secondary antibody and examined with a fluorescence 
microscopy using FITC and TRITC filter sets. The images were acquired using the same adjustments. 
Magnification: X200. A: unstained PDL cells. B: only secondary antibody treated PDL cells. C: PTH1R antibody 
and respective secondary FITC coupled antibody treated PDL cells. D: unstained PDL cells examined using 
TRITC filter sets.  
 
As shown in Figure 3.4, the autofluorescence was mainly localized in the perinuclear 
area, while in other parts of the cytoplasm and in the nucleus, it was hardly 
detectable. Moreover, the intensity of the autofluorescence differed among the cells 
examined, ranging from an extremely high level to almost no detectable 
autofluorescence in some cells. 
 
 
 
 
 
Figure 3.4 Localization of the green autofluorescence in PDL cells. The 4% paraformaldehyde fixed cells 
were examined with a fluorescence microscope. Magnification: X630. In this image, three cells can be seen, of 
which two exhibit high autofluorescence around the nucleus, while the last one has almost no detectable 
autofluorescence. The nuclei of the cells are indicated with N.  
 
In order to clarify the effect of fixation agents on autofluorescence, the PDL cell 
suspension in PBS and coverslip-cultured unfixed PDL cells were examined directly 
A B D C 
N 
N 
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using FITC filter sets. In both experimental setups, a high level of green 
autofluorescence was detected (Figure 3.5, A and B). This observation confirmed 
that the green fluorescence stems from PDL cells, and is not caused by the fixation 
agent. 
 
    
 
Figure 3.5 Green autofluorescence of unfixed PDL cells and PDL cell suspension. A: Unfixed PDL cells. 
PDL cells cultured on coverslip were washed once with PBS and mounted on a microscope slide.  B: PDL cell 
suspension. After trypsinizing, PDL cells were washed once with PBS and centrifuged down to pellet. The pellet 
was then resuspended in PBS and one drop of the suspension pipetted onto a microscope slide. The so prepared 
sections were then examined with a Zeiss Axioskop 2 fluorescence microscope using FITC filter sets. 
Magnification: X200.  
 
The autofluorescence characteristics of PDL cells were further investigated with a 
LSR II flow cytometry using different filter sets. For comparison, other cells lines such 
as HaCaT, MG63, HEK293 cells and oral keratinocytes were included. The flow 
cytometry data revealed that PDL cells exhibit very low autofluorescence in the long 
wavelength region (from red to far infrared) such as Alexa Fluor 645, being the 
lowest among the five investigated cell lines (Figure 3.6, A), and high auto 
fluorescence in short wavelength region such as FITC, being the highest among the 
cell lines investigated (Figure 3.6, B). Thus, based on the low autofluorescence 
characteristic of PDL cells in red fluorescence region and antibody availability, Texas 
Red and Alexa Fluor 647-conjugated antibodies were chosen for 
immunofluorescence staining and flow cytometry analysis of PDL cells, respectively.   
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Figure 3.6 Comparison of the autofluorescence of PDL, MG63, HaCa T, HEK293 cells and keratinocytes in 
Alexa Fluor 647 and FITC filter sets. After detachment, the cells were washed once with PBS and centrifuged. 
The cell pellet was then resuspended in sorting buffer (1% BSA in PBS) and screened using different filter sets 
with a LSR II flow cytometry. The data analysed with FlowJo 7.2.5 software.  As indicated above, the five cell 
types were represented with different colors. A: Autofluorescence intensity in Alexa Fuor 647 filter sets. B: 
Autofluorescence intensity in FITC filter sets.  
 
To elicit further information on the autofluorescence, PDL cells were permeabilized 
after a fixation step and viewed under a Zeiss Axioskop 2 fluorescence microscope. 
The permeabilization step decreased dramatically the autofluorescence of the cells, 
as shown below (Figure 3.7, A and B). This result was further confirmed by the flow 
cytometry analysis, wherein the autofluorescence intensity of fixed but not 
permeabilized PDL cells was compared to that of fixed and subsequently 
permeabilized PDL cells (Figure 3.7, C). Thus, in the immunofluorescence staining of 
the PTH1R, the problem of autofluorescence was circumvented by permeabilizing 
the PDL cells after a fixation step. 
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Figure 3.7 Comparison of autofluorescence in fixed and fixed subsequently permeabilized PDL cells. A: 
Fluorescence image of fixed PDL cells B: Fluorescence image of fixed and subsequently permeabilized PDL 
cells. C: Comparison of autofluorescence intensity of PDL cells after fixation and permeabilization. For fixation, 
cells were treated with 4 % paraformaldehyde for 10 min.  For permeabilization, cells were treated for 5 min with 
1% triton X-100 after a 15 min fixation. The sections were examined with a fluorescence microscope and LSR II 
flowcytometry. Magnification: X400. 
 
 
3.3 Analysis of relative gene expression level of PTH1R 
 
The relative expression levels of mRNA encoding the PTH1R was measured in PDL, 
MG63 and HEK293 cells, using real time PCR method. 
The results showed a distinct expression of PTH1R gene in the three cell lines. 
However, the gene expression level of the PTH1R varied among these cell lines. 
While the highest mRNA expression was found in HEK293 cells, with ~14-fold higher 
gene expression of PTH1R compared to PDL cells, MG63 cells expressed app. 2-
fold lower PTH1R mRNA level than PDL cells (Figure 3.8, A). The PCR products run 
on the agarose gel showed a distinct band of the correct size (250 bp) (Figure 3.8, 
B). 
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Figure 3.8 Comparison of gene expression level of PTH1R in PDL, MG63 and HEK293 cells. Real time PCR 
was performed from total RNA of PDL, MG63 and HEK293 cells. Expression of mRNA for PTH1R was normalized 
using expression of β-actin as a reference (relative expression). The values were then compared to that of PDL 
cells. A: Relative gene expression level analysis using real time PCR method. All values were expressed as 
mean ± SEM, and compared using one-way ANOVA. Statistical significance was accepted at p < 0.05 (*: p < 
0.05). B: The PCR products were run on a 2% agarose gel and the size of the PCR products was assessed using 
GeneRuler™ DNA Ladder, Low Range. As expected, the amplicon size was 250 bp. 
 
 
3.4 Detection and cellular localization of PTH1R 
 
Detection 
To detect the PTH1R in PDL tissues, paraffin-embedded tissue sections prepared 
from extracted teeth were stained with antibody against PTH1R.  
As Illustrated in Figure 3.9, a distinct positive immunoreaction for PTH1R was 
observed in the PDL tissue. The overall staining pattern indicated that the PTH1R 
was distributed equally throughout the whole PDL tissue. Meanwhile, no difference 
was observed in the distribution of the PTH1R on the side of alveolar bone and tooth 
root (Figure 3.9, A). At cellular level, the immunostaining for PTH1R was observed 
mainly in PDL fibroblasts and endothelial cells, whereas the epithelial cell rests of 
Malassez (ERM) remained unstained (Figure 3.9, B, C and D). As expected, 
cementoblasts and odontoblasts showed also a positive immunostaining for PTH1R 
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(Figure 3.9, E and F). The unstained negative control sections ensured the specificity 
of the used primary antibody (Figure 3.9, a and b). This PDL tissue as shown in 
Figure 3.9 was isolated mechanically and cultured for the establishment of the PDL 
cell culture, as described in the materials and methods section.  
 
 
 
 
 
 
 
 
 
 
 
  
 
                                                                                                        
 
 
 
 
 
 
 
 
Figure 3.9 Immunohistochemical detection of PTH1R in PDL tissue section of human. A: DAB stained PDL 
tissue section. Magnification: X100. B: X400 magnification of the with arrow indicated area in figure A. Black 
arrows indicate the PDL fibroblasts. C: Black arrows: the epithelial cell rests of Malassez (ERM). Magnification: 
X400. D: Black arrows: endothelial cells. Magnification: X400. E: Black arrows: cementoblasts. Magnification: 
X200. F: Black arrows: odontoblasts. Magnification: X200. a:  Negative control section in which the PTH1R 
antibody was omitted. Magnification: X100. b: X400 magnification of the with arrow indicated area in figure a. 
Magnification x400. The images were acquired with a light microscope. The figure is representative of sections 
from two separate specimens. 
 
The detection of PTH1R was further extended to in vitro by staining the cultured PDL 
cells using antibody-based methods.  
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As demonstrated in microscopic images A and B in Figure 3.10, the PTH1R in 
cultured PDL cells was visualized with DAB (brown) and Texas Red fluorochrome 
(red), respectively. Sections stained without the primary antibody served as negative 
control (Figure 3.10, a and b). 
 
 
 
 
 
 
 
 
 
            
Figure 3.10 Immunohistochemical detection of PTH1R in cultured PDL cells and semi-quantification of 
PTH1R in PDL, MG63 and HEK293 cells using western blot method.  A: PDL cells stained with DAB (brown 
color).  a: The negative control section in which the PTH1R antibody was omitted. B: Immunofluorescence 
staining of the PTH1R in PDL cells. For detection, a goat anti - mouse secondary antibody conjugated with Texas 
Red was used. b: The negative control section without the primary antibody. Magnification: X400. The figure is 
representative of two separate experiments. C: Semi-quantification of PTH1R in PDL, MG63 and HEK293 cells 
using western blot method. Cell lysates of PDL, MG63 and HEK293 cells were resolved by SDS-PAGE and the 
protein was detected with anti-PTH1R and anti-ß-actin antibody, respectively. In each lane, the same amount of 
protein was loaded and the protein levels were normalized by β-actin levels. 
 
As next, we investigated the PTH1R protein level in PDL, MG63 and HEK293 cells 
using westernblot method. As shown in Figure 3.10, C, the band detected in HEK293 
cells was much more intensive than those of in MG63 and PDL cells, while the 
intensities of the bands in these latter cell lines were at the same level. These results 
confirmed the presence of PTH1R at protein level in the three cell lines investigated 
and showed that HEK293 cells contain much more PTH1R proteins than PDL and 
MG63 cells, while the amount of this receptor protein was at the same level in the 
latter cell lines. This finding is in accordance with the result of the mRNA expression 
level of PTH1R in the three cell lines.  
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Localization  
After having established the immunohistochemical staining of PTH1R, we have 
addressed the question of the PTH1R localization in PDL, MG63 and HEK293 cells. 
As expected, a distinct immunostaining of the PTH1R was observed on the plasma 
membrane of all the three cell lines investigated (Figure 3.11, A, B, C and D). 
However, the strongest immunoreactivity was seen in the cytoplasm of the three cell 
lines. On the other hand, a weak nuclear staining for PTH1R was seen in MG63 and 
PDL cells, whereas the nuclei of HEK293 cells were almost devoid of staining. The 
specificity of the staining was ensured by the negative controls without the primary 
antibody was omitted (Figure 3.11, a, b, c and d). 
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Figure 3.11 Subcellular localization of PTH1R in PDL, MG63 and HEK293 cells. A: PDL cells were stained for 
PTH1R with Texas Red (red) and examined with a confocal laser scanning microscopy. Magnification: x400. B: 
PDL cells were stained for PTH1R with DAB (brown) and examined with a light microscope. Magnification: x400. 
C and D: MG63 and HEK293 cells were stained for PTH1R with Texas Red (red) and examined with a Leica 
TCS SP2 confocal laser scanning microscopy. Magnification: X630. The nucleus and plasma membrane were 
indicated with white arrows. N: nucleus; M: plasma membrane. Images: a, b, c and d are the corresponding 
negative controls of A, B, C and D, respectively. 
 
 
Internalization of PTH1R 
Agonist activation of G protein-coupled receptor (GPCR) results in the redistribution 
of the receptor protein away from the cell surface into internal cellular compartments 
through a process of endocytosis known as internalization. To demonstrate the 
internalization of the PTH1R from the plasma membrane upon ligand binding, PDL, 
MG63 and HEK293 cells were challenged with 10-7 M hPTH (1-34) for 30 min and 
stained for PTH1R. 
As shown with white arrows in Figure 3.12, the hPTH (1-34) treatment for the 
indicated period of time reduced dramatically the Texas Red fluorescence signal on 
the plasma membrane of PDL and MG63 cells. However, since HEK293 cells have a 
relative small cytoplasm and large nucleus, the difference in the fluorescence signal 
intensity on the plasma membrane could not be distinguished.  
The internalization process further confirmed the presence of functional PTH1R in 
PDL and MG63 cells. Regarding HEK293 cells, this process needs to be visualised 
by other approaches. 
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Figure 3.12 Internalization of PTH1R in PDL, MG63 and HEK293 cells. PDL, MG63 and HEK293 cells were 
stimulated with 10-7 M hPTH (1-34) for 30 min and subsequently stained for PTH1R with Texas Red (red). In 
control groups, PDL, MG63 and HEK293 cells were treated with vehicle for 30 min and subsequently stained for 
PTH1R with Texas Red. The specimens were examined with a Leica TCS SP2 confocal laser scanning 
microscopy. Magnification: X630. The detected PTH1R on the plasma membrane were indicated with white 
arrows. The figures are representative of two separate experiments. 
 
 
3.5 Flow cytometry analysis of the PTH1R-positive subpopulation in 
PDL, MG63 and HEK293 cells 
 
Albeit morphological homogeneity, PDL cells are considered to contain a variety of 
subpopulations with different functional characteristics. On the other hand, previous 
studies showed that MG63 cell line is representative of early undifferentiated 
osteoblast-like cells. Although HEK293 cells were originally derived from embryonic 
kidney, the exact cellular origin of these cells is still unclear, as embryonic kidney 
cultures may contain small numbers of almost all cell types of the body. These facts 
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lead to the question of whether these cell lines possess distinct subpopulations, 
which present PTH1R. To address this question, we analysed PDL, MG63 and 
HEK293 cells using a flow cytometery. To this end, we have established a protocol 
for the cell sorting analysis and optimized the antibody concentration. 
First, the living cells were sorted, as the antibody cannot penetrate the intact 
membrane effectively and can only bind the epitope in the extracellular part of the 
PTH1R on the plasma membrane. In each experiment, data from at least 10,000 
cells was acquired and analyzed with FlowJo 7.6.1 software.  Dead cells were 
excluded using a commercially available dead cell staining kit. In the course of data 
processing, cell clumps and debris were distinguished from the main population by 
gating the cells on the scatter plots with forward scatter (FSC) vs. side scatter (SSC). 
The forward scatter represents the size, and side scatter the granularity of cells 
(Figure 3.13, A). Subsequently, the gated cell population was further analyzed on the 
dot plot with the X-axis representing the fluorescence intensity of the fluorescent 
reactive dye used for dead cell discrimination and Y-axis representing the Alexa 
Fluor 647 dye. Mouse IgG1 monoclonal antibody served as isotype control (Figure 
3.13, B, D and F). The upper right quadrant (Q2) of each plot indicates the dead cells 
that are positive for PTH1R. The Q3 represents the PTH1R-positive cells, which are 
intact (Figure 3.13, C, E and G).  
After gating out dead cells, no PTH1R-positive subpopulation was detected in PDL 
cells, while almost all of the HEK293 cells were positive for PTH1R. In contrast, 
approximately 40% of MG63 cells were positive for PTH1R, indicating the presence 
of a subpopulation which contains PTH1R (Figure 3.14).  
 
 
 
 
Comp-Alexa Fluor 647-A
Co
m
p-
78
0_
60
n
m
(re
d)-
A
Comp-Alexa Fluor 647-A
Co
m
p-
78
0_
60
n
m
(re
d)-
A
FCS-A
SS
C-
A
PDL cells 
A B C 
Results 
 
 
86 
 
 
 
 
 
 
Figure 3.13 Flow cytometry analysis of PTH1R-positive subpopulation in intact PDL, MG63 and HEK293 
cells. A: A representative scatter plot. Cell clumps and debris were discriminated by gating the main population of 
PDL cells (circled). X-axis represents side scatter (SSC-A) and Y-axis represents forward scatter (FSC-A). B, D 
and F: Representatives of flow cytometry analysis of isotype control (mouse monoclonal antibody) treated cells. 
C, E and G: Representatives of flow cytometry analysis of PTH1R-positive subpopulation in cells. Dots in lower 
right quadrant (Q3) represent the intact PTH1R-positive cells. 
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Figure 3.14 Quantification of PTH1R-positive subpopulations in PDL, MG63 and HEK293 cells. Y-axis: 
Portion of intact cells positive for PTH1R (%).  Data were acquired from one of two separate experiments, both 
yielding comparable results. Each value represents the mean + SEM for 6 independent cultures. *** : P<0.001 
(Dunnett-test). 
 
We next permeabilized the cells and stained intracellular PTH1R. To this end, prior to 
the staining, the cells were fixed and subsequently permeabilized with a commercial 
kit. After gating the main population of cells, the SSC was plotted against Alexa Fluor 
647 on the Y-axis. Mouse IgG1 monoclonal antibody served as isotype control. In 
this case, all three cell lines showed ~100% positive population for PTH1R (blue 
circled region) (Figure 3.15).  
Taken together, in terms of surface PTH1R, we could observe a distinct PTH1R-
positive subpopulation in MG63 cells, but not in HEK293 cells. Regarding PDL cells, 
because of the used PTH1R antibody's inaccessibility to the surface antigen in living 
PDL cells, we could not detect any PTH1R-positive subpopulation. However, after 
permeabilization, all of the three cell lines were almost 100% positive for PTH1R. 
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Figure 3.15 Flow cytometry analysis of PTH1R-positive subpopulation in fixed and permeabilized PDL, 
MG63 and HEK293 cells. Cell clumps and debris were discriminated by gating the main population of cells. X-
axis represents side scatter (SSC-A) and Y-axis represents Alexa Fluor 647 dye. The population in red represents 
the isotype control (mouse monoclonal antibody) treated cells, as negative control. The population in blue 
represent the PTH1R-positive cells.  
 
 
Figure 3.16 Quantification of PTH1R-positive subpopulations in fixed and permeabilized PDL, MG63 and 
HEK293 cells. Y-axis: Portion of cells positive for PTH1R (%).  Data were acquired from one of two separate 
experiments, both yielding comparable results. Each value represents the mean + SEM for 6 independent 
cultures.  
 
 
3.6 Binding characteristics of PTH1R and its density 
 
The binding affinity and density of PTH1R have been intensively studied in 
osteoblast-like cells as well as in PTH1-transfected HEK293 cells, however not yet in 
PDL cells. To fill the gap, we assessed the binding characteristics of the PTH1R in 
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PDL, MG63 and HEK293 cells using a homologous competitive binding assay. In this 
assay, a constant concentration of radioactive labelled ligand, h[125I]-[Nle8,18, Tyr34]-
PTH (1-34) competed with a series of concentrations of its unlabelled homologous, 
hPTH (1-34) for the binding sites. The acquired data was analyzed with the nonlinear 
curve-fitting program of GraphPad PRISM™ 4.0 and IC50 (inhibitory concentration 
50%) was determined. Binding affinity (Kd) and receptor density (Bmax) were 
calculated by the equation of Cheng and Prusoff using IC50 values and the 
concentration of radioligand, as stated in materials and methods.  
 
 
Figure 3.17 Binding characteristics of PTH1R in PDL, MG63 and HEK293 cells. In the graphic, the 
competitive binding curves of hPTH (1-34) against [125I]-[Nle8,18, Tyr34]-PTH 1-34 (h) in PDL (▼), MG63 (■) and 
HEK293 cells (●) are shown. Y-axis: specific binding (%). X-axis: concentrations of hPTH (1-34), respectively: 10-
4.5
,10-5,10-5.5,10-6,10-6.5,10-7,10-7.5,10-8,10-8.5,10-9,10-9.5,10-10 M. In the table, the estimated Kd and Bmax values for 
PTH1Rs in PDL (blue), MG63 (red) and HEK293 cells (green) are shown. Data represent the average (± SD) of 
two independent experiments, each performed in triplicate. 
 
Among the three cell lines, the binding affinity of hPTH (1-34) to PTH1R in PDL cells 
was the lowest (Kd=1030±10 nM), while the PTH1R density in this cell line was the 
highest (3.03±0.57 million receptors/cell). The highest binding affinity was estimated 
in MG63 cells (Kd=80.1±20.2 nM), with the lowest receptor density (0.365±0.1 million 
receptors/cell. The binding affinity of hPTH (1-34) and the receptor density in 
HEK293 cells were Kd=670±417 nM and 2.27±1.4 million receptors/cell respectively, 
and these two values reside between those of PDL and MG63 cells. 
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3.7 Regulation of PTH1R gene expression in PDL cells 
 
It is well established that the expression of PTH1R mRNA in osteoblasts is regulated 
by extracellular factors, such as dexamethason (Ureña et al., 1994a; Yaghoobian 
and Drüeke, 1998; Haramoto et al., 2007), 1,25-dihydroxyvitamin D3 (Xie et al., 1996; 
Sneddon et al., 1998) and PTH (Jongen et al., 1996). Accordingly, we investigated 
the effects of these factors on the expression level of PTH1R mRNA in PDL cells. For 
this aim, PDL cells of three donors were stimulated with 10-6 M dexamethason, 10-7 
M 1,25(OH)2 D3 and 10-8 M hPTH (1-34) and the gene expression level was 
assessed using real time PCR method.  
 
Dexamethason 
As illustrated in Figure 3.18, A, stimulation with 10-6 M dexamethason led to a 
significant increase in PTH1R mRNA level over a period of 21 days, resulting in a 
148-fold higher level compared to the untreated group on day 1. In the corresponding 
control groups, the PTH1R mRNA level also increased in a time-dependent manner. 
The effect of dexamethason on PTH1R gene expression increased with the time in 
the first four days, with the highest increase in PTH1R mRNA level on the 4th day 
(~12-fold of the corresponding control group), as shown in graphic B (Figure 3.18). 
Thereafter, the effect of dexamethason declined gradually, resulting in the decrease 
of the PTH1R gene expression. Correspondingly, the relative increase in the PTH1R 
mRNA level on the 14th and 21st day dropped to ~3-fold of that of the control groups. 
(Figure 3.18, B). 
 
0
5
10
1d 2d 3d 4d 6d 14d 21d
Control
Dexamethason
* *
*
*
*
*
*
#
#
# # #
#
#
Exposure time
12
62
112
162
Re
la
tiv
e 
ge
n
e 
ex
pr
es
si
on
(fo
ld
 
o
f c
o
n
tr
o
l)
A 
Results 
 
 
91 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.18 Effect of 10-6 M dexamethason on mRNA level of PTH1R in PDL cells. The effect of 
dexamethason (10-6 M) on PDL cells of three donors was studied using real time PCR. Data were acquired from 
one of two separate experiments, both yielding comparable results. Each value represents the mean ±SEM for 6 
independent cultures. A: Comparison of all the experimental groups and vehicle-treated controls to the vehicle-
treated control of the 1st day. The vehicle-treated control on the 1st day was taken as reference for normalization. 
# : P<0.05 (t-test), experimental group vs. vehicle-treated control (at the same time point); * : vehicle-treated 
controls on the fist day vs. all other vehicle-treated controls and experimental groups (Dunnett-test). B: 
Comparison of experimental groups to corresponding vehicle-treated control (at the same time point). Each 
experimental group was normalized to the corresponding control group (at the same time point).  # : P<0.05 (t-
test), experimental group vs. corresponding vehicle-treated control.  
 
1,25-dihydroxyvitamin D3  
Over the 6 days of stimulation with 10-7M 1,25-dihydroxyvitamin D3, the PTH1R 
mRNA level was increased in a time-dependent manner, with the highest level on 6th 
day (~10-fold of the control group of the 1st day, as shown in graphic A (Figure 3.19). 
In the control groups, the mRNA level of PTH1R also increased with the time. 
An apparent effect of 1,25-dihydroxyvitamin D3 was seen on the 6th day of 
stimulation, with an increase of ~14-fold over the corresponding control group, as 
illustrated in graphic B (Figure 3.19). 
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Figure 3.19 Effect of 10-7 M 1,25-dihydroxyvitamin D3 on the gene expression level of PTH1R in PDL cells. 
The effect of 1,25-dihydroxyvitamin D3 (10-7 M) on PDL cells of three donors was studied using real time PCR. 
Data were acquired from one of two separate experiments, both yielding comparable results. Each value 
represents the mean ±SEM for 6 independent cultures. A: Comparison of all the experimental groups and vehicle-
treated controls to the vehicle-treated control on the 1st day. The vehicle-treated control on the 1st day was taken 
as reference for normalization. # : P<0.05 (t-test), experimental group vs. vehicle-treated control (at the same time 
point); * : vehicle-treated controls on the first day vs. all other vehicle-treated controls and experimental groups 
(Dunnett-test). B: Comparison of experimental groups to corresponding vehicle-treated control (at the same time 
point). Each experimental group was normalized to the corresponding control group (at the same time point). # : 
P<0.05 (t-test), experimental group vs. vehicle-treated control (at the same time point). 
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hPTH (1-34) 
PDL cells were exposed to 10-8 M hPTH (1-34) continuously as well as intermittently 
for 1 h and 24 h within 3 incubation cycles of 48 h each. In the first cycle, PTH1R 
mRNA expression was increased ~1.7-fold by 1h intermittent treatment and ~2.5-fold 
by continuous treatment (48h), but decreased ~2-fold by 24 h intermittent treatment, 
compared to the control group (Figure 3.20, A). In the second cycle, the mRNA level 
of PTH1R was further elevated to ~3-fold by the 1 h hPTH (1-34) application (Figure 
3.20, B). The 24 h/cycle intermittent treatment further decreased PTH1R mRNA 
expression to ~20% of the control (Figure 3.20, C). However, when hPTH (1-34) was 
continuously applied for 96 h, the PTH1R mRNA level was significantly down-
regulated to ~0.5-fold of the control group, which was a ~5-fold drop compared to the 
same treatment in the first cycle (Figure 3.20, D).  In the third cycle of treatment, the 
PTH1R mRNA level fell back almost to control levels, regardless of intermittent or 
continuous application of hPTH (1-34) (Figure 3.20, A).  
Taken together, a distinct effect of the hPTH (1-34) on PTH1R gene regulation was 
observed in the first two cycles of treatment. While the 1 h intermittent exposure up-
regulated PTH1R gene expression, 24 h intermittent administration inhibited it. The 
continuous administration of this peptide elevated the gene expression of PTH1R in 
the first cycle, but took an opposite effect in the second cycle and decreased the 
gene expression of PTH1R. 
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Figure 3.20 Effect of 10-8 M hPTH (1-34) on the gene expression level of PTH1R in PDL cells. The effect of 
intermittent (exposed respectively for 1 h and 24 h) and continuous application of hPTH (1-34) (10-8 M) on PDL 
cells of three donors was studied using Real time PCR. Data were acquired from one of two separate 
experiments, both yielding comparable results. Each value represents the mean ±SEM for 6 independent 
cultures. A: Graphic of all three incubation cycles. The vehicle-treated control in each cycle was taken as 
reference for normalization. # : P<0.05 (Dunnett-test), vehicle-treated control vs. each experimental group (in 
each cycle). B: Graphic of 1 h intermittent hPTH (1-34) (10-8 M) treatment in 3 incubation cycles. C: Graphic of 24 
h/cycle intermittent hPTH (1-34) (10-8 M) treatment in 3 incubation cycles. D: Graphic of continuous hPTH (1-34) 
(10-8 M) treatment in 3 incubation cycles. In Graphic B, C and D, * : P<0.05 (Tukey’s test). 
 
 
3.8 Signal transduction of PTH1R  
 
Upon ligand binding, PTH1R activates mainly two signalingpathways: cAMP/PKC 
and PLC/PKA (Mannstadt et al., 1999), which, in turn, regulate the downstream 
physiological response of cells. To elucidate the signal transduction of PTH1R, we 
exposed PDL cells of three donors, MG63 and HEK293 cells to 10-6, 10-7, 10-8, 10-9, 
B C 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
PTH 1h
control
1. cyc le 2. cyc le 3. cyc le
*
*
Exposure  time
Re
la
tiv
e 
ge
n
e 
ex
pr
es
si
o
n
(fo
ld
 
o
f c
o
n
tr
o
l)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PTH 24h
control
1. cycle 2. cycle 3. cycle
*
Exposure time
Re
la
tiv
e 
ge
n
e 
ex
pr
es
si
o
n
(fo
ld
 
o
f c
o
n
tr
o
l)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
1. cycle 2. cycle 3. cycle
PTH 48h
control
*
*
Exposure time
Re
la
tiv
e 
ge
n
e 
ex
pr
es
si
o
n
(fo
ld
 
o
f c
o
n
tr
o
l)
D 
Results 
 
 
95 
10-10 and 10-12 M hPTH (1-34) for 15 min and measured for cAMP accumulation level 
and PKC activity. 
 
cAMP accumulation 
The cAMP production of PDL cells in response to hPTH (1-34) after 15 min was not 
accumulative, but rather concentration-dependent (Figure 3.21, A).  The highest 
effect of hPTH (1-34) on PDL cells was seen at 10-12 M with a more than 120% 
increase, followed by a ~90% increase at 10-8 M. cAMP accumulation was also 
observed at 10-7 M treatment with a 60% increase. The PDL cells showed no 
apparent change in cAMP level, when exposed to 10-10, 10-9 and10-6 M hPTH (1-34). 
In HEK293 cells, low concentrations of hPTH (1-34) (10-12 and 10-10 M) did not induce 
apparent changes in the cAMP accumulation (Figure 3.21, C). The first response of 
cAMP to hPTH (1-34) stimulation was observed at 10-9 M, with a ~70% increase in 
the cAMP level compared to the control group. After a slight decrease at 10-8 M, the 
cAMP accumulation was increased to the highest level at 10-7 M of hPTH (1-34), with 
a ~230% increase in cAMP level in contrast to the control. The second highest 
response of cAMP to hPTH (1-34) was detected at concentration of 10-6 M, with a 
~120% increase in cAMP level (compared to control) 
Like HEK293 cells, the MG63 cells triggered no apparent response in terms of cAMP 
accumulation until stimulated with 10-9 M hPTH (1-34) (Figure 3.21, B). After a slight 
increase at 10-9 M, cAMP production dropped by ~35 % from the baseline level, when 
treated with 10-8 M hPTH (1-34). The highest cAMP accumulation was induced by10-6 
M hPTH (1-34) with 40% increase from the baseline level. 
The baseline cAMP production was not at the same level in the three cell lines 
studied. (PDL cells: 18.26 pmol/mg total protein, MG63 cells: 15.56 pmol/mg total 
protein and HEK293: 10.62 pmol/mg total protein) (Figure 3.21, D). No change in 
cAMP level was observed in all three cell lines, when exposed to 10-10 and 10-9 M 
hPTH (1-34).  Another similarity was seen at the 10-7 M of hPTH (1-34), with a 
significant increase in the cAMP production in all the three cell lines. When subjected 
to 10-12 and 10-8 M hPTH (1-34), PDL cells demonstrated a significantly higher 
increase in the cAMP accumulation compared to MG63 and HEK293 cells. 
 
 
Results 
 
 
96 
0 0.001 0.1 1 10 100 1000
0
5
10
15
20
25
*
*
*
 [PTH(1-34)] nM
cA
M
P 
pm
ol
/m
g 
to
ta
l p
ro
te
in
0 0.001 0.1 1 10 100 1000
0
5
10
15
20
25
30
35
40
45
*
*
*
 [PTH(1-34)] nM
c
AM
P 
pm
ol
/m
g 
to
ta
l p
ro
te
in
0 0.001 0.1 1 10 100 1000
0
10
20
30
40
*
*
 [PTH(1-34)] nM
cA
M
P 
pm
o
l/m
g 
to
ta
l p
ro
te
in
0 0.001 0.1 1 10 100 1000
0
5
10
15
20
25
30
35
40
45 PDL cells
MG63 cells
HEK293 cells
*
#
•
#
#
•
#
•
$
 [PTH(1-34)] nM
cA
M
P 
pm
o
l/m
g 
to
ta
l p
ro
te
in
$ $
#
$
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 Effect of hPTH (1-34) on cAMP accumulation in PDL, MG63 and HEK293 cells. The effect of 
hPTH (1-34) on cAMP production was analysed after 15 min of stimulation using a commercial cAMP assay kit. 
Each value represents the mean ± SEM for 6 independent experiments. A: cAMP accumulation upon hPTH (1-
A B 
C 
D 
HEK293 cells 
MG63 cells PDL cells 
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34) stimulation in PDL cells. B: cAMP accumulation upon hPTH (1-34) stimulation in MG63 cells. C: cAMP 
accumulation upon hPTH (1-34) stimulation in HEK293 cells. In Graphic, A, B and C, * : P<0.05 (Dunnett-test), 
vehicle-treated control vs. each experimental group. D: Comparison of cAMP accumulation in the three cell lines 
studied in response to hPTH (1-34) stimulation.  # : P<0.05  PDL cells vs. HEK293 cells, ● : P<0.05  PDL cells vs. 
MG63 cells, $ : P<0.05  MG63 cells vs. HEK293 cells (Tukey’s test). 
 
PKC activity 
The activity of PKC was assessed by quantifying the active PKC protein, which was 
produced in PDL, MG63 and HEK293 cells upon the stimulation with hPTH (1-34) for 
15 min. 
In PDL cells, the production of active PKC protein was again dependent on the 
concentration of hPTH (1-34) (Figure 3.22, A). At first, the level of the active PKC 
protein dropped slightly at 10-12 M and then increased to the highest level at 10-10 M 
(~23% increase). The 10-9 M stimulation had almost the same effect as the 10-10 M 
stimulation. The lowest active PKC amount was seen at 10-8 M with ~66% decrease, 
followed by ~36% decrease at 10-7 M (compared to control group). Stimulation with 
10-6 M hPTH (1-34) caused almost no change in the baseline level of active PKC 
protein. 
The response of MG63 to the stimulation was different from the other two cell lines 
(Figure 3.22, B). The effect of hPTH (1-34) was first seen at 10-9 M with ~43% 
decrease, which was then slightly up-regulated at 10-8 M (~20%). At concentrations 
10-7 M and 10-8 M, hPTH (1-34) demonstrated the same effect as observed with 10-9 
M treatment. 
In HEK293 cells, the amount of active PKC protein declined gradually from the 
baseline level to the lowest level, until 10-9 M treatment (~30% decrease from the 
baseline level) and was then subsequently up-regulated to the highest level with 
~24%, at 10-6 M (Figure 3.22, C). 
In average, the baseline amount of the active PKC protein in PDL cells was 5~7-fold 
higher than that in MG63 and HEK293 cells, while the last two cell lines produced 
almost the same baseline level of the active PKC protein.  
When the plots were combined into one graph, the response of the active PKC 
protein production to hPTH (1-34) stimulation in each cell line revealed an almost 
opposite direction of cAMP accumulation (Figure 3.22, D, E and F). At a given point 
of hPTH (1-34) stimulation, if the cAMP accumulation was up or down-regulated, the 
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active PKC protein level was down or up-regulated and the magnitude of the 
response was almost at the same level. 
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Figure 3.22 Effect of hPTH (1-34) on PKC activity in PDL, MG63 and HEK293 cells. The effect of hPTH (1-34) 
on PKC activity after was assessed using a commercial PKC activity assay kit. Each value represents the mean 
±SEM for 6 independent experiments. A: Active PKC amount upon hPTH (1-34) stimulation in PDL cells. B: 
Active PKC amount upon hPTH (1-34) stimulation in MG63 cells. C: Active PKC amount upon hPTH (1-34) 
stimulation in HEK293 cells. In Graphic, A, B and C, * : P<0.05 (Dunnett-test), vehicle-treated control vs. each 
experimental group. D: cAMP accumulation vs. active PKC protein level in PDL cells in response to hPTH (1-34) 
stimulation. E: cAMP accumulation vs. active PKC protein level in MG63 cells in response to hPTH (1-34) 
stimulation. F: cAMP accumulation vs. active PKC protein level in HEK293 cells in response to hPTH (1-34) 
stimulation. In Graphic, D, E and F, * : P<0.05 (Dunnett-test), vehicle-treated control vs. each experimental group 
in PKC activity assay. # : P<0.05 (Dunnett-test), vehicle-treated control vs. each experimental group in cAMP 
accumulation assay. 
 
 
3.9 Effect of 10-12 M hPTH (1-34) on osteoprotegerin 
 
The observation that a concentration as low as 10-12 M hPTH (1-34) triggers the 
cAMP/PKA pathway in PDL cells was further confirmed by other lines of data, 
wherein the effect of 10-12 M hPTH (1-34) on osteoprotegerin production of these 
cells was investigated. 
In confluent PDL cells, intermittent 10-12 M hPTH (1–34) administration for both 1 
h/cycle and 24 h/cycle significantly reduced osteoprotegerin at protein level (Figure 
3.23). This regulation scheme was sustained, when the PKC pathway was blocked 
with RO-32-0432. However, the blocking of PKA pathway with H8 did not induce any 
notable change in the basal protein level of this cytokine.  
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Figure 3.23 Regulation of the osteoprotegerin production by intermittent 10−12 M hPTH (1–34) in confluent 
PDL cells. The cells were treated intermittently with 10−12 M hPTH (1–34) for 1 or 24 h during three cycles of 48 h 
each. Vehicle treated cultures served as controls. The osteoprotegerin content in the conditioned medium was 
assayed by ELISA and expressed as a function of the cell number. From all data obtained, the osteoprotegerin 
level at the onset of hPTH (1-34) administration (T0) was subtracted serving as a baseline correction. Data were 
acquired from one of two separate experiments, both yielding comparable results. Each value represents the 
mean ± SEM for six independent cultures. * : P<0.05, experimental group vs. vehicle control at a particular 
maturation state. 
 
 
3.10 Effect of intermittent hPTH (1-34) on human periodontal 
ligament cells transplanted into immunocompromised mice. 
 
In this section, we analyzed the effect of an intermittent hPTH (1-34) administration 
on human periodontal ligament cells in vivo. To this end, gelatin sponges containing 
explanted and dexamethasone pre-differentiated human PDL cells were transplanted 
into immunocompromised mice and grown for 4 weeks with daily injections of hPTH 
(1-34). Markers of osteoblastic differentiation including alkaline phosphatase, 
osteopontin, and osteocalcin as well as well PTH1R were immunohistochemically 
determined. Meanwhile, the degree of mineralization was analyzed by staining tissue 
specimens with alizarin red.  
 
Effect of intermittent PTH (1-34) on osteocalcin blood serum level 
Daily subcutaneous injections of 40µg/kg hPTH (1-34) raised the blood serum level 
of osteocalcin by approximately factor 3 (41.61±13.02ng/ml) compared to the control 
animals which only received sham-injections (13.90±2.81ng/ml). These differences 
proved statistically significant (Figure 3.24). 
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Figure 3.24 hPTH (1-34)-induced increase of osteocalcin serum levels as a hint towards enhanced bone 
turnover. Prior to sacrifice of the animals at the end of the experimental period, blood was collected by cardiac 
puncture and the osteocalcin level was determined in the serum by ELISA. The bar graph shows the mean + SEM 
for 6 mice per experimental group. *: P<0.05, experimental group vs. vehicle control. 
 
Identification of human PDL cells in mouse tissue 
Proof of the human origin of the cells under investigation was provided by an 
immunohistochemical staining specific to human but not mouse cell nuclei. In all 
specimens, a positive immunoreaction demonstrated the presence of human 
transplanted PDL cells in the gelatin sponges after growing 4 weeks in the mouse 
(Figure.3.25, A). Mouse tissue, which served as a negative control, remained 
unstained (Figure.3.25, a). 
 
    
 
Figure 3.25 Proof of human cells in the specimens explanted from the mice. Following sacrifice, specimens 
were processed for immunohistochemical detection of human cell nuclei to identify human PDL cells. A: The 
nuclei of the transplanted PDL cells were immunohistochemically stained using an antibody specific to human, but 
not mouse cells. Open arrows indicated the stained PDL cells in the gelatin sponges. a: Mouse tissue, which 
served as a negative control, remained unstained. Magnification: x400. 
a A 
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Histology 
Histology of the recovered specimens revealed the collagenous structure of the 
scaffolds, which mostly appeared as a fibrous network containing porous spaces 
ranging from 5 to 10 µm. In those spaces, a gradual distribution of the PDL cells 
including extracellular matrix throughout the gelatin sponges with the outer areas 
being more populated by PDL cells than the inner regions became evident (Figure 
3.26). 
  
 
Figure 3.26 Histology of the recovered specimens. Following sacrifice, specimens were stained with 
haematoxylin-eosin (HE). Blue arrows indicate the gelatin sponges. The cytoplasm of transplanted PDL cells was 
stained red   A: Magnification: x200. B: Magnification: x400. 
 
ALP, osteopontin, osteocalcin and PTH1R immunohistochemistry 
In the control specimens, alkaline phosphatase, osteopontin, and osteocalcin 
immunoreactivity was detected in the cytoplasm of the PDL cells and in the 
extracellular matrix, respectively, with the intracellular staining being stronger than 
the extracellular. PTH1R exhibited the same staining pattern as found in PDL tissues, 
as described previously. Correlating with the cell distribution pattern, the staining was 
found to be more intense in the outer areas as compared to the inner zones of the 
specimens. Intermittent hPTH (1-34) administration in the post surgical period 
resulted in a visible increase of both the number of immunoreactive cells and the 
staining intensity for all four antigens under investigation as compared to the sham-
injected controls (Figure 3.27, A-D and a-d). This visual impression was further 
substantiated by semiquantitative assessment using a rating system ranging from 0 
to 3 and proved statistically significant for all parameters tested (Figure 3.28). 
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Figure 3.27 Immunohistochemical detection (DAB) of alkaline phosphatase (ALP), osteocalcin (Ocal), 
osteopontin (OP) and PTH1R in the explants retrieved from the immunodeficient mice after 28 days. The 
respective panels on the left represent specimens of the animals treated with hPTH (1-34) intermittently (A-D), 
whereas those on the right are representative of the sham-injected group (a-d). Magnification: x400.  
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Figure 3.28 Semiquantative immunohistochemical analysis of alkaline phosphatase (ALP), osteocalcin 
(Ocal), osteopontin (OP) and PTH1R protein expression in the transplanted human PDL cells. Fourth 
passage PDL cells from two donors were stimulated with dexamethasone for three weeks prior to implantation 
into 6 CD-1® nude mice using gelatin sponges as a carrier. Post implantation, 40µg hPTH (1-34)/kg body weight 
were administered subcutaneously once daily for a period of 4 weeks. Sham injections of saline served as vehicle 
controls. Following sacrifice, specimens were processed for immunohistochemical staining and semiquantitative 
assessment of immunoreactivity. The bar graph shows the mean + SEM for 36 specimens per experimental 
group. *: P<0.05, experimental group vs. vehicle control. 
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Biomineralization 
Alizarin red staining as a marker of biomineralization followed a similar staining 
pattern as described for the osteoblastic marker proteins with ossicles from hPTH (1-
34) treated animals exhibiting a significantly higher degree of mineralization than 
ossicles from vehicle-treated animals (Figure 3.29). 
 
 
 
 
 
 
 
Figure 3.29 Alizarin red staining of calcium deposits in the explants retrieved from immunodeficient mice 
after 28 days. Alizarin red staining indicates areas of mineralization. A: PTH-treated mice. a: sham-injected mice. 
Magnification: x100. 
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Figure 3.30 Semiquantative immunohistochemical analysis of mineralization of the transplanted human 
PDL cells. Fourth passage PDL cells from two donors were stimulated with dexamethasone for three weeks prior 
to implantation into 6 CD-1® nude mice using gelatin sponges as a carrier. Post implantation, 40µg hPTH (1-
34)/kg body weight were administered subcutaneously once daily for a period of 4 weeks. Sham injections of 
saline served as vehicle controls. Following sacrifice, specimens were processed for Alizarin red staining and 
semiquantitative assessment of staining intensity. The bar graph shows the mean + SEM for 36 specimens per 
experimental group. *: P<0.05, experimental group vs. vehicle control. 
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4 DISCUSSION 
In addition to the classic catabolic effects, it is now widely accepted that PTH exerts 
anabolic effects on bone, when administered intermittently. As a result of the 
regenerative characteristic, PTH (1-34) (Teriparatide) has been approved for the 
treatment of osteoporosis (Hodsman et al., 2003).  
Periodontitis is one of the most common diseases, which causes the resorption of 
alveolar bone and can result in the loss of teeth, if treated not adequately. Over the 
past several years, numerous in vivo and vitro studies have been conducted to reveal 
the anabolic effect of PTH on PDL tissue and alveolar bone (Nohutcu et al., 1995; 
Ouyang et al., 2000; Barros et al., 2003; Lossdörfer et al., 2005, 2006b). The result of 
these findings suggests that PTH has anabolic effects on oral bone. 
The dual actions of PTH are mediated primarily through the PTH1R, which is a class 
II G protein-coupled receptor. Upon ligand binding, PTH1R can activate diverse 
signaling pathways, including cAMP/PKA and PLC/PKC pathways (Vilardaga et al., 
2011).  In light of this, understanding the physiology of the PTH1R is crucial to 
promote the regenerative effect of PTH. PTH1R has been exclusively studied in 
kidney and bone cells. However, the knowledge on PTH1R characteristics and 
physiology in PDL cells is still in its infancy. 
The objective of this study was to characterize the PTH1R in PDL cells, in terms of its 
cellular localization, binding affinity, density, signal transduction and gene regulation 
by diverse stimulants such as dexamethasone, vitamin D3 and hPTH (1-34), as well 
as to compare these characteristics with those of MG63 and HEK293 cells as 
representatives of bone and kidney cells, respectively.    
 
 
4.1 Cell culture establishment and cell characterization 
 
A crucial aspect of in vitro study is the establishment of a healthy cell culture model, 
which promises the reproducibility of experimental data. This becomes even more 
important with the use of primary cell line cultures. Moreover, albeit the similarity in 
morphology, PDL cells are considered to possess multiple characteristics, including 
fibroblastic and osteoblastic properties (Yamashita et al., 1987).   The shift between 
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the multiple characteristics could be dependent on the condition and state of the PDL 
cell culture.  Therefore, in the whole project, healthy, fifth passage PDL cells from 
different donors were used for each experimental setup. Additionally, it has been 
demonstrated that the confluent degree of PDL cells is correlated with the expression 
of differentiation markers and responsiveness to hPTH (1-34) stimulation (Lossdörfer 
et al., 2006a, 2006b).  Along the line, it is likely that the expression of PTH1 is also 
dependent on the state of confluence. To address this question, PDL cells at 
confluent and preconfluent stages were characterized for marker genes involved in 
osteogenesis, and a comparative gene expression profile of these markers, confluent 
vs. preconlfuent, was established using real time PCR method. Accordingly, to 
assure the consistent expression of PTH1R, we used confluent PDL cells for each 
experimental setup in this study.  
PTH1R are abundantly expressed in the bone and kidney (Langub et al., 2001). 
MG63 cells are commonly used as osteoblastic models, and HEK293 cells originated 
from human embryonic kidney (Graham et al., 1977). Thus, these two cell lines were 
included in this study to compare the characteristics of PTH1R in these cell lines to 
those of PTH1R in PDL cells.   
 
 
4.2 Autofluorescence of PDL cells 
 
The high autofluorescence of PDL cells was a major obstacle in the successful 
immunofluorescence staining of PTH1R in these cells. The FITC-conjugated 
secondary antibody was the choice of method at the beginning of our 
immunofluorescence staining based experiments. However, we observed a very 
intensive green fluorescence also in the unstained PDL cells. There are generally two 
possible sources of this unspecific fluorescence; external factors and 
autofluorescence. The external factors include fixation agents such as 
paraformaldehyde and to some degree also the used culture medium. As next, we 
changed the culture medium and stained directly the cells without fixation, which did 
not alter the intensity of the unspecific green fluorescence.  
Autofluorescence, termed also as “natural fluorescence”, is the fluorescence found in 
natural substances. Cells in most organisms exhibit some intrinsic level of 
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autofluorescence, which is most commonly caused by metabolites and structural 
components such as NADH, riboflavins, and flavin coenzymes (Mosiman et al., 
1997). Autofluorescence spectra are generally broad and encompass most of the 
visible spectral range, overlapping the emission spectra of commonly used 
fluorescent dyes (Billinton and Knight, 2001) (Figure 4.1).  
 
 
 
Figure 4.1 Common biochemical sources of autofluorescence in a wide variety of cell types and 
organisms, with their respective emission and excitation maxima (Taken from: Billinton and Knight, 2001). 
 
The immunofluorescence images and flow cytometry analysis revealed that PDL 
cells exhibits a high green autofluorescence, which overlaps with the emission range 
of FITC. However, the autofluorescence decreases dramatically in the long 
wavelength region (from Alexa Fluor 647 to far infra red).  In order to cast further 
insight, the autofluorescence  characteristics of PDL cells were compared to those of 
MG63, HEK293, HaCaT cells and keratinocytes using FITC and Alexa Fluor 647 
sets. Interestingly, among these cell lines, PDL cells and MG63 showed similar 
properties in terms of autofluorescence intensity (Figure 3.6). This could mean that 
the two cell lines have similar metabolic activities, since the metabolites are the 
common cause of autofluorescence. Another interesting observation is that the 
intensity of autofluorescence of the five cell lines in the emission wavelengthes for 
FITC appears to reflect the capacity of these cell lines to synthesize extracellular 
matrix proteins and collagens. High amount of NAD(P)H and flavin molecules 
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indicate an intensive cellular metabolism, which in turn is a sign of an intensive 
synthesis of extracellular matrix proteins and collagens. Along the same line, the 
intensity of autofluorescence in the emission wavelengths for FITC would reflect the 
intensity of matrix proteins and collagens synthesis. Indeed, PDL cells and MG63 
cells are characterized by their intensive synthesis of extracellular matrix proteins 
and collagens, which are needed to form hard tissues. On the other hand, 
keratinocytes, and HaCat cells are of epithelial origin and associated with soft 
tissues. This would indicate that these cell lines are less specialized in synthesis of 
extracellular matrix proteins and collagens. Although HEK293 cells are considered to 
be of epithelial origin, they might be less mature than keratinocytes and HaCaT cells, 
because they were generated at a less mature stadium by transformation of human 
embryonic kidney cells.  
The intensity of autofluorescence was decreased significantly by permeabilization of 
the cells (Figure 3.7). One possible explanation could be that the agents which cause 
the autofluorescence are either quenched by permeabilizing reagents or washed out 
through the permeabilized cell membrane.  
 
 
4.3 Detection and comparison of the mRNA expression level of 
PTH1R in PDL, MG63 and HEK 293 cells. 
 
The real time PCR products run on the agarose gel confirmed the presence of 
PTH1R at transcriptional level in PDL, MG63 and HEK293 cells. It is well known that 
MG63 cells express PTH1R (Carpio et al., 2001; de Gortázar et al., 2006; Tenta et 
al., 2006; Avnet et al., 2008). However, to the best of our knowledge, this is the first 
evidence that native (non-transfected) HEK293 cells express PTH1R. In most studies 
related to PTH1R, the used HEK293 cells were transfected with PTH1R gene (Iida-
Klein et al., 1997; Ferrari et al., 1999; Chauvin et al., 2002; Gesty-Palmer et al., 
2006; Qiu et al., 2010; Feinstein et al., 2011). In terms of PTH1R mRNA expression 
level, the three cell lines differed significantly, with HEK293 cells expressing the 
highest level of PTH1R mRNA. This divergence in the gene expression level appears 
to be cell type specific. These results were further supported by the western blot 
anylsis of PTH1R, wherein this receptor protein was detected and semi-quantidfied in 
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PDL, MG63 and HEK293 cells, respectively. The semi-quantitavie analysis indicated 
that PTH1R in these cell lines follows at translational level the same regulation 
scheme as observed at trascriptional level, which was evidenced by the 
quantification of mRNA level of PTH1R.  
 
 
4.4 Detection of PTH1R proteins in PDL tissue as well as in PDL, 
MG63 and HEK293 cells 
 
The results of immunhistochemical staining of tissue sections not only confirmed the 
presence of PTH1R protein but also revealed an equal distribution of this receptor 
throughout the whole PDL tissue, with no prevalence to alveolar bone side or tooth 
root. At cellular level, PTH1R was found mainly in PDL fibroblasts as well as in 
endothelial cells, whereas no immunostaining was observed in epithelial cell rests of 
Malassez (ERM). ERM are discrete clusters of residual epithelial cells that arise from 
fragmentation of the Hertwig’s root sheath and persist in the periodontal ligament 
throughout life (Gonçalves et al., 2008). These cells form a network around the root 
and can be identified easily as small clumps of epithelial cells within the periodontal 
ligament, close to the surface of radicular cementum. Several studies have reported 
the expression of different types of proteins by the ERM, such as cytokeratins and 
neuropeptides, as well as extracellular matrix and cell-surface proteins including a 
variety of growth factors, cytokines and extracellular matrix-degrading proteinases 
(Rincon et al., 2006). To date, however, there is no available evidence that support 
the presence of PTH1R in these cells, although the expression of parathyroid 
hormone related protein (PTHrP) is postulated (Beck et al., 1995). The presence of 
PTH1R in endothelial cells was already reported by several researchers (Isales et al., 
2000; Rashid et al., 2007). Along with PDL fibroblasts and endothelial cells, 
cementoblasts and odontoblasts showed also positive immunostaining for PTH1R 
(Figure 3.9, E and F). These results are consistent with the already published data of 
other investigators (Tenorio and Hughes, 1996; Kato et al., 2005b, 2005a). 
As next, we confirmed the persistence of the expression of PTH1R in cultured PDL 
cells by staining the cells for PTH1R.  In this step, we established and optimized a 
suitable immunohistochemical staining protocol for PTH1R in PDL cells, as the 
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antigen accessibility of the antibody could vary depending on the cell type. In both of 
the tissue staining and cell staining for PTH1R, we could achieve better results using 
an antigen retrieval method. There have been several methods developed to 
circumvent the problem of antigen masking which is generally caused by aldehyde 
fixation. After having systematically tested and optimized these methods, we used 10 
mM citrate buffer (PH 9) for the antigen retrieval of PTH1R. To this end, the tissue 
sections as well as the cells were incubated in this buffer at 80°C  in an incubater for 
30 min. Additionly, the distinct bands of correct size detected by western blot method 
supported furhter the presecne of PTH1R protein in PDL, MG63 and HEK293 cells.  
 
 
4.5 Localization of PTH1R 
 
GPCRS are cell surface receptors located within the lipid bilayer of the cell with an 
extracellular N-terminal domain, a seven transmembrane domain and an intracellular 
C-terminal domain. The biosynthesis of GPCRs begins at the endoplasmatic 
reticulum (ER) where they are subsequently folded and assembled (Figure 4.2). 
Properly folded receptors are then recruited and packaged into ER-derived coat 
protein complex II (COPII) -coated vesicles (Dong et al., 2007). These transport 
vesicles carry the cargo receptors further to the ER-golgi intermediate complex, the 
Golgi apparatus and the trans-golgi network, where the receptors undergo post-
translation modifications (e.g. glycosylation). Once receptors have achieved their 
mature status, they leave the ER and are transported through the secretory pathway 
to their destination on the plasma membrane (Duvernay et al., 2005). On other hand, 
the misfolded receptors are transported back into the cytosol and degraded by the 
ER associated pathway (Tsai et al., 2002).  
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Figure 4.2 Schematic overview of GPCR physiology (Taken from: Duvernay et al., 2005).  GPCRs are 
synthesized, folded and assembled in ER (endoplasmic reticulum); post-translational modified in ERGIC (ER–
Golgi intermediate complex), TGN (trans-Golgi network) and finally transported through the secretory pathway to 
their destination at the plasma membrane. 
 
Thus, prior to activation, GPCRs are distributed not only on the plasma membrane, 
but also can be found in the ER, golgi apparatus and packaged in transport vesicles 
depending on their mature status. In addition, the nuclear localization of several 
members of class I and III GPCRs has been also reported (Lu et al., 1998; 
Bhattacharya et al., 1999; Lee et al., 2004; Jong et al., 2005).  
In all the three cell lines studied, PTH1R showed the classic scheme of GPCR 
localization, with distribution on the plasma membrane and in the cytoplasm (Figure 
3.11). However, unlike HEK293 cells, MG63 and PDL cells showed additionally a 
weak nuclear staining, implying the nuclear localization of these receptors (Figure 
3.11, C). Indeed, both nuclear and cytoplasmic localization of PTH1R were 
previously reported in cultured osteoblast-like cells (ROS 17/2.8, UMR-106, MC3T3-
E1, and SaOS-2) (Watson et al., 2000). In the cytoplasm, the staining was mainly 
observed around the nucleus, indicating the presence of premature PTH1R in the ER 
and golgi apparatus. Additionally, there were also intensively stained dots observed 
in the cytoplasm, which might represent the mature receptors heading to their 
destination on the cell membrane via the secretory pathway.  These findings are 
consistent with the GPCR physiology in inactive state. 
Like other GPCRs, the activation of PTH1R leads to phosphorylation of its 
cytoplasmic tail by GRKs, which then facilitate association with ß-arrestin proteins, 
resulting in internalization and desensitization of the receptor (Malecz et al., 1998; 
Tawfeek et al., 2002). ß-Arrestin-PTH1R interactions lead to internalization 
(endocytosis) of the receptor, which are then either destined for degradation, 
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resulting in receptor down-regulation (Tian et al., 1994; Ureña et al., 1994b; Massry 
and Smogorzewski, 1998), or recycled back to the cell surface, leading to receptor 
resensitization (Chauvin et al., 2002).   
In order to confirm the internalization of PTH1R upon ligand binding, the three cell 
lines were treated with 100nM hPTH (1-34) for 30 min and subsequently stained for 
PTH1R. This concentration and time period of stimulation was successfully applied 
by Qiu et al to observe the internalization of a tagged hPTH (1-34) along with PTH1R 
in osteoblasts (Qiu et al., 2010). 
As illustrated in Figure 3.12, the vivid line of membrane staining observed in 
unstimulated PDL and MG63 cells was not present in hPTH (1-34) stimulated cells, 
demonstrating  the internalization of the receptors upon ligand binding. However, as 
HEK293 cells have relative large nuclei and small space between plasma membrane 
and cytoplasm, the internalization of the receptors could not be successfully 
visualized.  
 
 
4.6 Identification of PTH1R-positive subpopulation  
 
To address the question of whether a PTH1R-positive subpopulation exists in PDL, 
MG63 and HEK293 cells, these cells were stained for PTH1R and analysed using 
flow cytometry method. 
At first, the living cells were analysed, since PTH1R resides on the plasma 
membrane and the PTH1R antibody binds an epitope in the extracellular part of the 
receptor. Furthermore, the receptors residing on the cell membrane are functional 
active, at least in terms of responsiveness to ligands. After gating out dead cells, MG 
63 cells revealed a PTH1R-positive subpopulation of 40%, while HEK293 cells were 
almost 100% positive. In PDL cells, however, no PTH1R-positive subpopulation 
could be detected. 
The heterogeneity of MG63 cells for PTH1R appears to be a matter of maturation 
state. Indeed, MG63 cells have been shown to exhibit both mature and immature 
osteoblastic features (Pautke et al., 2004), indicating the differentiation potential of 
this osteosarcoma cell line. On the other hand, PTH1R is widely recognized as an 
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osteoblast-differentiation marker. These facts along with our result are suggestive of 
the presence of a PTH1R-positive subpopulation in MG63 cells.  
In the data interpretation of HEK293 cells, we considered the shift of the whole cell 
population rather than recording the absolute percentage of the positive cells. In this 
case, the HEK293 cells reached an almost 100% positivity, which would be app.80%, 
if the absolute percentage of the positive cells would be taken into account. Indeed, 
depending on where to set the threshold between the positive and negative cells, 
there could be recorded false negative cells in the real negative cell population and 
vice versa.  
Despite numerous optimization steps including: titration of antibody concentration, 
cell-detachment with different reagents such as accutase, EDTA and trypsin and 
using PTH1R antibodies from other sources, we failed to detect any PTH1R-positive 
population in PDL cells. On the other side, the presence of PTH1R on the plasma 
membrane was visualized using immuno-staining method (Figure 3.11, A).  One 
possible explanation for this paradox is that the used primary antibodies cannot bind 
successfully to the corresponding epitope on PTH1R in PDL cells, because of the 
limited access of the antibody to its antigen. 
When permeabilized, all of the three cell lines showed almost 100% PTH1R-positive 
population. In fact, the permeabilized plasma membrane allows the antibody 
molecules to bind to intracellular antigens. Thus, having access to cell inside, the 
PTH1R antibody obviously can bind to receptors both on the plasma membrane and 
in the cytoplasm of MG63 and HEK293 cells. In case of PDL cells, the antibody can 
bind to the intracellular receptors. It might be also possible that the fixing and 
permeabilizing processes could have made the antigen accessible for the antibody, 
resulting in the successful staining of the plasma membrane receptors. Indeed, the 
optimal results of immunofluorescence staining of PTH1R were also achieved only 
after treating the cells with optimized fixing, permeabilizing and antigen retrieval 
methods. 
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4.7 Binding affinity and receptor density of PTH1R 
 
The binding affinity and density of PTH1R in PDL, MG63 and HEK293 cells were 
studied using a competitive radioactive binding assay. There are generally two types 
of this assay. One is performed with isolated cell membranes, while the other is 
performed with intact cells. In the present study, we have employed an intact cell 
binding assay. In the assays with intact cells, the plasma membrane receptors can 
be studied in their native environment without disturbing the membrane. PH gradients 
or other ions across the membrane remain intact during the binding assay. 
Additionally, interactions between the receptors and their associated effector systems 
as well as the cytoskeleton or other associated components also will be assured. 
However, in this assay, it is much more difficult to control the assay conditions to 
identify factors that modulate receptor binding. Another disadvantage of this assay is 
that certain radioligands may also be transported into the cell leading to an apparent 
nonspecific binding. On the other hand, this trapped radioligand can appear as 
specific binding without association, if the agent used to define nonspecific binding 
also inhibits the uptake of radioligand.  
The binding characteristics of PTH1R were quite different in the three lines, with the 
lowest affinity in PDL cells (Kd=1030±10 nM) and the highest in MG63 cells 
(Kd=80.1±20.2 nM). Both PDL (3.03±0.57 million receptors/cell) and HEK293 cells 
(2.27±1.4 million receptors/cell) revealed a relative high density of PTH1R, while 
MG63 cells showed the lowest receptor density (0.365±0.1). The calculated Kd value 
and the number of receptors in MG63 cells were similar to those in rat osteosarcoma 
cells, ROS 17/2.8 cells and in another rat osteosarcoma cell line, UMR-108 (Demay 
et al., 1985; Rao and Murray, 1985), while these results differed greatly from other 
reports on the binding characteristics of PTH1R (Pliam et al., 1982; Yamamoto et al., 
1988; Enomoto et al., 1989). These discrepancies might be due to changes in 
PTH1R depending on the cell type and different experimental conditions as well as to 
different ligands used in the respective binding assays. Virtually all the reports on the 
binding characteristics of PTH1R resulted from the HEK293 cells transfected with 
either native or mutant PTH1R. Thus, the results of these studies on binding 
characteristics of this receptor vary depending on the experimental purpose and 
design. In this study, we present the first results of binding studies on PTH1R in PDL 
cells, which showed low binding affinity, yet a relative high value for receptor density.  
Discussion 
 
 
116 
These data are suggestive of a cell type specific binding characteristic of PTH1R. On 
the other hand, as mentioned above, most of the studies on the binding 
characteristics of PTH1R were performed in cells transfected with either native 
PTH1R or mutant PTH1R. Additionally, the experimental conditions under which the 
binding assays were performed could have great impact on the results. 
 
 
4.8 Regulation of PTH1R mRNA level in PDL cells 
 
It is widely known that PTH1R is tightly regulated in osteoblast-like cells and 
opossum kidney (OK) cells by extracellular cell factors such as dexamethasone 
(Rodan et al., 1984; Ureña et al., 1994a), 1,25-dihydroxyvitamin D3 (Titus et al., 
1991) and PTH (Ureña et al., 1996; Jongen et al., 1996). In light of this, we have 
studied the effect of these factors on PTH1R mRNA expression using real time PCR 
method. 
We used the concentration of 10-6 M dexamethasone, according to a previous study 
in which the effect of dexamethasone on PTH1R mRNA has been examined in ROS 
17/2.8 (Ureña et al., 1994a). However, we prolonged the time course of the treatment 
to 21 days, in order to find out the time point at which this glucocorticoid exerts its 
highest effect on PTH1R mRNA expression. 
The effect of dexamethasone on PTH1R mRNA level in PDL cells was accumulative 
in the first four days, and exhibited its highest effect on the 4th day. Beginning on the 
6th day, it gradually lost its effect (Figure 3.18). These findings are consistent with the 
results of the studies in osteoblast-like cells, in which dexamethasone increased 
PTH1R mRNA level (Ureña et al., 1994a; Haramoto et al., 2007). 
We adopted the concentration of 10-6 M 1,25-dihydroxyvitamin D3 from a previous 
study in which the regulation of PTH1R mRNA level by 1,25-dihydroxyvitamin D3 has 
been examined in ROS 17/2.8 cells. Similarly, the exposure time was prolonged to 6 
days. No apparent effect of 1,25-dihydroxyvitamin D3 was observed in the first four 
days. However, on the 6th day, it dramatically increased PTH1 mRNA level, with 
almost 14 fold increase (compared to control) (Figure 3.19).  1,25-dihydroxyvitamin 
D3 has been reported to decrease mRNA level and receptor number of PTH1R in 
ROS 17/2.8 cells (Xie et al., 1996). This discrepancy could be cell type dependent. 
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Furthermore, ROS 17/2.8 cells were exposed to 1,25-dihydroxyvitamin D3 in that 
study for 3 days, which we prolonged to 6 days in our study. 
The pleiotropic actions of PTH are mediated primarily through the binding and 
activation of PTH1R, which in turn is regulated by PTH (Kawane et al., 2001). It has 
been reported that PTH either down-regulates or up-regulates PTH1R expression, 
depending on the cell type (Langub et al., 2001). Since PTH exerts dual effects 
depending on the administration mode, it is also plausible that this discrepancy in the 
regulation of PTH1R mRNA could be a result of different ways of its application. With 
this in mind, we have studied the effect of both intermittent and continuous PTH 
administration on PTH1R mRNA level in PDL cells. 
As expected, different ways of PTH administration exerted different effects on PTH1 
mRNA level. In the first two cycles, 1 h intermittent exposure increased the level of 
PTH1R mRNA, while 24 h intermittent treatment decreased it. The continuous 
treatment increased after the first cycle PTH1 mRNA expression, but decreased it 
after the second cycle. After the third cycle, none of the three ways of treatments 
showed an apparent effect. Thus, it is likely that different actions of PTH regulate the 
PTH1R expression specifically. The relationship between the dual effects of PTH and 
regulation of its receptor remains to be further elucidated. 
 
 
4.9 Signal transduction of PTH1R 
 
The actions of PTH1R are thought to be mediated mainly by activating Gs and Gq, 
which in turn regulate the activity of cAMP/PKA and PLC/PKC signaling cascades, 
respectively (Vilardaga et al., 2011). In light of this, we have investigated these two 
signaling pathways in PDL, MG63 and HEK293 cells, by challenging the cells with a 
series of hPTH (1-34) concentrations such as 10-6, 10-7, 10-8, 10-9, 10-10 and10-12 M. 
To this end, we quantified the cAMP accumulation and the active PKC protein using 
commercial kits. 
In terms of cAMP accumulation and active PKC amount, the three cell lines showed 
discrete patterns in response to the hPTH (1-34) stimulation. Interestingly, the 
response in PDL cells was not accumulative with increasing concentrations of hPTH 
(1-34), rather it was more of a concentration-dependent response, as evidenced by 
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10-12 M and 10-8 M hPTH (1-34) inducing the highest cAMP accumulation and by 10-
10
 M and 10-6 M hPTH (1-34) showing no effect on the basal level of cAMP. In 
contrast, the response in HEK293 cells followed more or less an additive curve up to 
the stimulation with 10-6 M hPTH (1-34). The same scheme of regulation by this 
peptide was also found in MG63 cells, although the amplitude of the increase in 
cAMP accumulation was much smaller than in HEK293 cells. However, the exception 
was observed at 10-8 M hPTH (1-34) with even lower amount of cAMP than at the 
basal level. We considered this value as a deviation caused by experimental 
conditions, since the degradation of cAMP molecule was avoided by inhibition of 
phosphodiesterase using 3-isobutyl-1-methylxanthine (IBMX). The classic view on 
the response of cAMP to hPTH (1-34) assumes the additive accumulation of the 
cAMP with growing concentrations, as evidenced with MG63 and HEK293 cells. 
However, to our knowledge, we present the first evidence of a none-additive 
accumulation of cAMP molecule in response to PTH stimulation, with different 
concentrations of the hormone inducing similar magnitude of cAMP response. 
Indeed, our other lines of data (Lossdörfer et al., 2005) proved the effect of 10-12 M 
hPTH (1-34) on the signaling pathways in PDL cells. In that study, confluent PDL 
cells were challenged intermittently with 10-12 M hPTH (1–34) for both 1 h/cycle and 
24 h/cycle. This treatment regime significantly reduced osteoprotegerin at protein 
level (Figure 3.23). Interestingly, blocking of the PKC pathway did not alter this 
regulation scheme, whereas blocking of the cAMP/PKA pathway hampered greatly 
the effect of 10-12 M hPTH (1–34) on the level of this cytokine. 
One possible explanation for the apparent discrepancy might be ascribed to the 
heterogeneity of PDL cells which contain PTH1R with different binding characteristics 
leading to different responsiveness to PTH. As addressed previously, PDL cells are 
considered to possess multiple characteristics, including fibroblastic and osteoblastic 
properties (Yamashita et al., 1987). On the other hand, PTH1R seems to have 
different binding characteristics depending on the cell type, as observed in our study 
as well as in reports by others (Jonsson et al., 2001; Smock et al., 2001; Gentili et al., 
2003; Alokail and Peddie, 2008). 
In all the three cell lines, the response of the active PKC to hPTH (1–34) showed an 
exact opposite scheme of regulation compared to the response of cAMP. This 
became evident, when the response curves of cAMP and PKC were plotted on the 
same graph. Interestingly, at a given concentration of hPTH (1-34), if the cAMP level 
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was up-regulated, then the active PKC amount level was down-regulated, and vice 
versa, indicating a synchronical regulation of the two pathways after stimulation with 
hPTH (1-34). Indeed, the important role of the cross talk between cAMP/PKA and 
PKC pathways in the regulation of collagenase production and DNA synthesis by 
PTH in osteoblasts was pointed out by Civitelli et al. and Sugimoto et al.   (Sugimoto 
et al., 1994), whereas studies in other cell systems showed that the interaction 
between the two signalling cascades does not follow the same pattern in all cell 
types. Depending on the agonist and cell line, synergistic or antagonistic actions 
might be found (Sugimoto et al., 1994).  Several studies have shown that the cross-
talk between these pathways leads to further modulation of hormonal responses and 
cellular integration of signals (Cole, 1997). Furthermore, the activation of PKC was 
thought to induce tissue- and cell-specific changes in adenylyl cyclase activity by 
altering the phosphorylation state of the components of the receptor-G protein-
effector complex (Cole, 1997). However, the nature of the interactions between PTH 
responsive dual signal transduction systems in PDL cells remains to be elucidated. 
Taken together, these findings suggest that the concentration of hPTH (1-34) plays a 
pivotal role in the regulation of downstream signal transduction of PTH1R, at least in 
our used cell culture model. With respect to the applied concentrations of hPTH (1-
34), the cAMP/PKA and PLC/PKC signal cascades are regulated in PDL cells in a 
different way compared to that in MG63 and HEK293 cells, indicating a cell type 
specificity of the regulation scheme of the signal transduction pathways. Alternatively, 
the heterogeneity of the primary PDL cell lines may be of importance. 
 
 
4.10 Effect of intermittent hPTH (1-34) on human periodontal 
ligament cells transplanted into immunodeficient mice. 
 
The last part of this project was to study the regenerative capacity of human PDL 
cells and the anabolic effect of intermittent hPTH (1-34) administration in vivo. For 
this aim, we implied a cell-based tissue engineering model, which was first utilized by 
Pettway et al (Pettway et al., 2005). In this model, the researchers implanted gelatin 
sponges containing dexamthasone pre-treated bone marrow stromal cells into 
immunodeficient mice, which were then given daily subcutaneous injections of hPTH 
Discussion 
 
 
120 
(1-34). The gelatin sponge serves as a structural scaffold for the transplanted cells 
and provides a temporary extracellular matrix to allow for cell attachment (Lutolf and 
Hubbell, 2005; Ma, 2008). The pre-treatment of PDL cells with dexamethasone was 
based on the results of studies that point to the necessity of this supplement for PDL 
cells to facilitate mineralization of the extracellular matrix (Mukai et al., 1993). In 
another study, PDL cells were reported to be unable to form mineral-like nodules 
without prior aplication of osteodifferentiation medium, while the dexamethasone 
supplementation resulted in positive von Kossa staining (Flores et al., 2008). 
According to Sheehan et al. (2010), the anabolic effect of intermittent PTH on bone 
varies with the species studied as well as with the duration and mode of 
administration. Studies conducted in murine models suggest that the anabolic effect 
of intermittent PTH on bone is variable depending on the dose and duration/mode of 
administration as well as the species studied (Sheehan et al., 2010). Based on the 
results of previous studies by Johnston et al. (Johnston et al., 2007), we decided for 
daily subcutaneous injections of 40µg/kg body weight hPTH (1-34) for a period of 4 
weeks starting at day 1 after PDL cell implantation. 
Albeit the high potential of PDL cells for the regeneration of PDL tissue, there have 
been few in vivo studies providing proofs on the regenerative capacity of these cells. 
Akitzuki et al. demonstrated a successful regeneration of periodontal tissue utilizing a 
PDL cell sheet in a dehiscence model in vivo in beagle dogs (Akizuki et al., 2005). In 
our study, we present the first in vivo evidence for an anabolic effect of intermittent 
hPTH (1-34) on human PDL cells in terms of osteoblastic/cementoblastic 
differentiation and biomineralization. To this end, key proteins in 
osteoblastic/cementoblastic differentiation such as alkaline phosphatase, 
osteopontin, osteocalcin and PTH1 were investigated using immunohistochemical 
methods. Additionally, as a measure for biomineralization, calicium deposits in tissue 
section were stained with alizarin red. In order to evaluate the skeletal response to 
subcutaneously injected hPTH (1-34), the serum level of osteocalcin was quantified. 
Osteocalcin is widely accepted as a marker for bone turnover and was shown to be 
influenced by PTH treatment under different conditions and in different mouse gene 
types (Sheehan et al., 2010). 
The results of the immunohistochemical analysis proved that the implanted human 
PDL cells not only survived, but also were able to develop a bone/cementum like 
tissue which closely resembles natural bone or cementum and that this capacity was 
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significantly enhanced by intermittent PTH administration. These results mirror the in 
vitro findings of our group, which point to a maturation state-dependent effect of 
intermittent PTH on nearly all major PDL cell functions (Lossdörfer et al., 2011c, 
2005, 2011a) and provide proof of their physiological relevance. The anabolic effect 
of intermittent PTH on bone marrow stromal cells (BMSCs) transplanted in 
immunocompromised mice was previously demonstrated by Pettway et al. (Pettway 
et al., 2008). According to their study, 4 weeks of intermittent PTH administration 
increased the bone volume and bone content of implanted collagen sponges 
containing the implanted cells. Another proof of the anabolic potential of PTH in 
dentofacial applications was recently provided by Bashutski et al. who demonstrated 
the therapeutic effect of intermittent PTH on the osseous defect in the oral cavity in 
humans (Bashutski et al., 2010). 
Taken together, our results indicate that intermittent PTH accelerates the PDL cell 
mediated periodontal regeneration and provide further proofs on the therapeutic 
potential of intermittent PTH in regenerating a functional periodontal ligament and 
alveolar bone.  
References 
 
 
122 
5 REFERENCES 
Abou-Samra, A. B., Jüppner, H., Force, T., Freeman, M. W., Kong, X. F., Schipani, 
E., Urena, P., Richards, J., Bonventre, J. V., and Potts, J. T., Jr (1992). 
Expression cloning of a common receptor for parathyroid hormone and 
parathyroid hormone-related peptide from rat osteoblast-like cells: a single 
receptor stimulates intracellular accumulation of both cAMP and inositol 
trisphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. 
U.S.A 89, 2732-2736. 
Akizuki, T., Oda, S., Komaki, M., Tsuchioka, H., Kawakatsu, N., Kikuchi, A., Yamato, 
M., Okano, T., and Ishikawa, I. (2005). Application of periodontal ligament cell 
sheet for periodontal regeneration: a pilot study in beagle dogs. Journal of 
Periodontal Research 40, 245-251. 
Alokail, M. S., and Peddie, M. J. (2008). Quantitative comparison of PTH1R in breast 
cancer MCF7 and osteosarcoma SaOS‐2 cell lines. Cell Biochemistry and 
Function 26, 522-533. 
Armamento-Villareal, R., Ziambaras, K., Abbasi-Jarhomi, S. H., Dimarogonas, A., 
Halstead, L., Fausto, A., Avioli, L. V., and Civitelli, R. (1997). An intact N 
terminus is required for the anabolic action of parathyroid hormone on adult 
female rats. J. Bone Miner. Res 12, 384-392. 
Arora, P. D., and McCulloch, C. A. (1994). Dependence of collagen remodelling on 
alpha-smooth muscle actin expression by fibroblasts. J. Cell. Physiol 159, 
161-175. 
Avnet, S., Longhi, A., Salerno, M., Halleen, J. M., Perut, F., Granchi, D., Ferrari, S., 
Bertoni, F., Giunti, A., and Baldini, N. (2008). Increased osteoclast activity is 
associated with aggressiveness of osteosarcoma. Int. J. Oncol. 33, 1231-
1238. 
Barros, S. P., Silva, M. A. D., Somerman, M. J., and Nociti, F. H., Jr (2003). 
Parathyroid hormone protects against periodontitis-associated bone loss. J. 
Dent. Res 82, 791-795. 
Bartold, P. M. (2006). Periodontal tissues in health and disease: introduction. 
Periodontol. 2000 40, 7-10. 
Bartold, P. M., McCulloch, C. A., Narayanan, A. S., and Pitaru, S. (2000). Tissue 
engineering: a new paradigm for periodontal regeneration based on molecular 
and cell biology. Periodontol. 2000 24, 253-269. 
Bashutski, J. D., and Wang, H.-L. (2009). Periodontal and endodontic regeneration. J 
Endod 35, 321-328. 
Bashutski, J. D., Eber, R. M., Kinney, J. S., Benavides, E., Maitra, S., Braun, T. M., 
Giannobile, W. V., and McCauley, L. K. (2010). Teriparatide and osseous 
regeneration in the oral cavity. N. Engl. J. Med 363, 2396-2405. 
References 
 
 
123 
Beck, F., Tucci, J., Russell, A., Senior, P. V., and Ferguson, M. W. (1995). The 
expression of the gene coding for parathyroid hormone-related protein 
(PTHrP) during tooth development in the rat. Cell Tissue Res. 280, 283-290. 
Becker, J., Schuppan, D., Rabanus, J. P., Rauch, R., Niechoy, U., and Gelderblom, 
H. R. (1991). Immunoelectron microscopic localization of collagens type I, V, 
VI and of procollagen type III in human periodontal ligament and cementum. J. 
Histochem. Cytochem 39, 103-110. 
Beertsen, W. (1975). Migration of fibroblasts in the periodontal ligament of the mouse 
incisor as revealed by autoradiography. Archives of Oral Biology 20, 659-666, 
IN17-IN19. 
Beertsen, W., McCulloch, C. A., and Sodek, J. (1997). The periodontal ligament: a 
unique, multifunctional connective tissue. Periodontol. 2000 13, 20-40. 
Bellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., Weinstein, R. 
S., O’Brien, C. A., Manolagas, S. C., and Jilka, R. L. (2003). Proteasomal 
degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic 
signaling in osteoblasts. A putative explanation for why intermittent 
administration is needed for bone anabolism. J. Biol. Chem 278, 50259-
50272. 
Berkovitz, B. K. (1990). The structure of the periodontal ligament: an update. Eur J 
Orthod 12, 51-76. 
Berkovitz, B. K. B., and Shore, R. C. (1995). The periodontal ligament in health and 
disease 2nd ed. (Lonodn: Mosby-Wolfe). 
Beutner, E. H., and Munson, P. L. (1960). Time course of urinary excretion of 
inorganic phosphate by rats after parathyroidectomy and after injection of 
parathyroid extract. Endocrinology 66, 610-616. 
Bhattacharya, M., Peri, K., Ribeiro-da-Silva, A., Almazan, G., Shichi, H., Hou, X., 
Varma, D. R., and Chemtob, S. (1999). Localization of functional 
prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J. Biol. 
Chem 274, 15719-15724. 
Billinton, N., and Knight, A. W. (2001). Seeing the wood through the trees: a review 
of techniques for distinguishing green fluorescent protein from endogenous 
autofluorescence. Anal. Biochem 291, 175-197. 
Bisello, A., Manen, D., Pierroz, D. D., Usdin, T. B., Rizzoli, R., and Ferrari, S. L. 
(2004). Agonist-specific regulation of parathyroid hormone (PTH) receptor 
type 2 activity: structural and functional analysis of PTH- and 
tuberoinfundibular peptide (TIP) 39-stimulated desensitization and 
internalization. Mol. Endocrinol 18, 1486-1498. 
Boyko, G. A., Melcher, A. H., and Brunette, D. M. (1981). Formation of new 
periodontal ligament by periodontal ligament cells implanted in vivo after 
culture in vitro. A preliminary study of transplanted roots in the dog. J. 
Periodont. Res 16, 73-88. 
References 
 
 
124 
Brixen, K. T., Christensen, P. M., Ejersted, C., and Langdahl, B. L. (2004). 
Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm 
in the treatment of osteoporosis. Basic Clin. Pharmacol. Toxicol 94, 260-270. 
Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., 
Hediger, M. A., Lytton, J., and Hebert, S. C. (1993). Cloning and 
characterization of an extracellular Ca2+-sensing receptor from bovine 
parathyroid. Nature 366, 575-580. 
Carpio, L., Gladu, J., Goltzman, D., and Rabbani, S. A. (2001). Induction of 
osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple 
signaling pathways. Am. J. Physiol. Endocrinol. Metab. 281, E489-499. 
Chauvin, S., Bencsik, M., Bambino, T., and Nissenson, R. A. (2002). Parathyroid 
Hormone Receptor Recycling: Role of Receptor Dephosphorylation and β-
Arrestin. Molecular Endocrinology 16, 2720 -2732. 
Chen, L.-P., Hsu, S.-P., Peng, Y.-S., Chiang, C.-K., and Hung, K.-Y. (2011). 
Periodontal disease is associated with metabolic syndrome in hemodialysis 
patients. Nephrol Dial Transplant. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21602185 [Accessed June 9, 2011]. 
Cheng, Y., and Prusoff, W. H. (1973). Relationship between the inhibition constant 
(K1) and the concentration of inhibitor which causes 50 per cent inhibition 
(I50) of an enzymatic reaction. Biochem. Pharmacol 22, 3099-3108. 
Cho, M. I., Matsuda, N., Lin, W. L., Moshier, A., and Ramakrishnan, P. R. (1992). In 
vitro formation of mineralized nodules by periodontal ligament cells from the 
rat. Calcif. Tissue Int 50, 459-467. 
Cole, J. A. (1997). Down‐Regulation of Protein Kinase C by Parathyroid Hormone 
and Mezerein Differentially Modulates cAMP Production and Phosphate 
Transport in Opossum Kidney Cells. Journal of Bone and Mineral Research 
12, 1223-1230. 
Davidovitch, Z., Musich, D., and Doyle, M. (1972). Hormonal effects on orthodontic 
tooth movement in cats--a pilot study. Am J Orthod 62, 95-96. 
Demay, M., Mitchell, J., and Goltzman, D. (1985). Comparison of renal and osseous 
binding of parathyroid hormone and hormonal fragments. Am. J. Physiol. 249, 
E437-446. 
Divieti, P., Inomata, N., Chapin, K., Singh, R., Jüppner, H., and Bringhurst, F. R. 
(2001). Receptors for the carboxyl-terminal region of pth(1-84) are highly 
expressed in osteocytic cells. Endocrinology 142, 916-925. 
Dong, C., Filipeanu, C. M., Duvernay, M. T., and Wu, G. (2007). Regulation of G 
protein-coupled receptor export trafficking. Biochim. Biophys. Acta 1768, 853-
870. 
 
References 
 
 
125 
Dublet, B., Dixon, E., de Miguel, E., and van der Rest, M. (1988). Bovine type XII 
collagen: amino acid sequence of a 10 kDa pepsin fragment from periodontal 
ligament reveals a high degree of homology with the chicken alpha 1(XII) 
sequence. FEBS Lett 233, 177-180. 
Duvernay, M. T., Filipeanu, C. M., and Wu, G. (2005). The regulatory mechanisms of 
export trafficking of G protein-coupled receptors. Cell. Signal 17, 1457-1465. 
El-Shinnawi, U. M., and El-Tantawy, S. I. (2003). The effect of alendronate sodium 
on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 5, 5-
10. 
Enomoto, M., Kinoshita, A., Pan, H. O., Suzuki, F., Yamamoto, I., and Takigawa, M. 
(1989). Demonstration of receptors for parathyroid hormone on cultured rabbit 
costal chondrocytes. Biochem. Biophys. Res. Commun. 162, 1222-1229. 
Feinstein, T. N., Wehbi, V. L., Ardura, J. A., Wheeler, D. S., Ferrandon, S., Gardella, 
T. J., and Vilardaga, J.-P. (2011). Retromer terminates the generation of 
cAMP by internalized PTH receptors. Nat. Chem. Biol. 7, 278-284. 
Ferguson, S. S. G. (2001). Evolving Concepts in G Protein-Coupled Receptor 
Endocytosis: The Role in Receptor Desensitization and Signaling. 
Pharmacological Reviews 53, 1 -24. 
Ferguson, S. S., Downey, W. E., 3rd, Colapietro, A. M., Barak, L. S., Ménard, L., and 
Caron, M. G. (1996). Role of beta-arrestin in mediating agonist-promoted G 
protein-coupled receptor internalization. Science 271, 363-366. 
Ferrari, S. L., Behar, V., Chorev, M., Rosenblatt, M., and Bisello, A. (1999). 
Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is 
protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring 
by fluorescence microscopy. J. Biol. Chem 274, 29968-29975. 
Flores, M. G., Hasegawa, M., Yamato, M., Takagi, R., Okano, T., and Ishikawa, I. 
(2008). Cementum-periodontal ligament complex regeneration using the cell 
sheet technique. J. Periodont. Res. 43, 364-371. 
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., and Schiöth, H. B. (2003). The G-
protein-coupled receptors in the human genome form five main families. 
Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol 63, 
1256-1272. 
Friedman, P. A., and Goodman, W. G. (2006). PTH(1-84)/PTH(7-84): a balance of 
power. Am. J. Physiol. Renal Physiol 290, F975-984. 
Friedman, P. A., Gesek, F. A., Morley, P., Whitfield, J. F., and Willick, G. E. (1999). 
Cell-Specific Signaling and Structure-Activity Relations of Parathyroid 
Hormone Analogs in Mouse Kidney Cells. Endocrinology 140, 301 -309. 
Fullmer, H. M. (1958). Differential staining of connective tissue fibers in areas of 
stress. Science 127, 1240. 
References 
 
 
126 
Gardella, T. J., and Jüppner, H. (2001). Molecular properties of the PTH/PTHrP 
receptor. Trends Endocrinol. Metab 12, 210-217. 
Gensure, R. C., Gardella, T. J., and Jüppner, H. (2005). Parathyroid hormone and 
parathyroid hormone-related peptide, and their receptors. Biochem. Biophys. 
Res. Commun 328, 666-678. 
Gensure, R. C., Ponugoti, B., Gunes, Y., Papasani, M. R., Lanske, B., Bastepe, M., 
Rubin, D. A., and Jüppner, H. (2004). Identification and Characterization of 
Two Parathyroid Hormone-Like Molecules in Zebrafish. Endocrinology 145, 
1634 -1639. 
Gentili, C., Morelli, S., and de Boland, A. R. (2003). Characterization of PTH/PTHrP 
receptor in rat duodenum: effects of ageing. J. Cell. Biochem. 88, 1157-1167. 
Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, 
A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., et al. (2006). Distinct beta-
arrestin- and G protein-dependent pathways for parathyroid hormone 
receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856-10864. 
Giannobile, W. V., and Somerman, M. J. (2003). Growth and amelogenin-like factors 
in periodontal wound healing. A systematic review. Ann. Periodontol 8, 193-
204. 
Gonçalves, J. S., Sasso-Cerri, E., and Cerri, P. S. (2008). Cell death and quantitative 
reduction of rests of Malassez according to age. J. Periodont. Res. 43, 478-
481. 
Goodman, O. B., Jr, Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., 
Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996). Beta-arrestin acts as a 
clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383, 
447-450. 
Goold, C. P., Usdin, T. B., and Hoare, S. R. J. (2001). Regions in Rat and Human 
Parathyroid Hormone (PTH) 2 Receptors Controlling Receptor Interaction with 
PTH and with Antagonist Ligands. Journal of Pharmacology and Experimental 
Therapeutics 299, 678 -690. 
de Gortázar, A. R., Alonso, V., Alvarez-Arroyo, M. V., and Esbrit, P. (2006). Transient 
exposure to PTHrP (107-139) exerts anabolic effects through vascular 
endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif. 
Tissue Int. 79, 360-369. 
Gould, T. R., Melcher, A. H., and Brunette, D. M. (1977). Location of progenitor cells 
in periodontal ligament of mouse molar stimulated by wounding. Anat. Rec 
188, 133-141. 
Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977). Characteristics of a 
human cell line transformed by DNA from human adenovirus type 5. J. Gen. 
Virol 36, 59-74. 
References 
 
 
127 
Grauschopf, U., Lilie, H., Honold, K., Wozny, M., Reusch, D., Esswein, A., Schäfer, 
W., Rücknagel, K. P., and Rudolph, R. (2000). The N-terminal fragment of 
human parathyroid hormone receptor 1 constitutes a hormone binding domain 
and reveals a distinct disulfide pattern. Biochemistry 39, 8878-8887. 
Guerreiro, P. M., Renfro, J. L., Power, D. M., and Canario, A. V. M. (2007). The 
parathyroid hormone family of peptides: structure, tissue distribution, 
regulation, and potential functional roles in calcium and phosphate balance in 
fish. Am. J. Physiol. Regul. Integr. Comp. Physiol 292, R679-696. 
Habener, J. F., Kemper, B. W., Rich, A., and Potts, J. T., Jr (1976). Biosynthesis of 
parathyroid hormone. Recent Prog. Horm. Res 33, 249-308. 
Habener, J. F., Rosenblatt, M., Kemper, B., Kronenberg, H. M., Rich, A., and Potts, 
J. T., Jr (1978). Pre-proparathyroid hormone; amino acid sequence, chemical 
synthesis, and some biological studies of the precursor region. Proc. Natl. 
Acad. Sci. U.S.A 75, 2616-2620. 
Häkkinen, L., Oksala, O., Salo, T., Rahemtulla, F., and Larjava, H. (1993). 
Immunohistochemical localization of proteoglycans in human periodontium. J. 
Histochem. Cytochem 41, 1689-1699. 
Hall, R. A., and Lefkowitz, R. J. (2002). Regulation of G Protein-Coupled Receptor 
Signaling by Scaffold Proteins. Circ Res 91, 672-680. 
Haramoto, N., Kawane, T., and Horiuchi, N. (2007). Upregulation of PTH receptor 
mRNA expression by dexamethasone in UMR-106 osteoblast-like cells. Oral 
Dis 13, 23-31. 
Hassell, T. M. (1993). Tissues and cells of the periodontium. Periodontol. 2000 3, 9-
38. 
Heijl, L., Heden, G., Svärdström, G., and Ostgren, A. (1997). Enamel matrix 
derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. J. 
Clin. Periodontol 24, 705-714. 
Hermans, E. (2003). Biochemical and pharmacological control of the multiplicity of 
coupling at G-protein-coupled receptors. Pharmacol. Ther 99, 25-44. 
Hoare, S. R., Bonner, T. I., and Usdin, T. B. (1999). Comparison of rat and human 
parathyroid hormone 2 (PTH2) receptor activation: PTH is a low potency 
partial agonist at the rat PTH2 receptor. Endocrinology 140, 4419-4425. 
Hoare, S. R., Clark, J. A., and Usdin, T. B. (2000). Molecular determinants of 
tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid 
hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 
receptor/PTH1 receptor binding selectivity. J. Biol. Chem 275, 27274-27283. 
 
 
References 
 
 
128 
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., 
Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005). 
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a 
review of the evidence and suggested guidelines for its use. Endocr. Rev 26, 
688-703. 
Hodsman, A. B., Fraher, L. J., Ostbye, T., Adachi, J. D., and Steer, B. M. (1993). An 
evaluation of several biochemical markers for bone formation and resorption in 
a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for 
osteoporosis. J. Clin. Invest 91, 1138-1148. 
Hodsman, A. B., Hanley, D. A., Ettinger, M. P., Bolognese, M. A., Fox, J., Metcalfe, 
A. J., and Lindsay, R. (2003). Efficacy and safety of human parathyroid 
hormone-(1-84) in increasing bone mineral density in postmenopausal 
osteoporosis. J. Clin. Endocrinol. Metab 88, 5212-5220. 
Hodsman, A. B., Hanley, D., Watson, P., and Fraher, L. (2002). Parathyroid 
hormone. In Principles of bone biology, J. P. Bilezikian and L. G. (Lawrence G. 
Raisz, eds. (San Diego, Calif.: Academic Press,), pp. 1305–1324. 
Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H., 
Toyama, Y., Bonewald, L. F., and Kudo, A. (1999). Identification and 
characterization of a novel protein, periostin, with restricted expression to 
periosteum and periodontal ligament and increased expression by 
transforming growth factor beta. J. Bone Miner. Res 14, 1239-1249. 
Iida-Klein, A., Guo, J., Takemura, M., Drake, M. T., Potts, J. T., Jr, Abou-Samra, A., 
Bringhurst, F. R., and Segre, G. V. (1997). Mutations in the second 
cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein 
receptor result in selective loss of PTH-stimulated phospholipase C activity. J. 
Biol. Chem. 272, 6882-6889. 
Isales, C. M., Sumpio, B., Bollag, R. J., Zhong, Q., Ding, K.-H., Du, W., Rodriguez-
Commes, J., Lopez, R., Rosales, O. R., Gasalla-Herraiz, J., et al. (2000). 
Functional parathyroid hormone receptors are present in an umbilical vein 
endothelial cell line. American Journal of Physiology - Endocrinology And 
Metabolism 279, E654 -E662. 
Jilka, R. L. (2007). Molecular and cellular mechanisms of the anabolic effect of 
intermittent PTH. Bone 40, 1434-1446. 
Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., and Manolagas, 
S. C. (1999). Increased bone formation by prevention of osteoblast apoptosis 
with parathyroid hormone. J. Clin. Invest 104, 439-446. 
John, M. R., Arai, M., Rubin, D. A., Jonsson, K. B., and Jüppner, H. (2002). 
Identification and characterization of the murine and human gene encoding 
the tuberoinfundibular peptide of 39 residues. Endocrinology 143, 1047-1057. 
 
References 
 
 
129 
Johnston, S., Andrews, S., Shen, V., Cosman, F., Lindsay, R., Dempster, D. W., and 
Iida-Klein, A. (2007). The effects of combination of alendronate and human 
parathyroid hormone(1-34) on bone strength are synergistic in the lumbar 
vertebra and additive in the femur of C57BL/6J mice. Endocrinology 148, 
4466-4474. 
Jong, Y.-J. I., Kumar, V., Kingston, A. E., Romano, C., and O’Malley, K. L. (2005). 
Functional metabotropic glutamate receptors on nuclei from brain and primary 
cultured striatal neurons. Role of transporters in delivering ligand. J. Biol. 
Chem 280, 30469-30480. 
Jongen, J. W., Willemstein-van Hove, E. C., van der Meer, J. M., Bos, M. P., 
Jüppner, H., Segre, G. V., Abou-Samra, A. B., Feyen, J. H., and Herrmann-
Erlee, M. P. (1996). Down-regulation of the receptor for parathyroid hormone 
(PTH) and PTH-related peptide by PTH in primary fetal rat osteoblasts. J. 
Bone Miner. Res. 11, 1218-1225. 
Jönsson, D., Nebel, D., Bratthall, G., and Nilsson, B.-O. (2011). The human 
periodontal ligament cell: a fibroblast-like cell acting as an immune cell. J. 
Periodont. Res 46, 153-157. 
Jonsson, K. B., John, M. R., Gensure, R. C., Gardella, T. J., and Jüppner, H. (2001). 
Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-
related peptide receptor, but functions as an antagonist. Endocrinology 142, 
704-709. 
Jouishomme, H., Whitfield, J. F., Gagnon, L., Maclean, S., Isaacs, R., Chakravarthy, 
B., Durkin, J., Neugebauer, W., Willick, G., and Rixon, R. H. (1994). Further 
definition of the protein kinase C activation domain of the parathyroid 
hormone. J. Bone Miner. Res 9, 943-949. 
Jung, R. E., Glauser, R., Schärer, P., Hämmerle, C. H. F., Sailer, H. F., and Weber, 
F. E. (2003). Effect of rhBMP-2 on guided bone regeneration in humans. Clin 
Oral Implants Res 14, 556-568. 
Juppner, H., Abou-Samra, A., Freeman, M., Kong, X., Schipani, E., Richards, J., 
Kolakowski, L., Hock, J., Potts, J., Kronenberg, H., et al. (1991). A G protein-
linked receptor for parathyroid hormone and parathyroid hormone-related 
peptide. Science 254, 1024 -1026. 
Karim, Z., Gérard, B., Bakouh, N., Alili, R., Leroy, C., Beck, L., Silve, C., Planelles, 
G., Urena-Torres, P., Grandchamp, B., et al. (2008). NHERF1 mutations and 
responsiveness of renal parathyroid hormone. N. Engl. J. Med 359, 1128-
1135. 
Karimbux, N. Y., Rosenblum, N. D., and Nishimura, I. (1992). Site-specific 
expression of collagen I and XII mRNAs in the rat periodontal ligament at two 
developmental stages. J. Dent. Res 71, 1355-1362. 
 
References 
 
 
130 
Kato, A., Suzuki, M., Karasawa, Y., Sugimoto, T., and Doi, K. (2005a). 
Immunohistochemical Detection of PTHrP and PTH/PTHrP Receptor 1 on the 
Odontoblastic Reparative Process after Actinomycin D Treatment in Rats. 
Journal of Toxicologic Pathology 18, 33-39. 
Kato, A., Suzuki, M., Karasawa, Y., Sugimoto, T., and Doi, K. (2005b). PTHrP and 
PTH/PTHrP receptor 1 expression in odontogenic cells of normal and HHM 
model rat incisors. Toxicol Pathol 33, 456-464. 
Kato, C., Kojima, T., Komaki, M., Mimori, K., Duarte, W. R., Takenaga, K., and 
Ishikawa, I. (2004). S100A4 inhibition by RNAi up-regulates osteoblast related 
genes in periodontal ligament cells. Biochemical and Biophysical Research 
Communications 326, 147-153. 
Kawane, T., Mimura, J., Fujii-Kuriyama, Y., and Horiuchi, N. (2001). Parathyroid 
hormone (PTH) suppresses rat PTH/PTH-related protein receptor gene 
promoter. Biochem. Biophys. Res. Commun 287, 313-322. 
Kebschull, M., Demmer, R. T., and Papapanou, P. N. (2010). “Gum bug, leave my 
heart alone!”--epidemiologic and mechanistic evidence linking periodontal 
infections and atherosclerosis. J. Dent. Res 89, 879-902. 
Kilav, R., Silver, J., and Naveh-Many, T. (1995). Parathyroid hormone gene 
expression in hypophosphatemic rats. J. Clin. Invest. 96, 327-333. 
King, G. L. (2008). The role of inflammatory cytokines in diabetes and its 
complications. J. Periodontol 79, 1527-1534. 
Kobilka, B. K. (2007). G Protein Coupled Receptor Structure and Activation. Biochim 
Biophys Acta 1768, 794-807. 
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227, 680-685. 
Langub, M. C., Monier-Faugere, M. C., Qi, Q., Geng, Z., Koszewski, N. J., and 
Malluche, H. H. (2001). Parathyroid hormone/parathyroid hormone-related 
peptide type 1 receptor in human bone. J. Bone Miner. Res 16, 448-456. 
Lawson, D. E., Fraser, D. R., Kodicek, E., Morris, H. R., and Williams, D. H. (1971). 
Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone 
controlling calcium metabolism. Nature 230, 228-230. 
Lee, D. K., Lança, A. J., Cheng, R., Nguyen, T., Ji, X. D., Gobeil, F., Jr, Chemtob, S., 
George, S. R., and O’Dowd, B. F. (2004). Agonist-independent nuclear 
localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. J. 
Biol. Chem 279, 7901-7908. 
Lekic, P., and McCulloch, C. A. (1996). Periodontal ligament cell population: the 
central role of fibroblasts in creating a unique tissue. Anat. Rec 245, 327-341. 
Lekic, P., Rojas, J., Birek, C., Tenenbaum, H., and McCulloch, C. A. (2001). 
Phenotypic comparison of periodontal ligament cells in vivo and in vitro. J. 
Periodont. Res 36, 71-79. 
References 
 
 
131 
Li, H., Bartold, P. M., Young, W. G., Xiao, Y., and Waters, M. J. (2001). Growth 
hormone induces bone morphogenetic proteins and bone-related proteins in 
the developing rat periodontium. J. Bone Miner. Res 16, 1068-1076. 
Liu, J., Cao, Z., and Li, C. (2009). Intermittent PTH administration: a novel therapy 
method for periodontitis-associated alveolar bone loss. Med. Hypotheses 72, 
294-296. 
Lossdörfer, S., Abuduwali, N., and Jäger, A. (2011a). Bone morphogenetic protein-7 
modifies the effects of insulin-like growth factors and intermittent parathyroid 
hormone (1-34) on human periodontal ligament cell physiology in vitro. J. 
Periodontol. 82, 900-908. 
Lossdörfer, S., Götz, W., and Jäger, A. (2005). PTH(1-34) affects osteoprotegerin 
production in human PDL cells in vitro. J. Dent. Res. 84, 634-638. 
Lossdörfer, S., Götz, W., and Jäger, A. (2011b). PTH(1-34)-induced changes in 
RANKL and OPG expression by human PDL cells modify osteoclast biology in 
a co-culture model with RAW 264.7 cells. Clin Oral Investig 15, 941-952. 
Lossdörfer, S., Götz, W., Rath-Deschner, B., and Jäger, A. (2006a). Parathyroid 
hormone(1-34) mediates proliferative and apoptotic signaling in human 
periodontal ligament cells in vitro via protein kinase C-dependent and protein 
kinase A-dependent pathways. Cell Tissue Res. 325, 469-479. 
Lossdörfer, S., Götz, W., and Jäger, A. (2011b). PTH(1-34)-induced changes in 
RANKL and OPG expression by human PDL cells modify osteoclast biology in 
a co-culture model with RAW 264.7 cells. Clin Oral Investig 15, 941-952. 
Lossdörfer, S., Kraus, D., Abuduwali, N., and Jäger, A. (2011c). Intermittent 
administration of PTH(1-34) regulates the osteoblastic differentiation of human 
periodontal ligament cells via protein kinase C- and protein kinase A-
dependent pathways in vitro. J. Periodont. Res. 46, 318-326. 
Lossdörfer, S., Stier, S., Götz, W., and Jäger, A. (2006b). Maturation-state 
dependent response of human periodontal ligament cells to an intermittent 
parathyroid hormone exposure in vitro. J. Periodont. Res 41, 62-72. 
Lu, B., Smock, S. L., Castleberry, T. A., and Owen, T. A. (2001). Molecular cloning 
and functional characterization of the canine androgen receptor. Mol. Cell. 
Biochem 226, 129-140. 
Lu, D., Yang, H., Shaw, G., and Raizada, M. K. (1998). Angiotensin II-induced 
nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. 
Endocrinology 139, 365-375. 
Luck, M. D., Carter, P. H., and Gardella, T. J. (1999). The (1-14) fragment of 
parathyroid hormone (PTH) activates intact and amino-terminally truncated 
PTH-1 receptors. Mol. Endocrinol 13, 670-680. 
References 
 
 
132 
Lukinmaa, P. L., and Waltimo, J. (1992). Immunohistochemical localization of types I, 
V, and VI collagen in human permanent teeth and periodontal ligament. J. 
Dent. Res 71, 391-397. 
Lutolf, M. P., and Hubbell, J. A. (2005). Synthetic biomaterials as instructive 
extracellular microenvironments for morphogenesis in tissue engineering. Nat 
Biotech 23, 47-55. 
Ma, P. X. (2008). Biomimetic Materials for Tissue Engineering. Adv Drug Deliv Rev 
60, 184-198. 
Mahon, M. J., and Segre, G. V. (2004). Stimulation by parathyroid hormone of a 
NHERF-1-assembled complex consisting of the parathyroid hormone I 
receptor, phospholipase Cbeta, and actin increases intracellular calcium in 
opossum kidney cells. J. Biol. Chem 279, 23550-23558. 
Mahon, M. J., Bonacci, T. M., Divieti, P., and Smrcka, A. V. (2006). A docking site for 
G protein betagamma subunits on the parathyroid hormone 1 receptor 
supports signaling through multiple pathways. Mol. Endocrinol 20, 136-146. 
Mahon, M. J., Donowitz, M., Yun, C. C., and Segre, G. V. (2002). Na(+)/H(+ ) 
exchanger regulatory factor 2 directs parathyroid hormone 1 receptor 
signalling. Nature 417, 858-861. 
Malecz, N., Bambino, T., Bencsik, M., and Nissenson, R. A. (1998). Identification of 
phosphorylation sites in the G protein-coupled receptor for parathyroid 
hormone. Receptor phosphorylation is not required for agonist-induced 
internalization. Mol. Endocrinol 12, 1846-1856. 
Mannstadt, M., Jüppner, H., and Gardella, T. J. (1999). Receptors for PTH and 
PTHrP: their biological importance and functional properties. Am. J. Physiol 
277, F665-675. 
Marchesan, J. T., Scanlon, C. S., Soehren, S., Matsuo, M., and Kapila, Y. L. (2011). 
Implications of cultured periodontal ligament cells for the clinical and 
experimental setting: A review. Arch Oral Biol. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21470594 [Accessed June 11, 2011]. 
Marinissen, M. J., and Gutkind, J. S. (2001). G-protein-coupled receptors and 
signaling networks: emerging paradigms. Trends Pharmacol. Sci 22, 368-376. 
Massry, S. G., and Smogorzewski, M. (1998). PTH-PTHrP receptor in chronic renal 
failure. Nephrol. Dial. Transplant 13 Suppl 1, 50-57. 
McCuaig, K. A., Clarke, J. C., and White, J. H. (1994). Molecular cloning of the gene 
encoding the mouse parathyroid hormone/parathyroid hormone-related 
peptide receptor. Proc. Natl. Acad. Sci. U.S.A 91, 5051-5055. 
McCulloch, C. A., Lekic, P., and McKee, M. D. (2000). Role of physical forces in 
regulating the form and function of the periodontal ligament. Periodontol. 2000 
24, 56-72. 
References 
 
 
133 
Mosiman, V. L., Patterson, B. K., Canterero, L., and Goolsby, C. L. (1997). Reducing 
cellular autofluorescence in flow cytometry: an in situ method. Cytometry 30, 
151-156. 
Mukai, M., Yoshimine, Y., Akamine, A., and Maeda, K. (1993). Bone-like nodules 
formed in vitro by rat periodontal ligament cells. Cell Tissue Res. 271, 453-
460. 
Murray, T. M., Rao, L. G., Divieti, P., and Bringhurst, F. R. (2005). Parathyroid 
hormone secretion and action: evidence for discrete receptors for the 
carboxyl-terminal region and related biological actions of carboxyl- terminal 
ligands. Endocr. Rev 26, 78-113. 
Nanci, A., and Bosshardt, D. D. (2006). Structure of periodontal tissues in health and 
disease. Periodontol. 2000 40, 11-28. 
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. 
Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. 
(2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral 
density in postmenopausal women with osteoporosis. N. Engl. J. Med 344, 
1434-1441. 
Nevins, M., Giannobile, W. V., McGuire, M. K., Kao, R. T., Mellonig, J. T., Hinrichs, J. 
E., McAllister, B. S., Murphy, K. S., McClain, P. K., Nevins, M. L., et al. (2005). 
Platelet-derived growth factor stimulates bone fill and rate of attachment level 
gain: results of a large multicenter randomized controlled trial. J. Periodontol 
76, 2205-2215. 
Nohutcu, R. M., Somerman, M. J., and McCauley, L. K. (1995). Dexamethasone 
enhances the effects of parathyroid hormone on human periodontal ligament 
cells in vitro. Calcif. Tissue Int 56, 571-577. 
Nojima, N., Kobayashi, M., Shionome, M., Takahashi, N., Suda, T., and Hasegawa, 
K. (1990). Fibroblastic cells derived from bovine periodontal ligaments have 
the phenotypes of osteoblasts. J. Periodont. Res 25, 179-185. 
Nyman, S., Lindhe, J., Karring, T., and Rylander, H. (1982). New attachment 
following surgical treatment of human periodontal disease. J. Clin. Periodontol 
9, 290-296. 
Offenbacher, S., Katz, V., Fertik, G., Collins, J., Boyd, D., Maynor, G., McKaig, R., 
and Beck, J. (1996). Periodontal infection as a possible risk factor for preterm 
low birth weight. J. Periodontol 67, 1103-1113. 
Onyia, J. E., Bidwell, J., Herring, J., Hulman, J., and Hock, J. M. (1995). In vivo, 
human parathyroid hormone fragment (hPTH 1-34) transiently stimulates 
immediate early response gene expression, but not proliferation, in trabecular 
bone cells of young rats. Bone 17, 479-484. 
 
References 
 
 
134 
Ouyang, H., McCauley, L. K., Berry, J. E., D’Errico, J. A., Strayhorn, C. L., and 
Somerman, M. J. (2000). Response of immortalized murine 
cementoblasts/periodontal ligament cells to parathyroid hormone and 
parathyroid hormone-related protein in vitro. Arch. Oral Biol 45, 293-303. 
Pautke, C., Schieker, M., Tischer, T., Kolk, A., Neth, P., Mutschler, W., and Milz, S. 
(2004). Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 
OS in comparison to human osteoblasts. Anticancer Res 24, 3743-3748. 
Periodontal Ligament - Studio Dentaire Available at: 
http://www.studiodentaire.com/en/glossary/periodontal_ligament.php 
[Accessed May 18, 2011]. 
Periodontitis Types: Periapical and Apical, Chronic and Aggressive Periodontitis 
Available at: http://periodontitis.dentalbuzz.org/types/periapical-apical-chronic-
aggressive-periodontitis/ [Accessed June 22, 2011]. 
Pettway, G. J., Meganck, J. A., Koh, A. J., Keller, E. T., Goldstein, S. A., and 
McCauley, L. K. (2008). Parathyroid Hormone Mediates Bone Growth through 
the Regulation of Osteoblast Proliferation and Differentiation. Bone 42, 806-
818. 
Pettway, G. J., Schneider, A., Koh, A. J., Widjaja, E., Morris, M. D., Meganck, J. A., 
Goldstein, S. A., and McCauley, L. K. (2005). Anabolic actions of PTH (1-34): 
use of a novel tissue engineering model to investigate temporal effects on 
bone. Bone 36, 959-970. 
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res 29, e45. 
Pihlstrom, B. L., Michalowicz, B. S., and Johnson, N. W. (2005). Periodontal 
diseases. Lancet 366, 1809-1820. 
Pliam, N. B., Nyiredy, K. O., and Arnaud, C. D. (1982). Parathyroid hormone 
receptors in avian bone cells. Proc. Natl. Acad. Sci. U.S.A. 79, 2061-2063. 
Potts, J. T., Jr, Bringhurst, F. R., Gardella, T. J., Nussbaum, S. R., Segre, G. V., and 
Kronenberg, H. M. (1995). Parathyroid hormone. physiology, 
chemistry,biosynthesis, secretion, metabolism,and mode of action. In 
Endocrinology, L. J. DeGroot,, ed. (Philadelphia: W.B. Saunders), pp. 920–
966. 
Pullman, T. N., Lavender, A. R., Aho, I., and Rasmussen, H. (1960). Direct renal 
action of a purified parathyroid extract. Endocrinology 67, 570-582. 
Qin, L., Li, X., Ko, J.-K., and Partridge, N. C. (2005). Parathyroid hormone uses 
multiple mechanisms to arrest the cell cycle progression of osteoblastic cells 
from G1 to S phase. J. Biol. Chem 280, 3104-3111. 
Qiu, T., Wu, X., Zhang, F., Clemens, T. L., Wan, M., and Cao, X. (2010). TGF-[beta] 
type II receptor phosphorylates PTH receptor to integrate bone remodelling 
signalling. Nat Cell Biol 12, 224-234. 
References 
 
 
135 
Quattrocchi, E., and Kourlas, H. (2004). Teriparatide: a review. Clin Ther 26, 841-
854. 
Rao, L. G., and Murray, T. M. (1985). Binding of intact parathyroid hormone to rat 
osteosarcoma cells: major contribution of binding sites for the carboxyl-
terminal region of the hormone. Endocrinology 117, 1632-1638. 
Rashid, G., Bernheim, J., Green, J., and Benchetrit, S. (2007). Parathyroid hormone 
stimulates the endothelial nitric oxide synthase through protein kinase A and C 
pathways. Nephrology Dialysis Transplantation 22, 2831 -2837. 
Rincon, J. C., Young, W. G., and Bartold, P. M. (2006). The epithelial cell rests of 
Malassez--a role in periodontal regeneration? J. Periodont. Res. 41, 245-252. 
Rios, H. F., Lin, Z., Oh, B., Park, C. H., and Giannobile, W. V. (2011). Cell- and 
Gene-Based Therapeutic Strategies for Periodontal Regenerative Medicine. J 
Periodontol. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21284553 
[Accessed June 9, 2011]. 
Rodan, S. B., Fischer, M. K., Egan, J. J., Epstein, P. M., and Rodan, G. A. (1984). 
The effect of dexamethasone on parathyroid hormone stimulation of adenylate 
cyclase in ROS 17/2.8 cells. Endocrinology 115, 951-958. 
Rubin, D. A., and Jüppner, H. (1999). Zebrafish express the common parathyroid 
hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel 
receptor (PTH3R) that is preferentially activated by mammalian and fugufish 
parathyroid hormone-related peptide. J. Biol. Chem 274, 28185-28190. 
Rubin, M. R., Cosman, F., Lindsay, R., and Bilezikian, J. P. (2002). The anabolic 
effects of parathyroid hormone. Osteoporos Int 13, 267-277. 
Schipani, E., and Provot, S. (2003). PTHrP, PTH, and the PTH/PTHrP receptor in 
endochondral bone development. Birth Defects Res. C Embryo Today 69, 
352-362. 
Schipani, E., Karga, H., Karaplis, A. C., Potts, J. T., Jr, Kronenberg, H. M., Segre, G. 
V., Abou-Samra, A. B., and Jüppner, H. (1993). Identical complementary 
deoxyribonucleic acids encode a human renal and bone parathyroid hormone 
(PTH)/PTH-related peptide receptor. Endocrinology 132, 2157-2165. 
Schneider, L. C., Hollinshead, M. B., and Lizzack, L. S. (1972). Tooth eruption 
induced in grey lethal mice using parathyroid hormone. Arch. Oral Biol 17, 
591-594. 
Seo, B.-M., Miura, M., Gronthos, S., Bartold, P. M., Batouli, S., Brahim, J., Young, M., 
Robey, P. G., Wang, C.-Y., and Shi, S. (2004). Investigation of multipotent 
postnatal stem cells from human periodontal ligament. Lancet 364, 149-155. 
Seymour, G. J., Ford, P. J., Cullinan, M. P., Leishman, S., and Yamazaki, K. (2007). 
Relationship between periodontal infections and systemic disease. Clin. 
Microbiol. Infect 13 Suppl 4, 3-10. 
References 
 
 
136 
Sheehan, S., Muthusamy, A., Paul, E., Sikes, R. A., and Gomes, R. R., Jr (2010). 
Short-term intermittent PTH 1-34 administration enhances bone formation in 
SCID/Beige mice. Endocr. J. 57, 373-382. 
Shenolikar, S., Voltz, J. W., Minkoff, C. M., Wade, J. B., and Weinman, E. J. (2002). 
Targeted disruption of the mouse NHERF-1 gene promotes internalization of 
proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate 
wasting. Proceedings of the National Academy of Sciences 99, 11470 -11475. 
Shimizu, M., Carter, P. H., and Gardella, T. J. (2000a). Autoactivation of Type-1 
Parathyroid Hormone Receptors Containing a Tethered Ligand. Journal of 
Biological Chemistry 275, 19456 -19460. 
Shimizu, M., Potts, J. T., Jr, and Gardella, T. J. (2000b). Minimization of parathyroid 
hormone. Novel amino-terminal parathyroid hormone fragments with 
enhanced potency in activating the type-1 parathyroid hormone receptor. J. 
Biol. Chem 275, 21836-21843. 
Shore, R. C., and Berkovitz, B. K. B. (1979). An ultrastructural study of periodontal 
ligament fibroblasts in relation to their possible role in tooth eruption and 
intracellular collagen degradation in the rat. Archives of Oral Biology 24, 155-
164. 
Shvil, Y., Naveh-Many, T., Barach, P., and Silver, J. (1990). Regulation of 
parathyroid cell gene expression in experimental uremia. J. Am. Soc. Nephrol 
1, 99-104. 
Silver, J., and Levi, R. (2005). Regulation of PTH synthesis and secretion relevant to 
the management of secondary hyperparathyroidism in chronic kidney disease. 
Kidney Int 67, s8-s12. 
Silver, J., Moallem, E., Kilav, R., Sela, A., and Naveh-Many, T. (1998). Regulation of 
the parathyroid hormone gene by calcium, phosphate and 1,25-
dihydroxyvitamin D. Nephrol. Dial. Transplant 13 Suppl 1, 40-44. 
Silver, J., Naveh-Many, T., Mayer, H., Schmelzer, H. J., and Popovtzer, M. M. (1986). 
Regulation by vitamin D metabolites of parathyroid hormone gene 
transcription in vivo in the rat. J. Clin. Invest 78, 1296-1301. 
Silver, J., Yalcindag, C., Sela-Brown, A., Kilav, R., and Naveh-Many, T. (1999). 
Regulation of the parathyroid hormone gene by vitamin D, calcium and 
phosphate. Kidney Int 56, 2-7. 
Singh, A. T. K., Gilchrist, A., Voyno-Yasenetskaya, T., Radeff-Huang, J. M., and 
Stern, P. H. (2005). G alpha12/G alpha13 subunits of heterotrimeric G 
proteins mediate parathyroid hormone activation of phospholipase D in UMR-
106 osteoblastic cells. Endocrinology 146, 2171-2175. 
Smith, D. P., Zhang, X. Y., Frolik, C. A., Harvey, A., Chandrasekhar, S., Black, E. C., 
and Hsiung, H. M. (1996). Structure and functional expression of a 
complementary DNA for porcine parathyroid hormone/parathyroid hormone-
related peptide receptor. Biochim. Biophys. Acta 1307, 339-347. 
References 
 
 
137 
Smock, S. L., Vogt, G. A., Castleberry, T. A., Lu, B., and Owen, T. A. (2001). 
Molecular cloning and functional characterization of the canine parathyroid 
hormone/parathyroid hormone related peptide receptor (PTH1). Mol. Biol. 
Rep. 28, 235-243. 
Sneddon, W. B., Barry, E. L., Coutermarsh, B. A., Gesek, F. A., Liu, F., and 
Friedman, P. A. (1998). Regulation of renal parathyroid hormone receptor 
expression by 1, 25-dihydroxyvitamin D3 and retinoic acid. Cell. Physiol. 
Biochem. 8, 261-277. 
Somerman, M. J., Archer, S. Y., Imm, G. R., and Foster, R. A. (1988). A comparative 
study of human periodontal ligament cells and gingival fibroblasts in vitro. J. 
Dent. Res 67, 66-70. 
Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., 
Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997). 
Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. 
Science 275, 73-77. 
Stewart, A. F. (1996). PTHrP(1-36) as a skeletal anabolic agent for the treatment of 
osteoporosis. Bone 19, 303-306. 
Sugimoto, T., Ikeda, K., Kano, J., Yamaguchi, T., Fukase, M., and Chihara, K. 
(1994). Cross-talk of parathyroid hormone-responsive dual signal transduction 
systems in osteoblastic osteosarcoma cells: its role in PTH-induced 
homologous desensitization of intracellular calcium response. J. Cell. Physiol. 
158, 374-380. 
Sutherland, M. K., Rao, L. G., Wylie, J. N., Gupta, A., Ly, H., Sodek, J., and Murray, 
T. M. (1994). Carboxyl-terminal parathyroid hormone peptide (53-84) elevates 
alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J. Bone 
Miner. Res 9, 453-458. 
Takasu, H., Gardella, T. J., Luck, M. D., Potts, J. T., Jr, and Bringhurst, F. R. (1999). 
Amino-terminal modifications of human parathyroid hormone (PTH) selectively 
alter phospholipase C signaling via the type 1 PTH receptor: implications for 
design of signal-specific PTH ligands. Biochemistry 38, 13453-13460. 
Takayama, S., Murakami, S., Miki, Y., Ikezawa, K., Tasaka, S., Terashima, A., 
Asano, T., and Okada, H. (1997). Effects of basic fibroblast growth factor on 
human periodontal ligament cells. J. Periodont. Res 32, 667-675. 
Tawfeek, H. A. W., Qian, F., and Abou-Samra, A. B. (2002). Phosphorylation of the 
receptor for PTH and PTHrP is required for internalization and regulates 
receptor signaling. Mol. Endocrinol 16, 1-13. 
Teare, J. A., Ramoshebi, L. N., and Ripamonti, U. (2008). Periodontal tissue 
regeneration by recombinant human transforming growth factor-beta 3 in 
Papio ursinus. J. Periodont. Res 43, 1-8. 
Ten Cate, A. R. (1998). Oral Histology: Development, Structure, and Function 5th ed. 
(St. Louis: Mosby). 
References 
 
 
138 
Ten Cate, A. R., Mills, C., and Solomon, G. (1971). The development of the 
periodontium. A transplantation and autoradiographic study. Anat. Rec 170, 
365-379. 
Tenorio, D., and Hughes, F. J. (1996). An immunohistochemical investigation of the 
expression of parathyroid hormone receptors in rat cementoblasts. Arch. Oral 
Biol 41, 299-305. 
Tenta, R., Sourla, A., Lembessis, P., and Koutsilieris, M. (2006). Bone-related growth 
factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation 
systems in MG-63 human osteosarcoma cells. Anticancer Res. 26, 283-291. 
Tian, J., Smogorzewski, M., Kedes, L., and Massry, S. G. (1994). PTH-PTHrP 
receptor mRNA is downregulated in chronic renal failure. Am. J. Nephrol 14, 
41-46. 
Titus, L., Jackson, E., Nanes, M. S., Rubin, J. E., and Catherwood, B. D. (1991). 
1,25-dihydroxyvitamin D reduces parathyroid hormone receptor number in 
ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these 
receptors: relationship to adenylate cyclase activation. J. Bone Miner. Res 6, 
631-637. 
Tsai, B., Ye, Y., and Rapoport, T. A. (2002). Retro-translocation of proteins from the 
endoplasmic reticulum into the cytosol. Nat. Rev. Mol. Cell Biol 3, 246-255. 
Turner, C. H. (2002). Biomechanics of bone: determinants of skeletal fragility and 
bone quality. Osteoporos Int 13, 97-104. 
Ureña, P., Ferreira, A., Morieux, C., Drüeke, T., and Christine de Vernejoul, M. 
(1996). PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage 
growth plate of uraemic rats. Nephrology Dialysis Transplantation 11, 2008 -
2016. 
Ureña, P., Iida-Klein, A., Kong, X. F., Jüppner, H., Kronenberg, H. M., Abou-Samra, 
A. B., and Segre, G. V. (1994a). Regulation of parathyroid hormone 
(PTH)/PTH-related peptide receptor messenger ribonucleic acid by 
glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology 134, 451-
456. 
Ureña, P., Kong, X. F., Abou-Samra, A. B., Jüppner, H., Kronenberg, H. M., Potts, J. 
T., Jr, and Segre, G. V. (1993). Parathyroid hormone (PTH)/PTH-related 
peptide receptor messenger ribonucleic acids are widely distributed in rat 
tissues. Endocrinology 133, 617-623. 
Ureña, P., Kubrusly, M., Mannstadt, M., Hruby, M., Trinh, M. M., Silve, C., Lacour, B., 
Abou-Samra, A. B., Segre, G. V., and Drüeke, T. (1994b). The renal 
PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. 
Kidney Int 45, 605-611. 
Usdin, T. B. (2000). The PTH2 receptor and TIP39: a new peptide-receptor system. 
Trends in Pharmacological Sciences 21, 128-130. 
References 
 
 
139 
Usdin, T. B., Bonner, T. I., and Hoare, S. R. J. (2002). The parathyroid hormone 2 
(PTH2) receptor. Recept. Channels 8, 211-218. 
Usdin, T. B., Bonner, T. I., Harta, G., and Mezey, E. (1996). Distribution of 
parathyroid hormone-2 receptor messenger ribonucleic acid in rat. 
Endocrinology 137, 4285-4297. 
Usdin, T. B., Gruber, C., and Bonner, T. I. (1995). Identification and Functional 
Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the 
PTH2 Receptor. Journal of Biological Chemistry 270, 15455 -15458. 
Usdin, T. B., Wang, T., Hoare, S. R., Mezey, E., and Palkovits, M. (2000). New 
members of the parathyroid hormone/parathyroid hormone receptor family: the 
parathyroid hormone 2 receptor and tuberoinfundibular peptide of 39 residues. 
Front Neuroendocrinol 21, 349-383. 
Vilardaga, J.-P., Romero, G., Friedman, P. A., and Gardella, T. J. (2011). Molecular 
basis of parathyroid hormone receptor signaling and trafficking: a family B 
GPCR paradigm. Cell. Mol. Life Sci 68, 1-13. 
Wada, N., Maeda, H., Tanabe, K., Tsuda, E., Yano, K., Nakamuta, H., and Akamine, 
A. (2001). Periodontal ligament cells secrete the factor that inhibits 
osteoclastic differentiation and function: the factor is 
osteoprotegerin/osteoclastogenesis inhibitory factor. J. Periodont. Res 36, 56-
63. 
Wang, B., Bisello, A., Yang, Y., Romero, G. G., and Friedman, P. A. (2007). NHERF1 
regulates parathyroid hormone receptor membrane retention without affecting 
recycling. J. Biol. Chem 282, 36214-36222. 
Wang, B., Yang, Y., Abou-Samra, A. B., and Friedman, P. A. (2009). NHERF1 
regulates parathyroid hormone receptor desensitization: interference with 
beta-arrestin binding. Mol. Pharmacol 75, 1189-1197. 
Watson, P. H., Fraher, L. J., Hendy, G. N., Chung, U. I., Kisiel, M., Natale, B. V., and 
Hodsman, A. B. (2000). Nuclear localization of the type 1 PTH/PTHrP receptor 
in rat tissues. J. Bone Miner. Res 15, 1033-1044. 
Wheeler, D., Sneddon, W. B., Wang, B., Friedman, P. A., and Romero, G. (2007). 
NHERF-1 and the Cytoskeleton Regulate the Traffic and Membrane Dynamics 
of G Protein-coupled Receptors. Journal of Biological Chemistry 282, 25076 -
25087. 
Whitfield, J. F., Isaacs, R. J., Chakravarthy, B., Maclean, S., Morley, P., Willick, G., 
Divieti, P., and Bringhurst, F. R. (2001). Stimulation of protein kinase C activity 
in cells expressing human parathyroid hormone receptors by C- and N-
terminally truncated fragments of parathyroid hormone 1-34. J. Bone Miner. 
Res 16, 441-447. 
Wong, S. K.-F. (2003). G protein selectivity is regulated by multiple intracellular 
regions of GPCRs. Neurosignals 12, 1-12. 
References 
 
 
140 
Xie, L. Y., Leung, A., Segre, G. V., Yamamoto, I., and Abou-Samra, A. B. (1996). 
Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-
like ROS 17/2.8 cells. Am. J. Physiol 270, E654-660. 
Yaghoobian, J., and Drüeke, T. B. (1998). Regulation of the transcription of 
parathyroid-hormone/parathyroid-hormone-related peptide receptor mRNA by 
dexamethasone in ROS 17/2.8 osteosarcoma cells. Nephrol. Dial. Transplant. 
13, 580-586. 
Yamamoto, I., Shigeno, C., Potts, J. T., Jr, and Segre, G. V. (1988). Characterization 
and agonist-induced down-regulation of parathyroid hormone receptors in 
clonal rat osteosarcoma cells. Endocrinology 122, 1208-1217. 
Yamashita, Y., Sato, M., and Noguchi, T. (1987). Alkaline phosphatase in the 
periodontal ligament of the rabbit and macaque monkey. Arch. Oral Biol 32, 
677-678. 
Zhang, X., Schuppan, D., Becker, J., Reichart, P., and Gelderblom, H. R. (1993). 
Distribution of undulin, tenascin, and fibronectin in the human periodontal 
ligament and cementum: comparative immunoelectron microscopy with ultra-
thin cryosections. J. Histochem. Cytochem 41, 245-251. 
Zhou, A. T., Assil, I., and Abou-Samra, A. B. (2000). Role of asparagine-linked 
oligosaccharides in the function of the rat PTH/PTHrP receptor. Biochemistry 
39, 6514-6520. 
Abbreviations 
 
 
141 
6 ABBREVIATIONS 
°C     degrees centigrade 
µg     micro grams 
µl     micro litre 
µM     micro molar 
µm    micro meter 
a.a.     amino acids 
APS     ammonium per sulfate 
ATP     adenosine triphosphate 
BCA     bicinchonic acid 
bp     base pairs 
BSA     bovine serum albumin 
cAMP    cyclic adenosine monophosphate 
cDNA    complementary deoxyribonucleic acid 
cm    centimeter 
DAB    diaminobenzidine 
DAPI     4', 6-Diamidino-2-phenylindole 
ddH2O    double distilled water 
dNTP     deoxynucleotide triphosphate 
DMEM    dulbecco´s modified Eagle’s medium 
DMSO    dimethyl sulphoxide 
DNA     deoxyribonucleic acid 
ECL     enhanced chemiluminescence 
EDTA    ethylene diamine tetra acetic acid 
ELISA    enzyme linked immunosorbant assay 
FACS    fluorescence actovated cell sorter 
FBS     fetal bovine serum 
FITC    fluorescein isothiocyanate 
gm     grams 
GPCR   G-protein coupled receptors 
GTP     guanosine triphosphate 
HRP     horse radish peroxide 
h    hour 
Abbreviations 
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IBMX     3-isobutyl-1-methylxanthine  
kb     kilo bases 
Kd    dissociation constant 
kDa     kilodalton 
kg    kilogram 
kV     kilovolts 
L    litre 
M     molar 
mg     milligrams 
min     minute(s) 
ml     milliliter 
mM     millimolar 
mm    millimeter 
ng     nanograms 
nm     nanometer 
mRNA   messenger ribonucleic acid  
O.D     optical density 
PCR    polymerase chian reaction 
pM    picomolar 
PKA    protein kinase A 
PKC    protein kinase C  
PTH    parathyroid hormone 
PTH1R   parathyroid hormone receptor 1 
PLC    phospholipase C 
RT    room temperature 
rpm     rounds per minute 
TBE    tris-borate-EDTA 
TBS    tris-buffered saline 
TRITC    tetramethylrhodamine isothiocyanate 
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